

## ATP III References

- Aalto-Setälä K, Weinstock PH, Bisagaier CL, Wu L, Smith JD, Breslow JL. Further characterization of the metabolic properties of triglyceride-rich lipoproteins from human and mouse apoC-III transgenic mice. *J Lipid Res* 1996;37:1802-11.
- Abate N, Vega GL, Grundy SM. Variability in cholesterol content and physical properties of lipoproteins containing apolipoprotein B-100. *Atherosclerosis* 1993;104:159-71.
- Abbott RD, Donahue RP, Kannel WB, Wilson PW. The impact of diabetes on survival following myocardial infarction in men vs. women: the Framingham Study. *JAMA* 1988;260:3456-60. [Erratum, *JAMA* 1989;261:1884].
- Abbott RD, Sharp DS, Burchfiel CM, Curb JD, Rodriguez BL, Hakim AA, Yano K. Cross-sectional and longitudinal changes in total and high-density-lipoprotein cholesterol levels over a 20-year period in elderly men: the Honolulu Heart Program. *Ann Epidemiol* 1997;7:417-24.
- Abbott RD, Wilson PWF, Kannel WB, Castelli WP. High density lipoprotein cholesterol, total cholesterol screening, and myocardial infarction. *Arteriosclerosis* 1988;8:207-211.
- Aengevaeren WR, Uijen GJ, Jukema JW, Bruschke AV, and van der Werf T. Functional evaluation of lipid-lowering therapy by pravastatin in the Regression Growth Evaluation Statin Study (REGRESS). *Circulation* 1997;96:429-35.
- Ahmad F, Considine RV, Bauer TL, Ohannesian JP, Marco CC, Goldstein BJ. Improved sensitivity to insulin in obese subjects following weight loss is accompanied by reduced protein-tyrosine phosphatases in adipose tissue. *Metabolism* 1997;46:1140-5.
- Al Shohaib S. Simvastatin-induced rhabdomyolysis in a patient with chronic renal failure. *Am J Nephrol* 2000;20:212-3.
- Alaupovic P, Mack WJ, Knight-Gibson C, Hodis HN. The role of triglyceride-rich lipoprotein families in the progression of atherosclerotic lesions as determined by sequential coronary angiography from a controlled clinical trial. *Arterioscler Thromb Vasc Biol* 1997;17:715-22.
- Albert CM, Hennekens CH, O'Donnell CJ, Ajani, UA, Carey VJ, Willett WC, Ruskin JN, Manson JE. Fish consumption and risk of sudden cardiac death. *JAMA* 1998;279:23-8.
- Albrink MJ, Krauss RM, Lindgrem FT, von der Groeben J, Pan S, Woo PD. Intercorrelations among plasma high density lipoprotein, obesity and triglycerides in a normal population. *Lipids* 1980;15:668-76.
- Alexander JH, Schapel GJ, Edwards KD. Increased incidence of coronary heart disease associated with combined elevation of serum triglyceride and cholesterol concentrations in the nephrotic syndrome in man. *Med J Aust* 1974;2:119-22.

Alfthan G, Pekkanen J, Jauhiainen M, Pitkaniemi J, Karvonen M, Tuomilehto J, Salonen JT, Ehnholm C. Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population-based study. *Atherosclerosis* 1994;106:9-19.

ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). *JAMA* 2000; 283:1967-75.

Allison DB, Egan SK, Basraj LM, Caughman C, Infante M, Heimbach JT. Estimated intakes of trans-fatty and other fatty acids in the U.S. population. *J Amer Diet Assoc* 1999;99:166-74.

Almendingen K, Jordal O, Kierulf P, Sandstad B, Pedersen JI. Effects of partially hydrogenated fish oil, partially hydrogenated soybean oil, and butter on serum lipoproteins and Lp[a] in men. *J Lipid Res* 1995;36:1370-84.

Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. *N Engl J Med* 1994;330:1029-35.

American College of Physicians. Guidelines for using serum cholesterol, high-density lipoprotein cholesterol, and triglyceride levels as screening tests for preventing coronary heart disease. *Ann Intern Med* 1996;124:515-7.

American Diabetes Association. Clinical practice recommendations 1998: screening for type 2 diabetes. *Diabetes Care* 1998;21(suppl 1):S1-98.

American Diabetes Association. Management of dyslipidemia in adults with diabetes. *Diabetes Care* 2001;24(suppl):S58-S61.

American Diabetes Association. Type 2 diabetes in children and adolescents. *Pediatrics* 2000;105:671-80.

American Heart Association. 1999 heart and stroke statistical update. Dallas, TX: American Heart Association, 1998.

Ames RP. A comparison of the blood lipid and blood pressure responses during the treatment of systematic hypertension with indapamide and with thiazides. *Am J Cardiol* 1996;77:12b-16b.

Ammerman AS, Haines PS, DeVellis RF, Strogatz DS, Keyserling TC, Simpson RJ Jr., Siscovick DS. A brief dietary assessment to guide cholesterol reduction in low-income individuals: Design and validation. *J Am Diet Assoc* 1991;91:1385-90.

Ammerman AS, Haines PS, DeVellis RF, Strogatz DS, Keyserling TC, Simpson RJ Jr., Siscovick DS. A brief dietary assessment to guide cholesterol reduction in low-income individuals: Design and validation. *J Am Diet Assoc* 1991;91:1385-90.

Anand SS, Enas EA, Pogue J, Haffner S, Pearson T, Yusuf S. Elevated lipoprotein(a) levels in South Asians in North America. *Metabolism* 1998;47:182-4.

Anderson JW, Hanna TJ. Impact of nondigestible carbohydrates on serum lipoproteins and risk for cardiovascular disease. *J Nutr* 1999;129:1457S-66S.

Anderson JW. Dietary fibre, complex carbohydrate and coronary artery disease. *Can J Cardiol* 1995;11(suppl G):55G-62G.

Anderson KM, Castelli WP, Levy D. Cholesterol and mortality. 30 years of follow-up from the Framingham Study. *JAMA* 1987;257:2176-80.

Anderson TJ, Meredith IT, Yeung AC, Frei B, Selwyn AP, Ganz P. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. *N Engl J Med* 1995;332:488-93.

Angelin B. Therapy for lowering lipoprotein(a) levels. *Curr Opin Lipidol* 1997;8:337-41.

Appel LJ, Moore FJ, Obarzanek E, Vollmer WM, Svetkey LP, Sacks FM, Bray GA, Vogt TM, Cutler JA, Windhauser MM, Lin Pao-Hwa, Karanja N. A clinical trial of the effects of dietary patterns on blood pressure. *N Engl J Med* 1997;336:1117-24.

Arad Y, Ramakrishnan R, Ginsberg HN. Effects of lovastatin therapy on very-low-density lipoprotein triglyceride metabolism in subjects with combined hyperlipidemia: evidence for reduced assembly and secretion of triglyceride-rich lipoproteins. *Metabolism* 1992;41:487-93.

Arad Y, Ramakrishnan R, Ginsberg HN. Lovastatin therapy reduces low-density lipoprotein apoB levels in subjects with combined hyperlipidemia by reducing the production of apoB-containing lipoproteins: implications for the pathophysiology of apoB production. *J Lipid Res* 1990;31:567-82.

Arad Y, Spadaro LA, Goodman K, Newstein D, Guerci AD. Prediction of coronary events with electron beam computed tomography. *J Am Coll Cardiol* 2000;36:1253-60.

Arnesen E, Refsum H, Bonna KH, Ueland PM, Forde OH, Nordrehaug JE. Serum total homocysteine and coronary heart disease. *Int J Epidemiol* 1995;24:704-9.

Arntz H, Agrawal R, Wunderlich W, Schnitzer L, Stern R, Fischer F, Schultheiss H. Beneficial effects of pravastatin ( $\pm$ colestyramine/niacin) initiated immediately after a coronary event (The randomized Lipid-Coronary Artery Disease [L-CAD] study). *Am J Cardiol* 2000;86:1293-8.

Aro A, Jauhiainen M, Partanen R, Salminen I, Mutanen M. Stearic acid, trans-fatty acids, and dairy fat: effects on serum and lipoprotein lipids, apolipoproteins, lipoprotein(a), and lipid transfer proteins in healthy subjects. *Am J Clin Nutr* 1997;65:1419-26.

Aro A, Kardinaal AFM, Kark JD, Riemersma RA, Delgado-Rodriguez M, Gomez-Aracena J, Huttunen JK, Kohlmeier L, Martin BC, Martin-Moreno JM, Mazaev VP, Ringstad J, Thamm M, vant Veer P, Kok, FJ. Adipose tissue isomeric trans fatty-acids and risk of myocardial infarction in nine countries: the EURAMIC study. *Lancet* 1995;345:273-8.

Ascherio A, Katan MB, Zock PL, Stampfer MJ, Willett WC. Trans-fatty acids and coronary heart disease. *N Engl J Med* 1999;340:1994-8.

Ascherio A, Rimm EB, Stampfer MJ, Giovannucci EL, Willett WC. Dietary intake of marine n-3 fatty acids, fish intake, and risk of coronary disease among men. *N Eng J Med* 1995;332:977-82.

Ashraf T, Hay JW, Pitt B, Wittels E, Crouse J, Davidson M, Furberg CD, Radican L. Cost-effectiveness of pravastatin in secondary prevention of coronary artery disease. *Am J Cardiol* 1996;78(4):409-14.

Assmann G, Brewer HB Jr. Genetic (primary) forms of hypertriglyceridemia. *Am J Cardiol* 1991;68(3):13A-16A.

Assmann G, Carmena R, Cullen P, Fruchart JC, Jossa F, Lewis B, Mancini M, Paoletti R. Coronary heart disease: reducing the risk: a worldwide view. International Task Force for the Prevention of Coronary Heart Disease. *Circulation* 1999a;100:1930-8.

Assmann G, Cullen P, Jossa F, Lewis B, Mancini M. Coronary heart disease: reducing the risk: the scientific background to primary and secondary prevention of coronary heart disease. A worldwide view. International Task force for the Prevention of Coronary Heart disease. *Arterioscler Thromb Vasc Biol* 1999b;19:1819-24.

Assmann G, Cullen P, Schulte H. The Munster Heart Study (PROCAM). Results of follow-up at 8 years. *Eur Heart J* 1998b;19(suppl A):A2-A11.

Assmann G, Schulte H, Funke H, von Eckardstein A. The emergence of triglycerides as a significant independent risk factor in coronary artery disease. *Eur Heart J* 1998a;19(suppl M):M8-M14.

Assmann G, Schulte H, von Eckardstein A, Huang Y. High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. *Atherosclerosis* 1996;124(suppl 6):S11-S20.

Assmann G, Schulte H. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Prospective Cardiovascular Munster Study. *Am J Cardiol* 1992;70:733-7.

Astrup A, Toubro S, Raben A, Skov AR. The role of low-fat diets and fat substitutes in body weight management: what have we learned from clinical studies? *J Am Diet Assoc* 1997;97(suppl 7):S82-S87.

Astrup A. Obesity and metabolic efficiency. *CIBA Found Symp* 1996;201:159-68.

Athyros VG, Papageorgiou AA, Hatzikonstandinou HA, Didangelos TP, Carina MV, Kranitsas DF, Kontopoulos AG. Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia. *Am J Cardiol* 1997;80:608-13.

Attman PO, Alaupovic P, Gustafson A. Serum apolipoprotein profile of patients with chronic renal failure. *Kidney Int* 1987;32:368-75.

Austin MA, Breslow JL, Hennekens CH, Buring JE, Willett WC, Krauss RM. Low-density lipoprotein subclass patterns and risk of myocardial infarction. *JAMA* 1988;260:1917-21.

Austin MA, Hokanson JE, Edwards KL. Hypertriglyceridemia as a cardiovascular risk factor. *Am J Cardiol* 1998;81:7B-12B.

Austin MA, Horowitz H, Wijsman E, Krauss RM, Brunzell J. Bimodality of plasma apolipoprotein B levels in a familial combined hyperlipidemia. *Atherosclerosis* 1992;92:67-77.

Austin MA, King MC, Vranizan KM, Krauss RM. Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. *Circulation* 1990;82:495-506.

Austin MA, McKnight B, Edwards KL, Bradley CM, McNeely MJ, Psaty BM, Brunzell JD, Motulsky AG. Cardiovascular disease mortality in familial forms of hypertriglyceridemia: A 20-year prospective study. *Circulation* 2000a;101:2777-82.

Austin MA, Rodriguez BL, McKnight B, McNeely MJ, Edwards KL, Curb JD, Sharp DS. Low-density lipoprotein particle size, triglycerides, and high-density lipoprotein cholesterol as risk factors for coronary heart disease in older Japanese-American men. *Am J Cardiol* 2000b;86:412-16.

Austin MA. Plasma triglyceride as a risk factor for cardiovascular disease. *Can J Cardiol* 1998;14(suppl B):14B-17B.

Azen SP, Mack WJ, Cashin-Hemphill L, LaBree L, Shircore AM, Selzer RH, Blankenhorn DH, Hodis HN. Progression of coronary artery disease predicts clinical coronary events. Long-term follow-up from the Cholesterol Lowering Atherosclerosis Study. *Circulation* 1996;93:34-41.

Bagdade JD, Porte D, Bierman EL. Hypertriglyceridemia. A metabolic consequence of chronic renal failure. *N Engl J Med* 1968;279:181-5.

Baird MG, Bentley-Taylor MM, Carruthers SG, Dawson KG, Laplante LE, Laroche P, MacCannell KL, Marquez-Julio A, Silverberg LR, Talbot P. A study of efficacy, tolerance and compliance of once-daily versus twice-daily metoprolol (Betaloc) in hypertension. Betaloc Compliance Canadian Cooperative Study Group. *Clin Invest Med* 1984;7:95-102.

Baker RC, Kirschenbaum DS. Self-monitoring may be necessary for successful weight control. *Behavior Therapy* 1993;24:377-94.

Bakker-Arkema RG, Davidson MH, Goldstein RJ, Davignon J, Isaacsoh JL, Weiss SR, Keilson LM, Brown WV, Miller VT, Shurzinske LJ, Blael DM. Efficacy and safety of new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. *JAMA* 1995;275:128-33.

Ball KP, Hanington E, McAllen PM. Low-fat diet in myocardial infarction. A controlled trial. *Lancet* 1965;2:501-4.

- Ballantyne CM. Clinical trial endpoints: angiograms, events, and plaque instability. *Am J Cardiol* 1998;82:5M-11M.
- Bandura A. Self-efficacy. The exercise of control. New York: W.H. Freeman and Company, 1997;500 pages.
- Baranowski T, Smith M, Baranowski J, Wang DT, Doyle C, Lin LS, Hearn MD, Resnicow K. Low validity of a seven-item fruit and vegetable food frequency questionnaire among third-grade students. *J Am Diet Assoc* 1997;97:66-8.
- Bargardi AM, Starling MR. Impact of nurse practitioner-implemented evidence-based clinical pathways on “best practice” in an interventional cardiology program. *Circulation* 1999;100:I-99[Abstract 510].
- Barnett HJ, Taylor DW, Eliasziw M, Fox AJ, Ferguson GG, Haynes RB, Rankin RN, Clagett GP, Hachinski VC, Sackett DL, Thorpe KE, Meldrum HE. Benefit of carotid endarterectomy in patients with symptomatic moderate or severe stenosis. North American Symptomatic Carotid Endarterectomy Trial Collaborators. *N Engl J Med* 1998;339:1415-25.
- Barosi G, Marchetti M, Dazzi L, Quaglini S. Testing for occult cancer in patients with idiopathic deep vein thrombosis—a decision analysis. *Thromb and Haemost* 1997;78:1319-26.
- Barrett-Connor E, Grady D. Hormone replacement therapy, heart disease, and other considerations. *Annu Rev Public Health* 1998;19:55-72.
- Barrett-Connor E, Khaw K. Family history of heart attack as an independent predictor of death due to cardiovascular disease. *Circulation* 1984;69:1065-9.
- Barrett-Connor E, Philippi T, Khaw KT. Lipoproteins as predictors of ischemic heart disease in non-insulin-dependent diabetic men. *Am J Prev Med* 1987;3:206-10.
- Barrett-Connor E. Hormone replacement therapy. *BMJ* 1998;317:457-61.
- Batal R, Tremblay M, Barrett PH, Jacques H, Fredenrich A, Mamer O, Davignon J, Cohn JS. Plasma kinetics of apoC-III and apoE in normolipidemic and hypertriglyceridemic subjects. *J Lipid Res* 2000;41:706-18.
- Baxter JH. Hyperlipoproteinemia in nephrosis. *Arch Intern Med* 1962;109:742-57.
- Becker DM, Becker LC, Pearson TA, Fintel DJ, Levine DM, Kwiterovich PO. Risk factors in siblings of people with premature coronary heart disease. *J Am Coll Cardiol* 1988;12:1273-80.
- Becker DM, Raqueno JV, Yook RM, Kral BG, Blumenthal RS, Moy TF, Bezirdjian PJ, Becker LC. Nurse-mediated cholesterol management compared with enhanced primary care in siblings of individuals with premature coronary disease. *Arch Intern Med* 1998;158:1533-9.
- Becker LA, Glanz K, Sobel E, Mossey J, Zinn SL, Knott KA. A randomized trial of special packaging of antihypertensive medications. *J Fam Pract* 1986;22:357-61.

Behar S, Boyko V, Reicher-Reiss H, Goldbourt U. Ten-year survival after acute myocardial infarction: comparison of patients with and without diabetes. SPRINT Study Group. Secondary Prevention Reinfarction Israeli Nifedipine Trial. *Am Heart J* 1997;133:290-6.

Beil U, Crouse JR, Einarsson K, Grundy SM. Effects of interruption of the enterohepatic circulation of bile acids on the transport of very low-density-lipoprotein triglycerides. *Metabolism* 1982a;31:438-44.

Beil U, Grundy SM, Crouse JR, Zech. Triglyceride and cholesterol metabolism in primary hypertriglyceridemia. *Arteriosclerosis* 1982b;2:44-57.

Belcher DW. Implementing preventive services. Success and failure in an outpatient trial. *Arch Intern Med* 1990;150:2533-41.

Bell LP, Hectorne K, Reynolds H, Balm TK, Hunninghake DB. Cholesterol-lowering effects of psyllium hydrophilic mucilloid-adjunct therapy to a prudent diet for patients with mild to moderate hypercholesterolemia. *JAMA* 1989;261:3419-23.

Benderly M, Behar S, Reicher-Reiss H, Boyko V, Goldbourt U. Long-term prognosis of women after myocardial infarction. SPRINT Study Group. Secondary Prevention Reinfarction Israeli Nifedipine Trial. *Am J Epidemiol* 1997;146:153-60.

Bensen JT, Li R, Hutchinson RG, Province MA, Tyroler HA. Family history of coronary heart disease and pre-clinical carotid artery atherosclerosis in African-Americans and whites: the ARIC study: Atherosclerosis Risk in Communities. *Genet Epidemiol* 1999;16:165-78.

Berchtold P, Berger M, Jorgens V, Daweke C, Chantelau E, Gries FA, Zimmermann H. Cardiovascular risk factors and HDL-cholesterol levels in obesity. *Int J Obes* 1981a;5:1-10.

Berchtold P, Jorgens V, Finke C, Berger M. Epidemiology of obesity and hypertension. *Int J Obesity* 1981b;5(suppl 1):1-7.

Berenson GS, Srinivasan SR, Bao W, Newman WP III, Tracy RE, Wattigney WA. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. *N Engl J Med* 1998;338:1650-6.

Berenson GS, Wattigney WA, Tracy RE, Newman WP III, Srinivasan SR, Webber LS, Dalferes ER Jr., Strong JP. Atherosclerosis of the aorta and coronary arteries and cardiovascular risk factors in patients aged 6 to 30 years and studies at necropsy (The Bogalusa Heart Study). *Am J Cardiol* 1992;70:851-8.

Berg A, Halle M, Franz I, Keul J. Physical activity and lipoprotein metabolism: epidemiological evidence and clinical trials. *Eur J Med Res* 1997;2:259-64.

Berg-Smith SM, Stevens VJ, Brown KM, Van Horn L, Gernhofer N, Peters E, Greenberg R, Snetselaar L, Ahrens L, Smith K. A brief motivational intervention to improve dietary adherence in adolescents. *Health Educ Res* 1999;14:399-410.

Berlowitz DR, Ash AS, Hickey EC, Friedman RH, Glickman M, Kader B, Moskowitz MA. Inadequate management of blood pressure in a hypertensive population. *N Engl J Med* 1998;339:1957-63.

Berlyne GM, Mallick, NP. Ischaemic heart-disease as a complication of nephrotic syndrome. *Lancet* 1969;2:399-400.

Bestehorn HP, Rensing UF, Roskamm H, Betz P, Benesch L, Schemeitat K, Blumchen G, Claus J, Mathes P, Kappenberger L, Wieland H, Neiss A. The effect of simvastatin on progression of coronary artery disease: the Multicenter Coronary Intervention Study (CIS). *Eur Heart J* 1997;18:226-34.

Bezafibrate Infarction Prevention (BIP) Study. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. *Circulation* 2000;102:21-7.

Bierman EL. George Lyman Duff Memorial Lecture. Atherogenesis in diabetes. *Arterioscler Thromb* 1992;12:647-56.

Bilheimer DW, Goldstein JL, Grundy SM, Brown MS. Reduction in cholesterol and low density lipoprotein synthesis after portacaval shunt surgery in a patient with homozygous familial hypercholesterolemia. *J Clin Invest* 1975;56:1420-30.

Bilheimer DW, Grundy SM, Brown MS, Goldstein JL. Mevinolin and colestipol stimulate receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholesterolemia heterozygotes. *Proc Natl Acad Sci U S A* 1983;80:4124-8.

Bilheimer DW. Portacaval shunt and liver transplantation in treatment of familial hypercholesterolemia. *Arteriosclerosis* 1989;9(suppl 1):1158-63.

Bjorkegren J, Boquist S, Samnegard A, Lundman P, Tornvall P, Ericsson CG, Hamsten A. Accumulation of apolipoprotein C-I-rich and cholesterol-rich VLDL remnants during exaggerated postprandial triglyceridemia in normolipidemic patients with coronary artery disease. *Circulation* 2000;101:227-30.

Bjorntorp P. Abdominal obesity and the metabolic syndrome. *Ann Med* 1992;24:465-8.

Bjorntorp P. Body fat distribution, insulin resistance, and metabolic diseases. *Nutrition* 1997;13:795-803.

Blackburn H. The public health view of the diet and mass hyperlipidemia. *Cardiovas Rev Rep* 1990;11:25-33.

Blair D, Habicht JP, Sims EA, Sylwester D, Abraham S. Evidence for an increased risk for hypertension with centrally located body fat and the effect of race and sex on this risk. *Am J Epidemiol* 1984;119:526-40.



Blair SN, Capuzzi DM, Gottlieb SO, Nguyen T, Morgan JM, Cater NB. Incremental reduction of serum total cholesterol and low-density lipoprotein cholesterol with the addition of plant stanol ester-containing spread to statin therapy. *Am J Cardiol* 2000;86:46-52.

Blair SN, Cooper KH, Gibbons LW, Gettman LR, Lewis S, Goodyear N. Changes in coronary heart disease risk factors associated with increased treadmill time in 753 men. *Am J Epidemiol* 1983;118:352-9.

Blair SN, Kohl HW III, Paffenbarger RS Jr., Clark DG, Cooper KH, Gibbons LW. Physical fitness and all-cause mortality. A prospective study of healthy men and women. *JAMA* 1989;262:2395-401.

Blair TP, Bryant J, Bocuzzi S. Treatment of hypercholesterolemia by a clinical nurse using a stepped-care protocol in a nonvolunteer population. *Arch Intern Med* 1988;48:1046-8.

Blankenhorn DH, Azen SP, Krams DM, Mack WJ, Cashin-Hemphill L, Hodis HN, DeBoer LW, Mahrer PR, Masteller MJ, Vailas LI. Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS). The MARS Research Group. *Ann Intern Med* 1993;119:969-76.

Blankenhorn DH, Nessim SA, Johnson RL, Sanmarco ME, Azen SP, Cashin-Hemphill L. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. *JAMA* 1987;257:3233-40.

Blauw GJ, Lagaay AM, Smelt AH, Westendorp RG. Stroke, statins, and cholesterol. A meta-analysis of randomized, placebo-controlled, double-blind trials with HMG-CoA reductase inhibitors. *Stroke* 1997;28:946-50.

Bloch S, Couderc R. Apolipoprotein B and LDL cholesterol: which parameter(s) should be included in the assessment of cardiovascular risk? *Ann Biol Clin* 1998;56:539-44.

Blot WJ, Li JY, Taylor PR, Guo W, Dawsey S, Wang GQ, Yang CS, Zheng SF, Gail M, Li GY, Yu Y, Liu B, Tangrea J, Sun Y, Liu F, Fraumeni JF Jr., Zhang YH, Li B. Nutrition intervention trials in Linxian, China: supplementation with specific vitamin/mineral combinations, cancer incidence, and disease-specific mortality in the general population. *J Nat'l Cancer Inst* 1993;85:1483-92.

Bluml BM, McKenney JM, Cziraky MJ. Pharmaceutical care services and results in Project ImPACT: hyperlipidemia. *J Am Pharm Assoc* 2000;40:157-65.

Bocuzzi SJ, Bocanegra TS, Walker JF, Shapiro DR, Keegan ME. Long-term safety and efficacy profile of simvastatin. *Am J Cardiol* 1991;68:1127-31.

Bodkin NL, Hannah JS, Ortmeyer HK, Hansen BC. Central obesity in rhesus monkeys: association with hyperinsulinemia, insulin resistance and hypertriglyceridemia? *Int J Obes Relat Metab Disord* 1993;17:53-61.

- Boer R, de Koning HJ, van der Maas PJ. A longer breast carcinoma screening interval for women age older than 65 years? *Cancer* 1999;86:1506-10.
- Boomsma DI, Kempen HJ, Gevers Leuven JA, Havekes L, de Knijff P, Frants RR. Genetic analysis of sex and generation differences in plasma lipid, lipoprotein, and apolipoprotein levels in adolescent twins and their parents. *Genet Epidemiol* 1996;13:49-60.
- Borchers AT, Keen CL, Stern JS, Gershwin ME. Inflammation and Native American medicine: the role of botanicals. *Am J Clin Nutr* 2000;72:339-47.
- Bostom AG, Rosenberg IH, Silbershatz H, Jacques PF, Selhub J, D'Agostino RB, Wilson PW, Wolf PA. Nonfasting plasma total homocysteine levels and stroke incidence in older patients: The Framingham Study. *Ann Intern Med* 1999;131:352-5.
- Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. *JAMA* 1995;274:1049-57.
- Bovbjerg VE, McCann BS, Brief DJ, Follette WC, Retzlaff BM, Dowdy AA, Walden CE, Knopp RH. Spouse support and long-term adherence to lipid-lowering diets. *Am J Epidemiol* 1995;141:451-60.
- Bowker TJ, Clayton TC, Ingham J, McLennan NR, Hobson HL, Pyke SD, Schofield B, Wood DA. A British Cardiac Society survey of the potential for the secondary prevention of coronary disease: ASPIRE (Action on Secondary Prevention through Intervention to Reduce Events). *Heart* 1996;75:334-42.
- Bradford RH, Shear CL, Chremos AN, Dujovne C, Downton M, Franklin FA, Gould AL, Hesney M, Higgins J, Hurley DP. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. *Arch Intern Med* 1991;151:43-9.
- Bradford RH, Shear CL, Chremos AN, Dujovne CA, Franklin FA, Grillo RB, Higgins J, Langendorfer A, Nash DT, Pool JL, Schnaper H. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results: two-year efficacy and safety follow-up. *Am J Cardiol* 1994;74:667-73.
- Brensike JF, Levy RI, Kelsey SF, Passamani ER, Richardson JM, Loh IK, Stone NJ, Aldrich RF, Battaglini JW, Moriarty DJ, Fisher MR, Friedman L, Friedewald W, Detre KM, Epstein SE. Effects of therapy with cholestyramine on progression of coronary arteriosclerosis: results of the NHLBI Type II Coronary Intervention Study. *Circulation* 1984;69:313-24.
- Breslow JL. Mouse models of atherosclerosis. *Science* 1996;272:685-8.
- Briefel RR, Sempos CT, McDowell MA, Chien S, Alaimo K. Dietary methods research in the third National Health and Nutrition Examination Survey: underreporting of energy intake. *Am J Clin Nutr* 1997;65:1203S-9S.

- Brinberg D, Axelson ML, Price S. Changing food knowledge, food choice, and dietary fiber consumption by using tailored messages. *Appetite* 2000;35:35-43.
- Brousseau ME, Schaefer EJ. Diet and coronary heart disease: clinical trials. *Curr Atheroscler Rep* 2000;2:487-93.
- Brown AS, Cofer LA. Lipid management in a private cardiology practice (the Midwest Heart experience). *Am J Cardiol* 2000;85:18A-22A.
- Brown B, Albers JJ, Fisher LD, Schaffer SM, Lin J-T, Kaplan C, Zhao XQ, Bisson BD, Fitzpatrick VF, Dodge HT. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. *N Engl J Med* 1990;323:1289-98.
- Brown BG, Bardsley J, Poulin D, Hillger LA, Dowdy A, Maher VM, Zhao XQ, Albers JJ, Knopp RH. Moderate dose, three-drug therapy with niacin, lovastatin, and colestipol to reduce low-density lipoprotein cholesterol <100 mg/dL in patients with hyperlipidemia and coronary artery disease. *Am J Cardiol* 1997;80:111-15.
- Brown BG, Zhao XQ, Chait A, Fisher LD, Dowdy A, Cheung M, Morse JJ, Serafini L, Huss-Frechette E, Deangelis D, Frohlich JJ, Albers JJ. Niacin plus simvastatin, but not antioxidant vitamins, protect against atherosclerosis and clinical events in CAD patients with low HDL cholesterol. *Circulation* 2000;102:II-506.
- Brown BG, Zhao XQ, Sacco DE, Albers JJ. Lipid lowering and plaque regression. New insights into prevention of plaque disruption and clinical events in coronary disease. *Circulation* 1993;87:1781-91.
- Brown BG, Zhao XQ. Lipid therapy to stabilize the vulnerable atherosclerotic plaque: new insights into the prevention of cardiovascular events. In: Grundy SM, ed. Cholesterol-lowering therapy: evaluation of clinical trial evidence. New York: Marcel Dekker, Inc., 2000;249-72.
- Brown CD, Higgins M, Donato KA, Rohde FC, Garrison R, Obarzanek E, Ernst ND, Horan M. Body mass index and the prevalence of hypertension and dyslipidemia. *Obes Res* 2000;8:605-19.
- Brown G, Stewart BF, Zhao XQ, Hillger LA, Poulin D, Albers JJ. What benefit can be derived from treating normocholesterolemic patients with coronary artery disease? *Am J Cardiol* 1995;76:93C-97C.
- Brown L, Rosner B, Willett WW, Sacks FM. Cholesterol-lowering effects of dietary fiber: a meta-analysis. *Am J Clin Nutr* 1999;69:30-42.
- Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. *Science* 1986;232:34-47.
- Broyles FE, Walden CE, Hunninghake DB, Hill-Williams D, Knopp RH. Effect of fluvastatin on intermediate density lipoprotein (remnants) and other lipoprotein levels in hypercholesterolemia. *Am J Cardiol* 1995;76:129A-135A.

Brunzell JD, Schrott HG, Motulsky AG, Bierman EL. Myocardial infarction in the familial forms of hypertriglyceridemia. *Metabolism* 1976;25:313-20.

Buchwald H, Varco RL, Matts JP, Long JM, Fitch LL, Campbell GS, Pearce MB, Yellin AE, Edmiston WA, Smink RD Jr. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH). *N Engl J Med* 1990;323:946-55.

Buchwald H. Program on the Surgical Control of the Hyperlipidemias (POSCH) trial: A pivotal 25-year study. In: Grundy SM, ed. Cholesterol-lowering therapy: evaluation of clinical trial evidence. New York: Marcel Dekker, Inc., 2000;117-49.

Budde T, Fechtrop C, Bosenberg E, Vielhauer C, Enbergs A, Schulte H, Assmann G, Breithardt G. Plasma Lp(a) levels correlate with number, severity, and length-extension of coronary lesions in male patients undergoing coronary arteriography for clinically suspected coronary atherosclerosis. *Arterioscler Thromb* 1994;14:1730-6.

Bulgin RH. Comparative costs of various dialysis treatments. *Peritoneal Dialysis Bulletin* 1981;1:88-91.

Burr ML, Fehily AM, Gilbert JF, Rogers S, Holliday RM, Sweetnam PM, Elwood PC, Deadman NM. Effects of changes in fat, fish and fibre intakes on death and myocardial reinfarction: Diet and Reinfarction Trial (DART). *Lancet* 1989;2:757-61.

Buxton MJ, West RR. Cost-benefit of long-term haemodialysis for chronic renal failure. *BMJ* 1975;2:376-9.

Byington RP, Davis BR, Plehn JF, White HD, Baker J, Cobbe SM, Shepherd J. Reduction of stroke events with pravastatin: the Prospective Pravastatin Pooling (PPP) Project. *Circulation* 2001;103:387-92.

Byington RP, Jukema JW, Salonen JT, Pitt B, Bruschke AV, Hoen H, Furberg CD, Mancini GB. Reduction in cardiovascular events during pravastatin therapy. Pooled analysis of clinical events of the Pravastatin Atherosclerosis Intervention Program. *Circulation* 1995;92:2419-25.

Cabana MD, Rand CS, Powe NR, Wu AW, Wilson MH, Abboud PA, Rubin HR. Why don't physicians follow clinical practice guidelines? A framework for improvement. *JAMA* 1999;282:1458-65.

Caggiula AW, Christakis G, Farrand M, Hulley SB, Johnson R, Lasser NL, Stamler J, Widdowson G. The Multiple Risk Intervention Trial (MRFIT). IV. Intervention on blood lipids. *Prev Med* 1981;10:443-75.

Caggiula AW, Watson JE, Kuller LH, Olson MB, Milas NC, Berry M, Germanowski J. Cholesterol-lowering intervention program. Effect of the step I diet in community office practices. *Arch Intern Med* 1996;156:1205-13.

Caggiula AW, Watson JE, Milas NC, Olson MB, Kuller LH, Orchard TJ. Evaluating the efficacy of the National Cholesterol Education Program adult treatment guidelines: cholesterol lowering intervention program. *Prev Med* 1995;24:485-91.

Calle EE, Thun MJ, Petrelli JM, Rodriguez C, Heath CW. Body-mass index and mortality in a prospective cohort of U.S. Adults. *N Engl J Med* 1999;341:1097-105.

Campbell MK, DeVellis BM, Strecher VJ, Ammerman AS, DeVellis RF, Sandler RS. Improving dietary behavior: the effectiveness of tailored messages in primary care settings. *Am J Public Health* 1994;84:783-7.

Canner PL, Berge KG, Wenger NK, Stamler J, Friedman L, Prineas RJ, Friedewald W. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. *J Am Coll Cardiol* 1986;8:1245-55.

Capuzzi DM, Guyton JR, Morgan JM, Goldberg AC, Kreisberg RA, Brusco OA, Brody J. Efficacy and safety of an extended-release niacin (Niaspan): a long-term study. *Am J Cardiol* 1998;82:74U-81U; discussion 85U-86U.

Carleton RA, Dwyer J, Finberg L, Flora J, Goodman DS, Grundy SM, Havas S, Hunter GT, Kritchevsky D, Lauer RM, Luepker RV, Ramirez AG, Van Horn L, Statson WB, Cleeman JI, Ernst N, Friedewald W, Rifkind B. Report of the Expert Panel on Population Strategies for Blood Cholesterol Reduction. A statement from the National Cholesterol Education Program, National Heart, Lung, and Blood Institute. *Circulation* 1991;83:2154-232.

Carlson LA, Hamsten A, Asplund A. Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidemic subjects treated with nicotinic acid. *J Intern Med* 1989;226:271-6.

Carlson LA, Rosenhamer G. Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. *Acta Med Scand* 1988;223:405-18.

Caro J, Klittich W, McGuire A, Ford I, Norrie J, Pettitt D, McMurray J, Shepherd J. The West of Scotland Coronary Prevention Study: economic benefit analysis of primary prevention with pravastatin. *BMJ* 1997;315:1577-82.

Carr MC, Hokanson JE, Deeb SS, Purnell JQ, Mitchell ES, Brunzell JD. A hepatic lipase gene promoter polymorphism attenuates the increase in hepatic lipase activity with increasing intra-abdominal fat in women. *Arterioscler Thromb Vasc Biol* 1999;19:2701-7.

Carter BL, Barnette DJ, Chrischilles E, Mazzotti GJ, Asali ZJ. Evaluation of hypertensive patients after care provided by community pharmacists in a rural setting. *Pharmacotherapy* 1997;17:1274-85.

CASANOVA Study Group. Carotid surgery versus medical therapy in asymptomatic carotid stenosis. *Stroke* 1991;22:1229-35.

- Casaretto A, Marchioro TL, Goldsmith R, Bagdade D. Hyperlipidaemia after successful renal transplantation. *Lancet* 1974;1:481-4.
- Castelli WP, Anderson K, Wilson PW, Levy D. Lipids and risk of coronary heart disease. The Framingham Study. *Ann Epidemiol* 1992;2:23-8.
- Cauley JA, LaPorte RE, Kuller LH, Bates M, Sandler RB. Menopausal estrogen use, high density lipoprotein cholesterol subfractions and liver function. *Atherosclerosis* 1983;49:31-9.
- Cavaghan MK, Ehrmann DA, Polonsky KS. Interactions between insulin resistance and insulin secretion in the development of glucose intolerance. *J Clin Invest* 2000;106:329-33.
- Centers for Disease Control and Prevention. Folate status in women of childbearing age—United States, 1999. *MMWR* 2000;49:962-5.
- Chait A, Albers JJ, Brunzell JD. Very low density lipoprotein overproduction in genetic forms of hypertriglyceridaemia. *Eur J Clin Invest* 1980;10:17-22.
- Chait A, Brunzell JD. Acquired hyperlipidemia (secondary dyslipoproteinemias). *Endocrinol Metab Clin North Am* 1990;19:259-78.
- Chait A, Brunzell JD. Chylomicronemia syndrome. *Adv Intern Med* 1992;37:249-73.
- Chambless LE, Heiss G, Folsom AR, Rosamond W, Szklo M, Sharrett AR, Clegg LX. Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the Atherosclerosis Risk in Communities (ARIC) Study. *Am J Epidemiol* 1997;146:483-94.
- Chen YD, Coulston AM, Zhou MY, Hollenbeck CB, Reaven GM. Why do low-fat high-carbohydrate diets accentuate postprandial lipemia in patients with NIDDM? *Diabetes Care* 1995;18:10-16.
- Chen Z, Peto R, Collins R, MacMahon S, Lu J, Li W. Serum cholesterol concentration and coronary heart disease in populations with low cholesterol concentrations. *BMJ* 1991;303:276-82.
- Chimowitz MI, Weiss DG, Cohen SL, Starling MR, Hobson RW. Cardiac prognosis of patients with carotid stenosis and no history of coronary artery disease. Veterans Affairs Cooperative Study Group 167. *Stroke* 1994;25:759-65.
- Chobanian AV, Hill M. National Heart, Lung, and Blood Institute Workshop on Sodium and Blood Pressure. A critical review of current scientific evidence. *Hypertension* 2000;35:858-63.
- Christie D. Screening for breast cancer: Cost-benefit analysis. *Mayo Clinic Proc* 1977;47:550-5.
- Churchill DN, Lemon BC, Torrance GW. A cost-effectiveness analysis of continuous ambulatory peritoneal dialysis and hospital dialysis. *Medical Decision Making* 1984;4:489-500.

Clark LT, Ferdinand KC, Flack JM, Gavin JR III, Hall WD, Kumanyika SK, Reed JW, Saunders E, Valentine HA, Watson K, Wenger NK, Wright JT. Coronary heart disease in African Americans. *Heart Disease* 2001;3:97-108.

Clark LT. Anatomic substrate differences between African American and white victims of sudden cardiac death: hypertension, coronary artery disease, or both? *Clin Cardiol* 1989;12:IV:13-17.

Clark LT. Primary prevention of cardiovascular disease in high-risk patients: physiologic and demographic risk factor differences between African American and white American populations. *Am J Med* 1999;107(2A):22S-24S.

Clark R, Collins R. Can dietary supplements with folic acid or vitamin B<sub>6</sub> reduce cardiovascular risk? Design of clinical trials to test the homocysteine hypothesis of vascular disease. *J Cardiovasc Risk* 1998;5:249-55.

Clarke R, Frost C, Collins R, Appleby P, Peto R. Dietary lipids and blood cholesterol: quantitative meta-analysis of metabolic ward studies. *BMJ* 1997;314:112-17 .

Cleeman JI, Grundy SM. National Cholesterol Education Program recommendations for cholesterol testing in young adults. A science-based approach. *Circulation* 1997;95:1646-50.

Cleeman JI, Lenfant C. The National Cholesterol Education Program: progress and prospects. *JAMA* 1998;280:2099-104.

Cohen JC, Wang Z, Grundy SM, Stoesz MR, Guerra R. Variation at the hepatic lipase and apolipoprotein AI/CIII/AIV loci is a major cause of genetically determined variation in plasma HDL cholesterol levels. *J Clin Invest* 1994;94:2377-84.

Colcher IS, Bass JW. Penicillin treatment of streptococcal pharyngitis. A comparison of schedules and the role of specific counseling. *JAMA* 1972;222:657-9.

Colditz GA, Bonita R, Stampfer MJ, Willett WC, Rosner B, Speizer FE, Hennekens CH. Cigarette smoking and risk of stroke in middle-aged women. *N Engl J Med* 1988;318:937-41.

Colditz GA, Egan KM, Stampfer MJ. Hormone replacement therapy and risk of breast cancer: results from epidemiologic studies. *Am J Obstet Gynecol* 1993;168:1473-80.

Colditz GA, Rimm EB, Giovannucci E, Stampfer MJ, Rosner B, Willett WC. A prospective study of parental history of myocardial infarction and coronary artery disease in men. *Am J Cardiol* 1991;67:933-8.

Colditz GA, Willett WC, Stampfer MJ, Rosner B, Speizer FE, Hennekens CH. Menopause and the risk of coronary heart disease in women. *N Engl J Med* 1987;316:1105-10.

Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. *Lancet* 1997;350:1047-59.

Committee of Principal Investigators. A co-operative trial in the primary prevention of ischemic heart disease using clofibrate. Report from the Committee of Principal Investigators. *Br Heart J* 1978;40:1069-118.

Compliance and adverse event withdrawal: their impact on the West of Scotland Coronary Prevention Study. *Eur Heart J* 1997;18:1718-24.

Connor SL, Gustafson JR, Sexton G, Becker N, Artaud-Wild S, Connor WE. The Diet Habit Survey: A new method of dietary assessment that relates to plasma cholesterol changes. *J Am Diet Assoc* 1992;92:41-7.

Connor SL, Gustafson JR, Sexton G, Becker N, Artaud-Wild S, Connor WE. The Diet Habit Survey: A new method of dietary assessment that relates to plasma cholesterol changes. *J Am Diet Assoc* 1992;92:41-7.

Connor WE. Fish oil in hypertriglyceridemia: safety and recommendations. *Lipids* 1999;34 (suppl):S271.

Conroy RM, Mulcahy R, Hickey N, Daly L. Is a family history of coronary heart disease an independent coronary risk factor? *Br Heart J* 1985;53:378-81.

Constantinides P. Plaque hemorrhages, their genesis and their role in supraplaque thrombosis and atherogenesis. In: Giagov S, Newman WP, Schaffer SA, eds. In: Pathobiology of the human atherosclerotic plaque. New York: Springer-Verlag, 1990;393-411.

Cook DG, Mendall MA, Whincup PH, Carey IM, Ballam L, Morris JE, Miller GJ, Strachan DP. C-reactive protein concentrations in children: relationship to adiposity and other cardiovascular risk factors. *Atherosclerosis* 2000;149:139-50.

Cooper RS, Liao Y, Rotimi C. Is hypertension more severe among U.S. blacks, or is severe hypertension more common? *Ann Epidemiol* 1996;6:173-80.

Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. *JAMA* 1975;231:360-81.

Coronary Drug Project Research Group. Gallbladder disease as a side effect of drugs influencing lipid metabolism. Experience in the Coronary Drug Project. *N Engl J Med* 1977;296:1185-90.

Coronary Drug Project Research Group. Influence of adherence to treatment and response of cholesterol on mortality in the coronary drug project. *N Engl J Med* 1980;303:1038-41.

Craighead LW, Stunkard AJ, O'Brien RM. Behavior therapy and pharmacotherapy for obesity. *Arch Gen Psychiatry* 1981;38:763-8.



Creager MA. Results of the CAPRIE trial: efficacy and safety of clopidogrel. Clopidogrel versus aspirin in patients at risk of ischaemic events. *Vasc Med* 1998;3:257-60.

Cressman MD, Hoogwerf BJ, Moodie DS, Olin JW, Weinstein CE. HMG-CoA reductase inhibitors. A new approach to the management of hypercholesterolemia. *Cleve Clin J Med* 1988; 55:93-100.

Criqui MH, Coughlin SS, Fronek A. Noninvasively diagnosed peripheral arterial disease as a predictor of mortality: results from a prospective study. *Circulation* 1985;72:768-73.

Criqui MH, Golomb BA. Epidemiologic aspects of lipid abnormalities. *Am J Med* 1998a;105:48S-57S.

Criqui MH, Langer RD, Fronek A, Feigelson HS, Klauber MR, McCann TJ, Browner D. Mortality over a period of 10 years in patients with peripheral arterial disease. *N Engl J Med* 1992;326:381-6.

Criqui MH. Alcohol and coronary heart disease: consistent relationship and public health implications. *Clinica Chim Acta* 1996;246:51-7.

Criqui MH. Alcohol and hypertension: new insights from population studies. *Eur Health J* 1987;(suppl B)19-26.

Criqui MH. Alcohol in the myocardial infarction patient. *Lancet* 1998b;352:1873.

Croghan IT, Offord KP, Evans RW, Schmidt S, Gomez-Dahl LC, Schroeder DR, Patten CA, Hurt RD. Cost-effectiveness of treating nicotine dependence: the Mayo Clinic experience. *Mayo Clinic Proc* 1997;72:917-24.

Cromwell J, Bartosch WJ, Fiore MC, Hasselblad V, Baker T. Cost-effectiveness of the clinical practice recommendations in the AHCPR guideline for smoking cessation. Agency for Health Care Policy and Research. *JAMA* 1997;278:1759-66.

Crook D, Cust MP, Gangar KF, Worthington M, Hillard TC, Stevenson JC, Whitehead MI, Wynn V. Comparison of transdermal and oral estrogen-progestin replacement therapy: effects on serum lipids and lipoproteins. *Am J Obstet Gynecol* 1992;166:950-5.

Crouse JR III, Byington RP, Bond MG, Espeland MA, Craven TE, Sprinkle JW, McGovern ME, Furberg CD. Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-II). *Am J Cardiol* 1995;75:455-9.

Crouse JR III, Byington RP, Furberg CD. HMG-CoA reductase inhibitor therapy and stroke risk reduction: an analysis of clinical trials data. *Atherosclerosis* 1998;138:11-24.

Crouse JR III, Byington RP, Hoen HM, Furberg CD. Reductase inhibitor monotherapy and stroke prevention. *Arch Intern Med* 1997;157:1305-10.

Crouse JR III, Morgan T, Terry JG, Ellis J, Vitolins M, Burke GL. A randomized trial comparing the effect of casein with that of soy protein containing varying amounts of isoflavones on plasma concentrations of lipids and lipoproteins. *Arch Intern Med* 1999;159:2070-6.

Crouse JR III. Effects of statins on carotid disease and stroke. *Curr Opin Lipidol* 1999;10:535-41.

Crouse JR III. Hypertriglyceridemia: a contraindication to the use of bile acid binding resins. *Am J Med* 1987;83:243-8.

Cui Y, Blumenthal RS, Flaws JA, Whiteman MK, Langenberg P, Bachorik PS, Bush TL. Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality. *Arch Intern Med* 2001;161:1413-9.

Cullen P, Assmann G. Treatment goals for low-density lipoprotein cholesterol in the secondary prevention of coronary heart disease: absolute levels or extent of lowering? *Am J Cardiol* 1997;80:1287-94.

Cullen P, von Eckardstein A, Assmann G. Diagnosis and management of new cardiovascular risk factors. *Eur Heart J* 1998;19(suppl O):O13-9.

Cummings SR, Rubin SM, Oster G. The cost-effectiveness of counseling smokers to quit. *JAMA* 1989;261:75-9.

Current Procedural Terminology: CPT 2001. Chicago, Illinois; American Medical Association, 2000:300 pages.

Cushman M, Legault C, Barrett-Connor E, Stefanick ML, Kessler C, Judd HL, Sakkinen PA, Tracy RP. Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Study. *Circulation* 1999;100:717-22.

Cutler JA, Psaty BM, MacMahon S, Furberg CD. Public health issues in hypertension control: what has been learned from clinical trials. In: Laragh JH, Brenner BM, eds. Hypertension: pathophysiology, diagnosis, and management;2nd ed. New York: Raven Press, 1995;253-70.

Cutter GR, Burke GL, Dyer AR, Friedman GD, Hilner JE, Hughes GH, Hulley SB, Jacobs DR, Liu K, Manolio TA, Oberman A, Perkins LL, Savage PJ, Serwitz JR, Sidney S, Wagenknecht LE. Cardiovascular risk factors in young adults. The CARDIA baseline monograph. *Control Clin Trials* 1991;12(1 suppl):1S-77S.

D'Agostino RB Sr., Grundy S, Sullivan LM, Wilson P. CHD Risk Prediction Group. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. *JAMA* 2001;286:180-7.

DAIS Investigators. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. *Lancet* 2001;357:905-10.

Daltroy LH, Godin G. The influence of spousal approval and patient perception of spousal approval on cardiac participation in exercise programs. *J Cardiopulmonary Rehabilitation* 1989;9:363-7.

Danesh J, Collins R, Peto R. Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. *Circulation* 2000;102:1082-5.

Davidson MH, Dillon MA, Gordon B, Jones P, Samuels J, Weiss S, Isaacsohn J, Toth P, Burke SK. Colesevelam hydrochloride (cholestagel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects. *Arch Intern Med* 1999;159:1893-1900.

Davidson MH, Dugan LD, Burns JH, Bova J, Story K, Drennan KB, Anderson V, Fulgoni L, Saldanha L, Olson B. The hypocholesterolemic effects of beta-glucan in oatmeal and oat bran. A dose-controlled study. *JAMA* 1991;265:1833-9.

Davidson MH, Stein EA, Hunninghake DB, Ose L, Dujovne CA, Insull W Jr., Bertolami M, Weiss SR, Kastelein JJ, Scott RS, Campodonico S, Escobar ID, Schrott HG, Bays H, Stepanavage ME, Wu M, Tate AC, Melino MR, Kush D, Mercuri M, Mitchel YB for the Worldwide Expanded Dose Simvastatin Study Group. Lipid-altering efficacy and safety of simvastatin 80 mg/day: Worldwide long-term experience I patients with hypercholesterolemia. *Nutr Metab Cardiovasc Dis* 2000;10:253-262.

Davidson MH, Toth P, Weiss S, McKenney J, Hunninghake D, Isaacsohn J, Donovan JM, Burke SK. Low-dose combination therapy with colesevelam hydrochloride and lovastatin effectively decreases low-density lipoprotein cholesterol in patients with primary hypercholesterolemia. *Clin Cardiol* 2001;24:467-74.

Davidson MH. Does differing metabolism by cytochrome P450 have clinical importance? *Curr Atheroscler Reports* 2000;2:14-9.

Daviglus ML, Stamler J, Orenca AJ, Dyer AR, Liu K, Greenland P, Walsh MK, Morris D, Shekelle RB. Fish consumption and the 30-year risk of fatal myocardial infarction. *N Engl J Med* 1997;336:1046-53.

Davignon J, Montigny M, Dufour R. HMG-CoA reductase inhibitors: a look back and a look ahead. *Can J Cardiol* 1992;8:843-64.

Davignon J, Roederer G, Montigny M, Hayden MR, Tan MH, Connelly PW, Hegele R, McPherson R, Lupien PJ, Gagne C. Comparative efficacy and safety of pravastatin, nicotinic acid, and the two combined in patients with hypercholesterolemia. *Am J Cardiol* 1994;73:339-45.

Davis BR, Cutler JA, Gordon DJ, et al. Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) *Am J Hypertens* 1996;9:342-60.

Davis DA, Thomson MA, Oxman AD, Haynes RB. Changing physician performance. A systematic review of the effect of continuing medication education strategies. *JAMA* 1995;274:700-5.

Dayton S, Pearce ML, Goldman H, Harnish A, Plotkin D, Shickman M, Winfield M, Zager A, Dixon W. Controlled trial of a diet high in unsaturated fat for prevention of atherosclerotic complications. *Lancet* 1968;2:1060-102.

de Koning HJ, van Ineveld BM, van Oortmarssen GJ, de Haes JC, Collette HJ, Hendriks JH, van der Maas PJ. Breast cancer screening and cost-effectiveness: policy alternatives, quality of life considerations, and the possible impact of uncertain factors. *Int J Cancer* 1991;49:531-7.

de Lorgeril M, Salen P, Martin JL, Monjaud I, Boucher P, Mamelle N: Mediterranean dietary pattern in a randomized trial: prolonged survival and possible reduced cancer rate. *Arch Intern Med* 1998;158:1181-7.

de Lorgeril M, Salen P, Martin JL, Monjaud I, Delaye J, Mamelle N. Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: Final report of the Lyon Diet Heart Study. *Circulation* 1999;99:779-85.

de Vreede-Swagemakers JJM, Gorgels APM, Dubois-Arbouw WI, van Ree JW, Daemen MJAP, Houben LGE, Wellens HJJ. Out-of-hospital cardiac arrest in the 1990s: a population-based study in the Maastricht area on incidence, characteristics and survival. *J Am Coll Cardiol* 1997;30:1500-5.

Deaths for 282 selected causes by 5-year age groups, race, and sex: United States, 1979–98. Retrieved from <http://www.cdc.gov/nchs/datawh/statab/unpubd/mortabs/gmwk292.html>

DeBusk RF, Miller NH, Superko HR, Dennis CA, Thomas RJ, Lew HT, Berger WE III, Heller RS, Rompf J, Gee D, Kraemer HC, Bandura A, Ghandour G, Clark M, Shah RV, Fisher L, Taylor CB. A case-management system for coronary risk factor modification after acute myocardial infarction. *Ann Intern Med* 1994;120:721-9.

Dengel DR, Galecki AT, Hagberg JM, Pratley RE. The independent and combined effects of weight loss and aerobic exercise on blood pressure and oral glucose tolerance in older men. *Am J Hypertens* 1998;11:1405-12.

Denke MA, Grundy SM. Efficacy of low-dose cholesterol-lowering drug therapy in men with moderate hypercholesterolemia. *Arch Intern Med* 1995;155:393-9.

Denke MA, Grundy SM. Hypercholesterolemia in elderly persons: resolving the treatment dilemma. *Ann Intern Med* 1990;112:780-92.

Denke MA, Grundy SM. Individual responses to a cholesterol-lowering diet in 50 men with moderate hypercholesterolemia. *Arch Intern Med* 1994;154:317-25.

Denke MA, Sempos CT, Grundy SM. Excess body weight. An underrecognized contributor to high blood cholesterol levels in white American men. *Arch Intern Med* 1993;153:1093-103.

Denke MA, Sempos CT, Grundy SM. Excess body weight. An underrecognized contributor to dyslipidemia in white American women. *Arch Intern Med* 1994;154:401-10.

Denke MA. Individual responsiveness to a cholesterol-lowering diet in postmenopausal women with moderate hypercholesterolemia. *Arch Intern Med* 1994;154:1977-82.

Denke MA. Review of human studies evaluating individual dietary responsiveness in patients with hypercholesterolemia. *Am J Clin Nutr* 1995;62:471S-77S.

Despres JP. Abdominal obesity as important component of insulin-resistance syndrome. *Nutrition* 1993;9:452-9.

Despres JP. The insulin resistance-dyslipidemic syndrome of visceral obesity: effect on patients' risk. *Obes Res* 1998;6(suppl 1):8S-17S.

Detrano RC, Wong ND, Doherty TM, Shavelle RM, Tang W, Ginzton LE, Budoff MJ, Narahara KA. Coronary calcium does not accurately predict near-term future coronary events in high-risk adults. *Circulation* 1999;99:2633-8.

Devaraj S, Vega G, Lange R, Grundy SM, Jialal I. Remnant-like particle cholesterol levels in patients with dysbetalipoproteinemia or coronary artery disease. *Am J Med* 1998;104:445-50.

Devlin JT. Effects of exercise on insulin sensitivity in humans. *Diabetes Care* 1992;15:1690-3.

Diabetes Control and Complications Trial Research Group (DCCT). The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. *N Engl J Med* 1993;329:977-86.

Dietrich AJ, O'Connor GT, Keller A, Carney PA, Levy D, Whaley FS. Cancer: improving early detection and prevention. A community practice randomised trial. *BMJ* 1992;304:687-91.

Do KA, Green A, Guthrie JR, Dudley EC, Burger HG, Dennerstein L. Longitudinal study of risk factors for coronary heart disease across the menopausal transition. *Am J Epidemiol* 2000;151:584-93.

Dolecek TA, Grandits G. Dietary polyunsaturated fatty acids and mortality in the Multiple Risk Factor Intervention Trial (MRFIT). *World Rev Nutr Diet* 1991;66:205-16.

Doll R, Gray R, Hafner B, Peto R. Mortality in relation to smoking: 22 years' observations on female British doctors. *BMJ* 1980;280:967-71.

Doll R, Peto R. Mortality in relation to smoking: 20 years' observations on male British doctors. *BMJ* 1976;2:1525-36.

Donner MG, Klein GK, Mathes PB, Schwandt P, Richter WO. Plasma total homocysteine levels in patients with early-onset coronary heart disease and a low cardiovascular risk profile. *Metabolism* 1998;47:273-9.

- Douzdjian V, Ferrara D, Silvestri G. Treatment strategies for insulin-dependent diabetics with ESRD: a cost-effectiveness decision analysis model. *Am J Kidney Dis* 1998;31:794-802.
- Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto AM Jr. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. *JAMA* 1998;279:1615-22.
- Drood JM, Zimetbaum PJ, Fishman WH. Nicotinic acid for the treatment of hyperlipoproteinemia. *J Clin Pharmacol* 1991;31:641-50.
- Duell PB, Connor WE, Illingworth DR. Rhabdomyolysis after taking atorvastatin with gemfibrozil. *Am J Cardiol* 1998;81:368-9.
- Dufour MC. If you drink alcoholic beverages do so in moderation: what does this mean? *J Nutr* 2001;131(suppl 1):552S-61S.
- Dunn FL, Grundy SM, Bilheimer DW, Havel RJ, Raskin P. Impaired catabolism of very low-density lipoprotein-triglyceride in a family with primary hypertriglyceridemia. *Metab* 1985;34:316-24.
- Durrington PN. Diabetic dyslipidaemia. *Baillieres Best Pract Res Clin Endocrinol Metab* 1999;13:265-78.
- Dyer AR, Liu K, Walsh M, Kiefe C, Jacobs DR Jr., Bild DE. Ten-year incidence of elevated blood pressure and its predictors: the CARDIA study. Coronary Artery Risk Development in (Young) Adults. *J Hum Hypertens* 1999;13:13-21.
- East C, Bilheimer DW, Grundy SM. Combination drug therapy for familial combined hyperlipidemia. *Ann Intern Med* 1988;109:25-32.
- East CA, Grundy SM, Bilheimer DW. Preliminary report: treatment of type 3 hyperlipoproteinemia with mevinolin. *Metabolism* 1986;35:97-8.
- Eaton CB, Bostom AG, Yanek L, Laurino JP, McQuade W, Hume A, Selhub J. Family history and premature coronary heart disease. *J Am Board Fam Pract* 1996;9:312-8.
- Ebara T, Ramakrishnan R, Steiner G, Shachter NS. Chylomicronemia due to apolipoprotein CIII overexpression in apolipoprotein E-null mice. Apolipoprotein CIII-induced hypertriglyceridemia is not mediated by effects on apolipoprotein E. *J Clin Invest* 1997;99:2672-81.
- Eccles M, Freemantle N, Mason J. North of England evidence based guideline development project: guideline on the use of aspirin as secondary prophylaxis for vascular disease in primary care. North of England Aspirin Guideline Development Group. *BMJ* 1998;316:1303-9.
- Eckel RH, Krauss RM. American Heart Association call to action: obesity as a major risk factor for coronary heart disease. AHA Nutrition Committee. *Circulation* 1998;97:2099-100.

Eckel RH. Obesity and heart disease: a statement for healthcare professionals from the Nutrition Committee, American Heart Association. *Circulation* 1997;96:3248-50.

Eddy DM, Hasselblad V, McGivney W, Hendee W. The value of mammography screening in women under age 50 years. *JAMA* 1988;259:1512-9.

Edelson JT, Weinstein MC, Tosteson AN, Williams L, Lee TH, Goldman L. Long-term cost-effectiveness of various monotherapies for mild to moderate hypertension. *JAMA* 1990;263:407-13.

Edelstein SL, Knowler WC, Bain RP, Andres R, Barrett-Connor EL, Dowse GK, Haffner SM, Pettitt DJ, Sorkin JD, Muller DC, Collins VR, Hamman RF. Predictors of progression from impaired glucose tolerance to NIDDM: an analysis of six prospective studies. *Diabetes* 1997;46:701-10.

Edmonds D, Foerster E, Groth H, Greminger P, Siegenthaler W, Vetter W. Does self-measurement of blood pressure improve patient compliance in hypertension? *J Hypertens Suppl* 1985;3:S31-S34.

Eisenberg S, Gavish D, Oschry Y, Fainaru M, Deckelbaum RJ. Abnormalities in very low, low and high density lipoproteins in hypertriglyceridemia. Reversal toward normal with bezafibrate treatment. *J Clin Invest* 1984;74:470-82.

Eisenhauer T, Armstrong VW, Wieland H, Fuchs C, Nebendahl K, Scheler F, Seidel D. Selective continuous elimination of low density lipoproteins (LDL) by heparin precipitation: first clinical application. *ASAIO Trans* 1986;32:104-7.

Ekelund LG, Haskell WL, Johnson JL, Whaley FS, Criqui MH, Sheps DS. Physical fitness as a predictor of cardiovascular mortality in asymptomatic North American men: the Lipid Research Clinics Mortality Follow-up Study. *N Engl J Med* 1988;319:1379-84.

Elam MB, Hunninghake DB, Davis KB, Garg R, Johnson C, Egan D, Kostis JB, Sheps DS, Brinton EA. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: A randomized trial. Arterial Disease Multiple Intervention Trial. *JAMA* 2000;284:1263-70.

Ellen RL, McPherson R. Long-term efficacy and safety of fenofibrate and a statin in the treatment of combined hyperlipidemia. *Am J Cardiol* 1998;81:60B-65B.

Enas EA, Yusuf S, Sharma S. Coronary artery disease in South Asians. Second meeting of the International Working Group. 16 March 1997, Anaheim, California. *Indian Heart J* 1998;50:105-13.

Endo A. The discovery and development of HMG-CoA reductase inhibitors. *J Lipid Res* 1992;33:1569-82.

- Ericsson CG, Hamsten A, Nilsson J, Grip L, Svane B, de Faire U. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. *Lancet* 1996;347:849-53.
- Ernst E. Fibrinogen: its emerging role as a cardiovascular risk factor. *Angiology* 1994;45:87-93.
- Ernst ND, Sempos CT, Briefel RR, Clark MB. Consistency between U.S. dietary fat intake and serum total cholesterol concentrations: the National Health and Nutrition Examination Surveys. *Am J Clin Nutr* 1997;66(suppl 4):965S-72S.
- Esrey KL, Joseph L, Grover SA. Relationship between dietary intake and coronary heart disease mortality: lipid research clinics prevalence follow-up study. *J Clin Epidemiol* 1996;49:211-6.
- Etchason JA, Miller TD, Squires RW, Allison TG, Gau GT, Marttila JK, Kottke BA. Niacin-induced hepatitis: a potential side effect with low-dose time-release niacin. *Mayo Clinic Proc* 1991;66:23-8.
- Evans RW, Shaten BJ, Hempel JD, Cutler JA, Kuller LH. Homocyst(e)ine and risk of cardiovascular disease in the Multiple Risk Factor Intervention Trial. *Arterioscler Thromb Vasc Biol* 1997;17:1947-53.
- Everson GT, Daggy BP, McKinley C, Story J. Effects of psyllium hydrophilic mucilloid on LDL-synthesis and bile acid synthesis in hypercholesterolemic men. *J Lipid Res* 1992;33:1183-92.
- Executive Committee for the Asymptomatic Carotid Atherosclerosis Study. Endarterectomy for Asymptomatic Carotid Artery Stenosis. *JAMA* 1995;273:1421-8.
- Faergemén O. New British recommendations for prevention of coronary heart disease in clinical practice [Editorial]. *Heart* 1999;81:335.
- Falk E, Shah PK, Fuster V. Coronary plaque disruption. *Circulation* 1995;92:657-71.
- Falkner B, Sherif K, Sumner AE, Kushner H. Blood pressure increase with impaired glucose tolerance in young adult American blacks. *Hypertension* 1999;34:1086-90.
- Farnier M, Dejager S. Effect of combined fluvastatin-fenofibrate therapy compared with fenofibrate monotherapy in severe primary hypercholesterolemia. French Fluvastatin Study Group. *Am J Cardiol* 2000;85:53-7.
- Farrell SW, Kampert JB, Kohl HW III, Barlow CE, Macera CA, Paffenbarger RS Jr., Gibbons LW, Blair SN. Influences of cardiorespiratory fitness levels and other predictors on cardiovascular disease mortality in men. *Med Sci Sports Exerc* 1998;30:899-905.
- Feher M, Webb JC, Patel DD, Lant AF, Mayne PD, Knight BL, Soutar AK. Cholesterol-lowering drug therapy in a patient with receptor-negative homozygous familial hypercholesterolaemia. *Atherosclerosis* 1993;103:171-80.



Feit F, Brooks MM, Sopko G, Keller NM, Rosen A, Krone R, Berger PB, Shemin R, Attubato MJ, Williams DO, Frye R, Detre KM. Long-term clinical outcome in the Bypass Angioplasty Revascularization Investigation registry: comparison with the randomized trial. BARI Investigators. *Circulation* 2000;101:2795-802.

Ferguson GC, Eliasziw M, Barr HW, Clagett P, Barnes RW, Wallace C, Taylor W, Haynes B, Finan JW, Hachinski VC, Barnett HJ, for the North American Symptomatic Carotid Endarterectomy Trial (NASCET) Collaborators. The North American Symptomatic Carotid Endarterectomy Trial. Surgical Results in 1415 Patients. *Stroke* 1999;30:1751-8.

Ferguson JA, Tierney WM, Westmoreland GR, Mamlin LA, Segar DS, Eckert GJ, Zhou X, Martin DK, Weinberger M. Examination of racial differences in management of cardiovascular disease. *J Am Coll Cardiol* 1997;30:1707-13.

Finnerty FA Jr., Shaw LW, Himmelsbach CK. Hypertension in the inner city. II. Detection and follow-up. *Circulation* 1973;47:76-8.

Fiscella K, Franks P. Cost-effectiveness of the transdermal nicotine patch as an adjunct to physicians' smoking cessation counseling. *JAMA* 1996;275:1247-51.

Fitzgibbon ML, Stolley MR, Kirschenbaum DS. An obesity prevention pilot program for African-American mothers and daughters. *J Nutr Educ* 1995;27:93-9.

Fletcher GF, Balady G, Blair SN, Blumenthal J, Caspersen C, Chaitman B, Epstein S, Sivarajan Froelicher ES, Froelicher VF, Pina IL, Pollock ML. Statements on exercise: benefits and recommendations for physical activity programs for all Americans. A statement for health professionals by the Committee on Exercise and Cardiac Rehabilitation of the Council on Clinical Cardiology. American Heart Association. *Circulation* 1996;94:857-62.

Fodor JG, Frohlich JJ, Genest JJ Jr., McPherson PR. Recommendations for the management and treatment of dyslipidemia. Report of the Working Group on Hypercholesterolemia and Other Dyslipidemias. *CMAJ* 2000;162:1441-7.

Folsom AR, Nieto FJ, McGovern PG, Tsai MY, Malinow MR, Eckfeldt JH, Hess DL, Davis CE. Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphisms, and B vitamins: the Atherosclerosis Risk in Communities (ARIC) study. *Circulation* 1998;98:204-10.

Fonorow G, Gawlinski A. Rationale and design of the Cardiac Hospitalization Atherosclerosis Management Program at the University of California, Los Angeles. *Am J Cardiol* 2000;85:10A-17A.

Fontbonne AM, Eschwege EM. Insulin and cardiovascular disease. Paris Prospective Study. *Diabetes Care* 1991;14:461-9.

- Foody JM, Milberg JA, Robinson K, Pearce GL, Jacobsen DW, Sprecher DL. Homocysteine and lipoprotein(a) interact to increase CAD risk in young men and women. *Arterioscler Thromb Vasc Biol* 2000;20:493-9.
- Ford ES. Body mass index, diabetes, and C-reactive protein among U.S. adults. *Diabetes Care* 1999;22:1971-7.
- Fortson MR, Freedman SN, Webster PD III. Clinical assessment of hyperlipidemic pancreatitis. *Am J Gastroenterol* 1995;90:2134-9.
- Franceschi S, Favero A, Decarli A, Negri E, LaVecchia C, Ferraroni M, Russo A, Salvini S, Amadori D, Conti E, Montella M, Giacosa A. Intake of macronutrients and risk of breast cancer. *Lancet* 1996;347:1351-6.
- Franklin SS, Khan SA, Wong ND, Larson MG, Levy D. Is pulse pressure useful in predicting risk for coronary heart disease? The Framingham Heart Study. *Circulation* 1999;100:354-60.
- Frantz ID Jr., Dawson EA, Ashman PI, Gatewood LC, Bartsch GE, Kuba K, Brewer ER. Test of effect of lipid lowering by diet on cardiovascular risk. The Minnesota Coronary Survey. *Arteriosclerosis* 1989;9:129-35.
- Fredrickson DS, Levy RI, Lees RS. Fat transport in lipoproteins – an integrated approach to mechanisms and disorders. *N Engl J Med* 1967a;276:34-42.
- Fredrickson DS, Levy RI, Lees RS. Fat transport in lipoproteins – an integrated approach to mechanisms and disorders (continued). *N Engl J Med* 1967b;276:94-103.
- Fredrickson DS, Levy RI, Lees RS. Fat transport in lipoproteins – an integrated approach to mechanisms and disorders (continued). *N Engl J Med* 1967c;276:148-56.
- Fredrickson DS, Levy RI, Lees RS. Fat transport in lipoproteins – an integrated approach to mechanisms and disorders (continued). *N Engl J Med* 1967d;276:215-25.
- Fredrickson DS, Levy RI, Lees RS. Fat transport in lipoproteins – an integrated approach to mechanisms and disorders (concluded). *N Engl J Med* 1967e;276:273-81.
- Freis ED. The efficacy and safety of diuretics in treating hypertension. *Ann Intern Med* 1995;122:223-6.
- Frick MH, Elo MO, Haapa K, Heinonen OP, Heinsalmi P, Helo P, Huttunen JK, Kaitaniemi P, Koskinen P, Manninen V. Helsinki Heart Study: Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. *N Engl J Med* 1987;317:1237-45.

Frick MH, Syvanne M, Nieminen MS, Kauma H, Majahalme S, Virtanen V, Kesaniemi YA, Pasternack A, Taskinen MR. Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lopid Coronary Angiography Trial (LOCAT) Study Group. *Circulation* 1997;96:2137-43.

Friedewald WT, Levy RI, Frederickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. *Clin Chem* 1972;18:499-502.

Friedman RH, Kazis LE, Jette A, Smith MB, Stollerman J, Torgerson J, Carey K. A telecommunications system for monitoring and counseling patients with hypertension. Impact on medication adherence and blood pressure control. *Am J Hypertens* 1996;9:285-92.

Frohlich J, Fodor G, McPherson R, Genest J, Langner N. Rationale for and outline of the recommendations of the Working Group on Hypercholesterolemia and Other Dyslipidemias: interim report. Dyslipidemia Working Group of Health Canada. *Can J Cardiol* 1998;14(suppl A):17A-21A.

Frolkis JP, Zyzanski SJ, Schwartz JM, Suhan PS. Physician noncompliance with the 1993 National Cholesterol Education Program (NCEP-ATP II) guidelines. *Circulation* 1998;98:851-5.

Frost PH, Havel RJ. Rationale for use of non-high-density lipoprotein cholesterol rather than low-density lipoprotein cholesterol as a tool for lipoprotein cholesterol screening and assessment of risk and therapy. *Am J Cardiol* 1998;81:26B-31B.

Fruchart JC, Brewer HB Jr., Leitersdorf E. Consensus for the use of fibrates in the treatment of dyslipoproteinemia and coronary heart disease. Fibrate Consensus Group. *Am J Cardiol* 1998;81:912-7.

Furberg CD, Adams HP Jr., Applegate WB, Byington RP, Espeland MA, Hartwell T, Hunninghake DB, Lefkowitz DS, Probstfield J, Riley WA, Young B. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. *Circulation* 1994;90:1679-87.

Fuster V, Fayad ZA, Badimon JJ. Acute coronary syndromes: biology. *Lancet* 1999;353(suppl 2):SII5-9.

Fuster V, Lewis A. Conner Memorial Lecture. Mechanisms leading to myocardial infarction: insights from studies of vascular biology. *Circulation* 1994;90:2126-46.

Galton DJ. Common genetic determinants of dyslipidemia: the hypertriglyceridemia/low-high-density lipoprotein syndrome. *J Cardiovasc Pharmacol* 1995;25(suppl 4):S35-40.

Gans KM, Lapane KL, Lasater TM, Carleton RA. Effects of intervention on compliance to referral and lifestyle recommendations given at cholesterol screening programs. *Am J Prev Med* 1994;10:275-82.

Gans KM, Sundaram SG, McPhillips JB, Hixson ML, Linnan L, Carleton RA. Rate your plate: An eating pattern assessment and educational tool used at cholesterol screening and education programs. *J Nutr Educ* 1993;25:29-36.

Gans KM, Sundaram SG, McPhillips JB, Hixson ML, Linnan L, Carleton RA. Rate your plate: An eating pattern assessment and educational tool used at cholesterol screening and education programs. *J Nutr Educ* 1993;25:29-36.

Gardner CD, Fortmann SP, Krauss RM. Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. *JAMA* 1996;276:875-81.

Garg A, Bantle JP, Henry RR, Coulston AM, Griver KA, Raatz SK, Brinkley L, Chen YD, Grundy SM, Huet BA, et al. Effects of varying carbohydrate content of diet in patients with non-insulin-dependent diabetes mellitus. *JAMA* 1994;271:1421-8.

Garg A, Grundy SM, Unger RH. Comparison of effects of high and low carbohydrate diets on plasma lipoproteins and insulin sensitivity in patients with mild NIDDM. *Diabetes* 1992;41:1278-85.

Garg A, Grundy SM. Cholestyramine therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. A short-term, double-blind, crossover trial. *Ann Intern Med* 1994;121:416-22.

Garg A, Grundy SM. Gemfibrozil alone and in combination with lovastatin for treatment of hypertriglyceridemia in NIDDM. *Diabetes* 1989;38:364-72.

Garg A, Grundy SM. Nicotinic acid as therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. *JAMA* 1990;264:723-6.

Garg A. High-monounsaturated-fat diets for patients with diabetes mellitus: a meta-analysis. *Am J Clin Nutr* 1998;67(suppl 3):577S-82S.

Garg A. Lipodystrophies. *Am J Med* 2000;108:142-52.

Garrison RJ, Wilson PW, Castelli WP, Feinleib M, Kannel WB, McNamara PM. Obesity and lipoprotein cholesterol in the Framingham offspring study. *Metabolism* 1980;29:1053-60.

Gavin JR III. Diabetes in Minorities: Reflections on the medical dilemma and the health care crisis. *Trans Am Clin Climatol Assoc* 1995;107:213-23.

Gavin JR, Alberti KGMM, Davidson MB, DeFronzo RA, Drash A, Gabbe SG, Genuth S, Harris MI, Kahn R, Keen H, Knowler WC, Lebovitz H, Maclaren NK, Palmer JP, Raksin P, Rizza RA, Stern MP. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. *Diabetes Care* 1998;21:S5-S19.

Gavish D, Oschry Y, Fainaru M, Eisenberg S. Change in very low-, low- and high-density lipoproteins during lipid-lowering (bezafibrate) therapy: studies in type IIA and type IIB hyperlipoproteinemia. *Eur J Clin Invest* 1986;16:61-8.

- Gerstein HC, Pais P, Pogue J, Yusuf S. Relationship of glucose and insulin levels to the risk of myocardial infarction: a case-control study. *J Am Coll Cardiol* 1999;33:612-9.
- Gibbons LW, Gonzalez V, Gordon N, Grundy S. The prevalence of side effects with regular and sustained-release nicotinic acid. *Am J Med* 1995;99:378-85.
- Giles WH, Croft JB, Greenlund KJ, Ford ES, Kittner SJ. Association between total homocyst(e)ine and the likelihood for a history of acute myocardial infarction by race and ethnicity: Results from the Third National Health and Nutrition Examination Survey. *Am Heart J* 2000;139:446-53.
- Gillum RF, Mussolino ME, Madans JH. Coronary heart disease incidence and survival in African-American women and men. The NHANES I Epidemiologic Follow-up Study. *Ann Intern Med* 1997;127:111-8.
- Gillum RF. Sudden cardiac death in Hispanic Americans and African Americans. *Am J Public Health* 1997;87:1461-6.
- Ginsberg HN, Kris-Etherton P, Dennis B, Elmer PJ, Ershow A, Lefevre M, Pearson T, Roheim P, Ramakrishnan R, Reed R, Stewart K, Stewart P, Phillips K, Anderson N, for the Delta Research Group. Effects of reducing dietary saturated fatty acids on plasma lipids and lipoproteins in healthy subjects. The Delta Study, Protocol 1. *Arterioscler Thromb Vasc Biol* 1998;18:441-9.
- Giovannucci E, Goldin B. The role of fat, fatty acids, and total energy intake in the etiology of human colon cancer. *Am J Clin Nutr* 1997;66(suppl 6):1564S-71S.
- GISSI-Prevenzione Investigators. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. *Lancet* 1999;354:447-55.
- Gjonca A, Bobak M. Albanian paradox, another example of protective effect of Mediterranean lifestyle? *Lancet* 1997;350:1815-17.
- Glanz K, Patterson RE, Kristal AR, DiClemente CC, Heimendinger J, Linnan L, McLerran DF. Stages of change in adopting healthy diets: fat, fiber, and correlates of nutrient intake. *Health Educ Q* 1994;21:499-519. [Erratum, *Health Educ Q* 1994;22:261].
- Glasziou PP, Mulray SE, Hall JP, Martin A, Harris P, Thompson P, Tonkin A, Simes RJ. Cost effectiveness with pravastatin in patients with coronary heart disease and average cholesterol level (abstract). *Med Decis Making* 1998;18:475.
- Glick H, Heyse JF, Thompson D, Epstein RS, Smith ME, Oster G. A model for evaluating the cost-effectiveness of cholesterol-lowering treatment. *Int J Tech Assess Health Care* 1992;8:719-34.
- Glueck CJ, Gartside F, Fallart RW, Sielski J, Steiner PM. Longevity syndromes: Familial hypobeta- and familial hyperalphalipoproteinemia. *J Lab Clin Med* 1976;88:941-57.

Glueck CJ, Gordon DJ, Nelson JJ, Davis CE, Tyroler HA. Dietary and other correlates of changes in total and low density lipoprotein cholesterol in hypercholesterolemic men: the Lipid Research Clinics Coronary Primary Prevention Trial. *Am J Clin Nutr* 1986;44:489-500.

Gokal R, Mann JI, Moore RA, Morris PJ. Hyperlipidaemia following renal transplantation: a study of the prevalence, "natural history," and dietary treatment. *Q J Med* 1979;48:507-17.

Goldberg A, Alagona P Jr., Capuzzi DM, Guyton J, Morgan JM, Rodger J, Sachson R, Samuel P. Multiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemia. *Am J Cardiol* 2000;85:1100-5.

Goldberg AC, Schonfeld G, Feldman EB, Ginsberg HN, Hunninghake DB, Insull W, Knopp RH Jr., Kwiterovich PO, Mellies MJ, Pickering J, Samuel P. Fenofibrate for the treatment of type IV and V hyperlipoproteinemias: a double-blind, placebo-controlled multicenter U.S. study. *Clin Ther* 1989;11:69-83.

Goldberg RB, Mellies MJ, Sacks FM, Moyé LA, Howard BV, Howard WJ, Davis BR, Cold TG, Pfeffer MA, Braunwald E. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels. Subgroup analyses in the cholesterol and recurrent events (CARE) trial. *Circulation* 1998;98:2513-9.

Goldberg RJ, Burchfiel CM, Benfante R, Chiu D, Reed DM, Yano K. Lifestyle and biologic factors associated with atherosclerotic disease in middle-aged men. 20-year findings from the Honolulu Heart Program. *Arch Intern Med* 1995;155:686-94.

Goldman JA, Fishman AB, Lee JE, Johnson RJ. The role of cholesterol-lowering agents in drug-induced rhabdomyolysis and polymyositis. [Letter to the Editor]. *Arthritis Rheum* 1989;32:358-9.

Goldman L, Coxson P, Hunink MG, Goldman PA, Tosteson AN, Mittleman M, Williams L, Weinstein MC. The relative influence of secondary versus primary prevention using the National Cholesterol Education Program Adult Treatment Panel II guidelines. *J Am Coll Cardiol* 1999;34:768-76.

Goldstein JL, Brown MS. Familial hypercholesterolemia. In: Scriver CR, Beaud et al., Sly WS, Vallee D, eds. *The metabolic basis of inherited disease*. New York: McGraw-Hill, 1989;1215-50.

Goldstein JL, Brown MS. Familial hypercholesterolemia. In: Scriver CR, Beaud et al., Sly WS, Valle D, eds. *The metabolic basis of inherited disease*. New York: McGraw-Hill, 1995; 198-203.

Goldstein JL, Hazzard WR, Schrott HG, Bierman EL, Motulsky AG. Hyperlipidemia in coronary heart disease. I. Lipid levels in 500 survivors of myocardial infarction. *J Clin Invest* 1973a;52:1533-43.

Goldstein JL, Schrott HG, Hazzard WR, Bierman EL, Motulsky AG. Hyperlipidemia in coronary heart disease. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. *J Clin Invest* 1973b;52:1544-68.

Golper TA, Illingworth DR, Morris CD, Bennett WM. Lovastatin in the treatment of multifactorial hyperlipidemia associated with proteinuria. *Am J Kidney Dis* 1989;13:312-20.

Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD, Jacobs DR Jr., Bangdiwala S, Tyroler HA. High-density lipoprotein cholesterol and cardiovascular disease: Four prospective American studies. *Circulation* 1989;79:8-15.

Gordon DJ. Cholesterol lowering and total mortality. In: Rifkind BM, ed. Contemporary issues in cholesterol lowering: clinical and population aspects. New York: Marcel Dekker Inc., 1994;33-48.

Gordon DJ. Cholesterol and mortality: what can meta-analysis tell us. In: Gallo LL, ed. Cardiovascular disease 2: cellular and molecular mechanisms, prevention, and treatment. New York: Plenum Press, 1995a;333-40.

Gordon DJ. Cholesterol lowering and total mortality. In: Rifkind BM, ed. Lowering cholesterol in high-risk individuals and populations. New York: Marcel Dekker Inc., 1995b;33-47.

Gordon DJ. Cholesterol lowering reduces mortality: the statins. In: Grundy SM, ed. Cholesterol-lowering therapy: evaluation of clinical trial evidence. New York: Marcel Dekker Inc., 2000; 299-311.

Gotto AM Jr., Grundy SM. Lowering LDL cholesterol: questions from recent meta-analyses and subset analyses of clinical trial data issues from the Interdisciplinary Council on Reducing the Risk for Coronary Heart Disease, Ninth Council Meeting. *Circulation* 1999;99:E1-7.

Gotto AM Jr., Whitney E, Stein EA, Shapiro DR, Clearfield M, Weis S, Jou JY, Langendörfer A, Beere PA, Watson DJ, Downs JR, de Cani JS. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). *Circulation* 2000;101:477-84.

Gould AL, Rossouw JE, Santanello NC, Heyse JF, Furberg CD. Cholesterol reduction yields clinical benefit: a new look at old data. *Circulation* 1995;91:2274-82.

Gould AL, Rossouw JE, Santanello NC, Heyse JF, Furberg CD. Cholesterol reduction yields clinical benefit: impact of statin trials. *Circulation* 1998;97:946-52.

Government Printing Office, ed. Reducing the health consequences of smoking: 25 years of progress. Washington D.C.: Government Printing Office, 1989:702 pages.

Grady D, Wenger NK, Herrington D, Khan S, Furberg CD, Hunninghake D, Vittinghoff E, Hulley S. Postmenopausal hormone therapy increases risk for thromboembolic disease: the heart and estrogen/progestin replacement study (HERS). *Ann Intern Med* 2000;132:689-96.

Graham IM, Daly LE, Refsum HM, Robinson K, Brattström LE, Ueland PM, Palma-Reis RJ, Boers GHJ, Sheahan RG, Israelsson B, Uiterwaa CS, Meleady R, McMaster D, Verhoef P, Witteman J, Rubba P, Bellet H, Wautrecht JC, deValk HW, Sales Luis AC, Parrot-Rouland FM, Tan KS, Higgins I, Garcon D, Medrano MJ, Candito M, Evans AE, Andria G. Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. *JAMA* 1997;277:1775-81.

Graham NM. Metabolic disorders among HIV-infected patients treated with protease inhibitors: a review. *J Acquir Immune Defic Syndr* 2000;25(suppl 1):S4-11.

Granfone A, Campos H, McNamara JR, Schaefer MM, Lamon-Fava S, Ordovas JM, Schaefer EJ. Effects of estrogen replacement on plasma lipoproteins and apolipoproteins in postmenopausal, dyslipidemic women. *Metabolism* 1992;41:1193-8.

Greenberg BH, Blackwelder WC, Levy RI. Primary type V hyperlipoproteinemia. A descriptive study in 32 families. *Ann Intern Med* 1977;87:526-34.

Greenland P, Abrams J, Aurigemma GP, Bond MG, Clark LT, Criqui MH, Crouse JR III, Friedman L, Fuster V, Herrington DM, Kuller LH, Ridker PM, Roberts WC, Stanford W, Stone N, Swan HJ, Taubert KA, Wexler L. Prevention Conference V: Beyond secondary prevention: identifying the high-risk patient for primary prevention: noninvasive tests of atherosclerotic burden: Writing Group III. *Circulation* 2000;101:E16-22.

Greenwald P, Sherwood K, McDonald SS. Fat, caloric intake, and obesity: lifestyle risk factors for breast cancer. *J Am Diet Assoc* 1997;97(suppl 7):S24-30.

Grimley DM, Prochaska JO, Velicer WF, Prochaska GE. Contraceptive and condom use adoption and maintenance: a stage paradigm approach. *Health Educ Q* 1995;22:20-35.

Groop LC. Insulin resistance: the fundamental trigger of type 2 diabetes. *Diabetes Obes Metab* 1999;1(suppl 1):S1-7.

Group of Physicians of the Newcastle-upon-Tyne Region. Trial of clofibrate in the treatment of ischaemic heart disease: five year study by a group of physicians of the New Castle-upon-Tyne region. *BMJ* 1971;4:767-75.

Grover SA, Abrahamowicz M, Joseph L, Brewer C, Coupal L, Suissa S. The benefits of treating hyperlipidemia to prevent coronary heart disease. *JAMA* 1992;267:816-22.

Grover SA, Coupal L, Paquet S, Zowall H. Cost-effectiveness of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the secondary prevention of cardiovascular disease: forecasting the incremental benefits of preventing coronary and cerebrovascular events. *Arch Intern Med* 1999;159:593-600.

Gruer PJ, Vega JM, Mercuri MF, Dobruska MR, Tobert JA. Concomitant use of cytochrome P-450 3A4 inhibitors and simvastatin. *Am J Cardiol* 1999;84:811-5.



Grundy SM, Ahrens EH Jr., Salen G. Interruption of the enterohepatic circulation of bile acids in apolipoprotein E-3/E-2 pattern. *Metabolism* 1992;41:241-5.

Grundy SM, Barrett-Connor E, Rudel LL, Miettinen T, Spector AA. Workshop on the impact of dietary cholesterol on plasma lipoproteins and atherogenesis. *Arteriosclerosis* 1988;8:95-101.

Grundy SM, Bazzarre T, Cleeman J, D'Agostino RB Sr., Hill M, Houston-Miller N, Kannel WB, Krauss R, Krumholz HM, Lauer RM, Ockene IS, Pasternak RC, Pearson T, Ridker PM, Wood D. Prevention Conference V: Beyond secondary prevention: identifying the high-risk patient for primary prevention: medical office assessment: Writing Group I. *Circulation* 2000;101:E3-11.

Grundy SM, Blackburn G, Higgins M, Lauer R, Perri MG, Ryan D. Physical activity in the prevention and treatment of obesity and its comorbidities: evidence report of independent panel to assess the role of physical activity in the treatment of obesity and its comorbidities. *Med Sci Sports Exerc* 1999a;31:1493-500.

Grundy SM, Cleeman JI, Rifkind BM, Kuller LH. Cholesterol lowering in the elderly population. *Arch Intern Med* 1999b;159:1670-8.

Grundy SM, D'Agostino RD Sr., Mosca L, Burke G, Wilson PWF, Rader D, Cleeman JI, Roccella E, Cutler JA, Friedman L. Cardiovascular Risk Assessment Based on U.S. Cohort Studies: findings from a National Heart, Lung, and Blood Institute workshop. *Circulation* 2001a;104:491-6.

Grundy SM, Denke MA. Dietary influences on serum lipids and lipoproteins. *J Lipid Res* 1990;31:1149-72.

Grundy SM, ed. Cholesterol-lowering trials: a historical perspective. In: Grundy SM, ed. Cholesterol lowering therapy: evaluation of clinical trial evidence. New York: Marcel Dekker Inc., 2000a;1-329.

Grundy SM, Mok HY, Zech L, Berman M. Influence of nicotinic acid on metabolism of cholesterol and triglycerides in man. *J Lipid Res* 1981;22:24-36.

Grundy SM, Mok HY, Zech L, Steinberg D, Berman M. Transport of very low density lipoprotein triglycerides in varying degrees of obesity and hypertriglyceridemia. *J Clin Invest* 1979;63:1274-83.

Grundy SM, Pasternak R, Greenland P, Smith S Jr., Fuster V. Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. *Circulation* 1999c;100:1481-92.

Grundy SM, Vega GL, McGovern ME. Effects of extended-release niacin on lipoproteins and glycemic control in patients with type 2 diabetes mellitus: results of a randomized, double-blind, placebo-controlled multicenter trial. *JACC* 2001b;37(suppl A):249A.

Grundey SM, Wilhelmsen L, Rose G, Campbell RW, Assmann G. Coronary heart disease in high-risk populations: lessons from Finland. *Eur Heart J* 1990;11:462-71.

Grundey SM. Early detection of high cholesterol levels in young adults[Editorial]. *JAMA* 2000b;284:365-7.

Grundey SM. Primary prevention of coronary heart disease: integrating risk assessment with intervention. *Circulation* 1999b;100:988-98.

Grundey SM. Comparison of monounsaturated fatty acids and carbohydrates for lowering plasma cholesterol. *N Engl J Med* 1986;314:745-8.

Grundey SM. Coronary plaque as a replacement for age as a risk factor in global risk assessment. *Am J Cardiol* 2001;88(2-A):8E-11E.

Grundey SM. George Lyman Duff Memorial Lecture. Multifactorial etiology of hypercholesterolemia. Implications for prevention of coronary heart disease. *Arterioscler Thromb* 1991;11:1619-35.

Grundey SM. Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrome. *Am J Cardiol* 1998a;81:18B-25B.

Grundey SM. Hypertriglyceridemia, insulin resistance, and the metabolic syndrome. *Am J Cardiol* 1999a;83:25F-29F.

Grundey SM. Management of hyperlipidemia of kidney disease. *Kidney Int* 1990;37:847-53.

Grundey SM. Statin trials and goals of cholesterol-lowering therapy. *Circulation* 1998b;97:1436-9.

Gustafsson I, Hildebrandt P, Seibaek M, Melchior T, Torp-Pedersen C, Kober L, Kaiser-Nielsen P, and the TRACE Study Group. Long-term prognosis of diabetic patients with myocardial infarction: relation to antidiabetic treatment regimen. *Eur Heart J* 2000;21:1937-43.

Guyton JR, Blazing MA, Hagar J, Kashyap ML, Knopp RH, McKenney JM, Nash DT, Nash SD. Extended-release niacin vs. gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Niaspan-Gemfibrozil Study Group. *Arch Intern Med* 2000;160:1177-84.

Guyton JR, Capuzzi DM. Treatment of hyperlipidemia with combined niacin-statin regimens. *Am J Cardiol* 1998;82:82U-84U; discussion 85U-86U.

Guyton JR, Goldberg AC, Kreisberg RA, Sprecker DL, Superko HR, O'Connor CM. Effectiveness of once-nightly dosing of extended release niacin alone and in combination for hypercholesterolemia. *Am J Cardiol* 1998;82:737-43.

Guyton JR. Treatment of type III hyperlipoproteinemia. *Am Heart J* 1999;138:17-8.

Gylling H, Miettinen TA. Lipid lowering during concomitant cholesterol synthesis inhibition and cholesterol and bile acid malabsorption in coronary patients. *Circulation* 1999b;100:1-825.

Gylling H, Miettinen TA. Cholesterol reduction by different plant stanol mixtures and with variable fat intake. *Metabolism* 1999a;48:575-80.

Gylling H, Miettinen TA. Serum cholesterol and cholesterol and lipoprotein metabolism in hypercholesterolaemic NIDDM patients before and during sitostanol ester-margarine treatment. *Diabetol* 1994;37:773-80.

Gylling H, Radhakrishnan R, Miettinen TA. Reduction of serum cholesterol in postmenopausal women with previous myocardial infarction and cholesterol malabsorption induced by dietary sitostanol ester margarine: women and dietary sitostanol. *Circulation* 1997;96:4226-31.

Gylling H, Siimes MA, Miettinen TA. Sitostanol ester margarine in dietary treatment of children with familial hypercholesterolemia. *J Lipid Res* 1995;36:1807-12.

Gylling H. Studies of plant stanol esters in different patient populations. *European Heart Journal* 1999;1(suppl):S109-13.

Gyrd-Hansen D. The relative economics of screening for colorectal cancer, breast cancer and cervical cancer. *Crit Rev Oncol Hematol* 1999;32:133-44.

Haffner SM, Alexander CM, Cook TJ, Boccuzzi SJ, Musliner TA, Pedersen TR, Kjekshus J, Pyörälä K. Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses from the Scandinavian Simvastatin Survival Study. *Arch Intern Med* 1999a;159:2661-7.

Haffner SM, D'Agostino R Jr., Saad MF, O'Leary DH, Savage PJ, Rewers M, Selby J, Bergman RN, Mykkänen L. Carotid artery atherosclerosis in type 2 diabetic and non-diabetic subjects with and without symptomatic coronary artery disease: The Insulin Resistance Atherosclerosis Study. *Am J Cardiol* 2000;85:1395-400.

Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. *N Engl J Med* 1998;339:229-34.

Haffner SM, Miettinen H, Gaskill SP, Stern MP. Decreased insulin action and insulin secretion predict the development of impaired glucose tolerance. *Diabetologia* 1996;39:1201-7.

Haffner SM, Mykkänen L, Stern MP, Paldi M, Howard BV. Greater effect of diabetes on LDL size in women than in men. *Diabetes Care* 1994;17:1164-71.

Haffner SM. Epidemiology of insulin resistance and its relation to coronary artery disease. *Am J Cardiol* 1999;84:11J-14J.

Haffner SM. Impaired glucose tolerance: is it relevant for cardiovascular disease? *Diabetologia* 1997;40(suppl 2):S138-40.

- Hak AE, Stehouwer CD, Bots ML, Polderman KH, Schalkwijk CG, Westendorp IC, Hofman A, Witteman JC. Associations of c-reactive protein with measures of obesity, insulin resistance, and subclinical atherosclerosis in healthy, middle-aged women. *Arterioscler Thromb Vasc Biol* 1999;19:1986-91.
- Hallikainen MA, Uusitupa MI. Effects of 2 low-fat stanol ester-containing margarines on serum cholesterol concentrations as part of a low-fat diet in hypercholesterolemic subjects. *Am J Clin Nutr* 1999;69:403-10.
- Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S, Ménard J, Rahn KH, Wedel H, Westerling S. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. *Lancet* 1998;351:1755-62.
- Hanston PD, Horn JR. Drug interactions with HMG CoA reductase inhibitors. *Drug Interactions Newsletter* 1998;103-6.
- Hardman AE. Physical activity, obesity and blood lipids. *Int J Obes Relat Metab Disord* 1999;23(suppl 3):S64-71.
- Harnick DJ, Cohen JL, Schechter CB, Fuster V, Smith DA. Effects of practice setting on quality of lipid-lowering management in patients with coronary artery disease. *Am J Cardiol* 1998;81:1416-20.
- Harris WS, Rothrock DW, Fanning A, Inkeles SB, Goodnight SH, Illingworth DR, Connor W. Fish oils in hypertriglyceridemia: a dose-response study. *Am J Clin Nutr* 1990;51:399-406.
- Harris WS. Fish oils and plasma lipid and lipoprotein metabolism in humans: a critical review. *J Lipid Res* 1989;30:785-807.
- Harris WS. n-3 fatty acids and serum lipoproteins: human studies. *Am J Clin Nutr* 1997;65(suppl 5):1645-54.
- Harrison RA, Waterbor JW. Understanding meta-analysis in cancer epidemiology: dietary fat and breast cancer. *Cancer Detect Prev* 1999;23:97-106.
- Hartz AJ, Rupley DC, Kalkhoff RD, Rimm AA. Relationship of obesity to diabetes: influence of obesity level and body fat distribution. *Prev Med* 1983;12:351-7.
- Harvald B, Christiansen T, Pederson KM, Rasmussen K, Strate M, Thygesen K. Cost-benefit in treatment of mild hypertension. *Acta Medica Scandinavia* 1983;686:81-7.
- Harvey-Berino J. The efficacy of dietary fat vs. total energy restriction for weight loss. *Obes Res* 1998;6:202-7.

Haskell WL, Alderman EL, Fair JM, Maron DJ, Mackey SF, Superko HR, Williams PT, Johnstone IM, Champagne MA, Krauss RM, Farquhar JW. Effects of intensive multiple risk factor reduction on coronary atherosclerosis and clinical cardiac events in men and women with coronary artery disease: The Stanford Coronary Risk Intervention Project (SCRIP). *Circulation* 1994;89:975-90.

Hatziandreu EI, Koplan JP, Weinstein MC, Caspersen CJ, Warner KE. A cost-effectiveness analysis of exercise as a health promotion activity. *Am J Public Health* 1988;78:1417-21.

Havel RJ. Remnant lipoproteins as therapeutic targets. *Curr Opin Lipidol* 2000;11:615-20.

Havel RJ. Role of triglyceride-rich lipoproteins in progression of atherosclerosis. *Circulation* 1990;81:694-6.

Hay JW, Yu WM, Ashraf T. Pharmacoeconomics of lipid-lowering agents for primary and secondary prevention of coronary artery disease. *Pharmacoeconomics* 1999;15:47-74.

Haynes RB, Montague P, Oliver T, McKibbin KA, Brouwers MC, Kanani R. Interventions for helping patients follow prescription medications (Cochrane Review). In: The Cochrane Library, Issue 4, 1999. Oxford: Update Software.

Haynes RB, Sackett DL, Gibson ES, Taylor DW, Hackett BC, Roberts RS, Johnson AL. Improvement of medication compliance in uncontrolled hypertension. *Lancet* 1976;1:1265-8.

Hazzard WR, Goldstein JL, Schrott MG, Motulsky AG, Bierman EL. 3. Hyperlipidemia in coronary heart disease. Evaluation of lipoprotein phenotypes of 156 genetically defined survivors of myocardial infarction. *J Clin Invest* 1973;52:1569-77.

Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk persons. The Heart Outcomes Prevention Evaluation Study Investigators. *N Engl J Med* 2000a;342:145-53.

Heart Outcomes Prevention Evaluation Study Investigators. Vitamin E supplementation and cardiovascular events in high-risk patients. *N Engl J Med* 2000b;342:154-60.

Hebert PR, Gaziano JM, Chan KS, Hennekens CH. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. *JAMA* 1997;278:313-21.

Heiberg A. The risk of atherosclerotic vascular disease in subjects with xanthomatosis. *Acta Med Scand* 1975;198(4):249-61.

Heinonen TM, Schrott H, McKenney JM, Sniderman AD, Broyles FE, Zavoral JH, Kivel F, Black DM. Atorvastatin, a new HMG-CoA reductase inhibitor as monotherapy and combined with colestipol. *J Cardiovasc Pharmacol Therapeut* 1996;1:117-22.

Heiss G, Tamir I, Davis CE, Tyroler HA, Rifkind BM, Schonfeld G, Jacobs D, Frantz ID Jr. Lipoprotein-cholesterol distributions in selected North American populations: the lipid research clinics program prevalence study. *Circulation* 1980;61:302-15.

Heitmann BL, Lissner L, Sorensen TI, Bengtsson C. Dietary fat intake and weight gain in women genetically predisposed for obesity. *Am J Clin Nutr* 1995;61:1213-7.

Heller DA, de Faire U, Pedersen NL, Dahlen G, McClearn GE. Genetic and environmental influences on serum lipid levels in twins. *N Engl J Med* 1993;328:1150-6.

Helmrich SP, Ragland DR, Leung RW, Paffenbarger RS Jr. Physical activity and reduced occurrence of non-insulin-dependent diabetes mellitus. *N Engl J Med* 1991;325:147-52.

Hendriks HF, Weststrate JA, van Vliet T, Meijer GW. Spreads enriched with three different levels of vegetable oil sterols and the degree of cholesterol lowering in normocholesterolaemic and mildly hypercholesterolaemic subjects. *Eur J Clin Nutr* 1999;53:319-27.

Henken Y, Shap I, Zuk R, Brickner D, Zuilli I, Neumann L, Shany S. Dietary treatment of hypercholesterolemia: do dietitians do it better? A randomized controlled trial. *Am J Med* 2000;109:549-55.

Hennekens CH, Buring JE, Manson JE, Stampfer M, Rosner B, Cook NR, Belanger C, LaMotte F, Gaziano JM, Ridker PM, Willett W, Peto R. Lack of effect of long-term supplementation with beta-carotene on the incidence of malignant neoplasms and cardiovascular disease. *N Engl J Med* 1996;334:1145-9.

Hennekens CH, Dyken ML, Fuster V. Aspirin as a therapeutic agent in cardiovascular disease: a statement for healthcare professionals from the American Heart Association. *Circulation* 1997;96:2751-3.

Herd JA, Ballantyne CM, Farmer JA, Ferguson JJ, Jones PH, West MS, Gould KL, Gotto AM. Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS]); *Am J Cardiol* 1997;80:278-86.

Herlitz J, Karlson BW, Edwardsson N, Emanuelsson H, Hjalmarson A. Prognosis in diabetics with chest pain or other symptoms suggestive of acute myocardial infarction. *Cardiology* 1992;80:237-45.

Herlitz J, Karlson BW, Karlsson T, Lindqvist J, and Sjolín M. Predictors of death during 5 years after hospital discharge among patients with a suspected acute coronary syndrome with particular emphasis on whether an infarction was developed. *Int J Cardiol* 1998;66(1):73-80.

Herlitz J, Wognsen GB, Karlson BW, Sjöland H, Karlsson T, Caidahl K, Hartford M, Haglid M. Mortality, mode of death and risk indicators for death during 5 years after coronary artery bypass grafting among patients with and without a history of diabetes mellitus. *Coron Artery Dis* 2000;11:339-46.

Herrington DM, Reboussin DM, Brosnihan KB, Sharp PC, Shumaker SA, Snyder TE, Furberg CD, Kowalchuk GJ, Stuckey TD, Rogers WJ, Givens DH, Waters D. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. *N Engl J Med* 2000;343:522-9.

Hertzner NR. Fatal myocardial infarction following abdominal aortic aneurysm resection. Three hundred forty-three patients followed 6-11 years postoperatively. *Ann Surg* 1980;192:667-73.

Hirsch J, Hudgins LC, Leibel RL, Rosenbaum M. Diet composition and energy balance in humans. *Am J Clin Nutr* 1998;67(suppl):551S-5S.

Historic income tables—people. Retrieved from <http://www.census.gov/hhes/income/histinc/incperdet.html>.

Hjermann I, Holme I, Velve Byre K, Leren P. Effect of diet and smoking intervention on the incidence of coronary heart disease: report from the Oslo study group of a randomised trial in healthy men. *Lancet* 1981;2:1303-10.

Hlatky MA, Rogers WJ, Johnstone I, Boothroyd D, Brooks MM, Pitt B, Reeder G, Ryan T, Smith H, Whitlow P, Wiens R, Mark DB. Medical care costs and quality of life after randomization to coronary angioplasty or coronary bypass surgery. Bypass Angioplasty Revascularization Investigation (BARI) Investigators. *N Engl J Med* 1997;336:92-9.

Hobbs HH, Brown MS, Goldstein JL. Molecular genetics of the LDL receptor gene in familial hypercholesterolemia. *Hum Mutat* 1992;1:445-66.

Hobbs HH, Russell DW, Brown MS, Goldstein JL. The LDL receptor locus in familial hypercholesterolemia: mutational analysis of a membrane protein. *Annu Rev Genet* 1990;24:133-70.

Hobson RW 2nd, Weiss DG, Fields WS, Goldstone J, Moore WS, Towne JB, Wright CB. Efficacy of carotid endarterectomy for asymptomatic carotid stenosis. The Veterans Affairs Cooperative Study Group. *N Engl J Med* 1993;328:221-7.

Hodgson TA, Cohen AJ. Medical care expenditures for selected circulatory diseases. *Medical Care* 1999;37:994-1012.

Hodis HN, Mack WJ, Azen SP, Alaupovic P, Pogoda JM, LaBree L, Hemphill LC, Krams DM, Blankenhorn DH. Triglyceride- and cholesterol-rich lipoproteins have a differential effect on mild/moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin. *Circulation* 1994;90:42-9.

Hodis HN, Mack WJ, LaBree L, Selzer RH, Liu CR, Liu CH, Azen SP. The role of carotid arterial intima-media thickness in predicting clinical coronary events. *Ann Intern Med* 1998;128:262-9.

Hoerger TJ, Bala MV, Bray JW, Wilcosky TC, LaRosa J. Treatment patterns and distribution of low-density lipoprotein cholesterol levels in treatment-eligible United States adults. *Am J Cardiol* 1998;82:61-5.

Holme I. An analysis of randomized trials evaluating the effect of cholesterol reduction on total mortality and coronary heart disease incidence. *Circulation* 1990;82:1916-24.

Holme I. Relation of coronary heart disease incidence and total mortality to plasma cholesterol reduction in randomised trials: use of meta-analysis. *Br Heart J* 1993;69(suppl 1):S42-S7.

Holme I. Relationship between total mortality and cholesterol reduction as found by meta-regression analysis of randomized cholesterol-lowering trials. *Control Clin Trials* 1996;17:13-22.

Holmes CL, Schulzer M, Mancini GB. Angiographic results of lipid-lowering trials: a systematic review and meta-analysis. In: Grundy SM, ed. Cholesterol-lowering therapy: evaluation of clinical trial evidence. New York: Marcel Dekker Inc., 2000;191-220.

Holmes MD, Hunter DJ, Colditz GA, Stampfer MJ, Hankinson SE, Speizer FE, Rosner B, Willett WC. Association of dietary intake of fat and fatty acids with risk of breast cancer. *JAMA* 1999;281:914-20.

Homma Y, Mikami Y, Tamachi H, Nakaya N, Nakamura H, Araki G, Goto Y. Comparison of selectivity of LDL removal by double filtration and dextran-sulfate cellulose column plasmapheresis. *Atherosclerosis* 1986;60:23-7.

Honda T, Kai I, Ohi G: Fat and dietary fiber intake and colon cancer mortality: a chronological comparison between Japan and the United States. *Nutr Cancer* 1999;33:95-99.

Hong MK, Romm PA, Reagan K, Green CE, Rackley CE. Usefulness of the total cholesterol to high-density lipoprotein cholesterol ratio in predicting angiographic coronary artery disease in women. *Am J Cardiol* 1991;68:1646-50.

Hoogwerf BJ, Bantle JP, Kuba K, Frantz ID Jr., Hunninghake DB. Treatment of type III hyperlipoproteinemia with four different treatment regimens. *Atherosclerosis* 1984;51:251-9.

Hoogwerf BJ, Frolkis JP, Pearce GP, Vidt D, Pashkow FJ, Cross JA, Sprecher DL. Use of treatment algorithms by physician extenders in a preventive cardiology clinic for LDL-cholesterol, blood pressure, and HbA1c in diabetic patients. *Circulation* 1999a;100:1-100.

Hoogwerf BJ, Waness A, Cressman M, Canner J, Campeau L, Domanski M, Geller N, Herd A, Hickey A, Hunninghake DB, Knatterud GL, White C. Effects of aggressive cholesterol lowering and low-dose anticoagulation on clinical and angiographic outcomes in patients with diabetes. The Post Coronary Artery Bypass Graft Trial. *Diabetes* 1999b;48:1289-94.

Hopkins PN, Williams RR, Kuida H, Stults BM, Hunt SC, Barlow GK, Ash KO. Family history as an independent risk factor for incident coronary artery disease in a high-risk cohort in Utah. *Am J Cardiol* 1988;62:703-7.



Hopkins PN. Effects of dietary cholesterol on serum cholesterol: a meta-analysis and review. *Am J Clin Nutr* 1992;55:1060-70.

Horwitz RI, Horwitz SM. Adherence to treatment and health outcomes. *Arch Intern Med* 1993;153:1863-8.

Howard BV, Lee ET, Cowan LD, Devereaux RB, Galloway JM, Go OT, Howard WJ, Rhoades ER, Robbins DC, Sievers MC, Welty TK. Rising tide of cardiovascular disease in American Indians. *Circulation* 1999;99:2389-95.

Howard BV, Lee ET, Cowan LD, Fabsitz RR, Howard WJ, Oopik AJ, Robbins DC, Savage PJ, Yeh JL, Welty TK. Coronary heart disease prevalence and its relation to risk factors in American Indians. The Strong Heart Study. *Am J Epidemiol* 1995;142:254-68.

Howell WH, McNamara DJ, Tosca MA, Smith BT, Gaines JA. Plasma lipid and lipoprotein responses to dietary fat and cholesterol: a meta-analysis. *Am J Clin Nutr* 1997;65:1747-64.

Hristova L, Hakama M. Effect of screening for cancer in the Nordic countries on deaths, cost and quality of life up to the year 2017. *Acta Oncologica* 1997;36(suppl 9):S1-60.

Hruz PW, Murata H, Mueckler M. Adverse metabolic consequences of HIV protease inhibitor therapy: the search for a central mechanism. *Am J Physiol Endocrinol Metab* 2001;280:E549-53.

Hsu I, Spinler SA, Johnson NE. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia. *Ann Pharmacother* 1995;29:743-59.

Hu FB, Stampfer MJ, Manson JE, Ascherio A, Colditz GA, Speizer FE, Hennekens CH, Willett WC. Dietary saturated fats and their food sources in relation to the risk of coronary heart disease in women. *Am J Clin Nutr* 1999a;70:1001-8b.

Hu FB, Stampfer MJ, Manson JE, Rimm E, Colditz GA, Rosner BA, Hennekens CH, Willett WC. Dietary fat intake and the risk of coronary heart disease in women, *N Engl J Med* 1997;337:1491-9.

Hu FB, Stampfer MJ, Rimm EB, Manson JE, Ascherio A, Colditz GA, Rosner BA, Hennekens CH, Spiegelman D, Speizer FE, Sacks FM, Willett WC. A prospective study of egg consumption and risk of cardiovascular disease in men and women. *JAMA* 1999b;281:1387-94a.

Hu FB, Stampfer MJ, Solomon C, Liu S, Colditz GA, Speizer FE, Willett WC, Manson JE. Physical activity and risk for cardiovascular events in diabetic women. *Ann Intern Med* 2001;134:96-105.

Hu FB, Stampfer MJ, Solomon C, Willett WC, Manson JE. Diabetes mellitus and mortality from all causes and coronary heart disease in women: 20 years of follow-up. *Diabetes* 2000;49(suppl 1):A20.

- Hubert HB, Feinleib M, McNamara PM, Castelli WP. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. *Circulation* 1983;67:968-77.
- Hulley S, Grady S, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff FE. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. *JAMA* 1998;280:605-13.
- Hulley SB, Rosenman RH, Bawol RD, Brand RJ. Epidemiology as a guide to clinical decisions: The association between triglyceride and coronary heart disease. *N Engl J Med* 1980;302:1383-9.
- Humphries SE, Peacock R, Dunning A, Lane A, Green F, Hamsten A. Identification of genetic variation that determines levels of plasma triglycerides and hypercoagulability. *Clin Genet* 1994;46(1 Spec No):19-31.
- Hunninghake DB, Stein EA, Bremner WF, Greenland P, Demke DM, Oliphant TH. Dose-response study of colestipol tablets in patients with moderate hypercholesterolemia. *Am J Therapeut* 1995; 2:180-9.
- Hunninghake DB, Stein EA, Dujovne CA, Harris WS, Feldman EB, Miller VT, Tobert JA, Laskarzewski PM, Quiter E, Held J, Taylor AM, Hopper S, Leonard SB, Brewer BK. The efficacy of intensive dietary therapy alone or combined with lovastatin in outpatients with hypercholesterolemia. *N Engl J Med* 1993;328:1213-9.
- Hunninghake DB. Drug treatment of dyslipoproteinemia. *Endocrinol Metab Clin North Am* 1990;19:345-60.
- Hunt SC, Williams RR, Barlow GK. A comparison of positive family history definitions for defining risk of future disease. *J Chronic Dis* 1986;39:809-21.
- Hunter DJ, Spiegelman D, Adami HO, et al: Cohort studies of fat intake and the risk of breast cancer—a pooled analysis. *N Engl J Med* 1996;334:356-61.
- Hutchinson RG, Watson RL, Davis CE, Barnes R, Brown S, Romm F, Spencer JM, Tyroler HA, Wu K. Racial Differences in risk factors for atherosclerosis. The ARIC Study. Atherosclerosis Risk in Communities. *Angiology* 1997;48:279-90.
- Huttunen JK, Heinonen OP, Manninen V, Koskinen P, Hakulinen T, Teppo L, Mänttari M, Frick MH. The Helsinki Heart Study: an 8.5-year safety and mortality follow-up. *J Intern Med* 1994;235:31-9.
- Huttunen JK, Manninen V, Mänttari M, Koskinen P, Romo M, Tenkanen L, Heinonen OP, Frick MH. The Helsinki Heart Study: central findings and clinical implications. *Ann Med* 1991;23:155-9.
- Hypercholesterolemia in elderly patients: resolving the treatment dilemma. *Ann Intern Med* 1990;112:780-92.

- Ibels LS, Alfrey AC, Weil R II. Hyperlipidemia in adult, pediatric and diabetic renal transplant recipients. *Am J Med* 1978;64:634-42.
- Iida H, Izumino K, Asaka M, Fujita M, Nishino A, Sasayama S. Effect of probucol on hyperlipidemia in patients with nephrotic syndrome. *Nephron* 1987;47:280-3.
- Iliadis EA, Rosenson RS. Long-term safety of pravastatin-gemfibrozil therapy in mixed hyperlipidemia. *Clin Cardiol* 1999;22:25-8.
- Illingworth DR, Olsen GD, Cook SF, Sexton GJ, Wendel HA, Connor WE. Ciprofibrate in the therapy of type II hypercholesterolemia. A double-blind trial. *Atherosclerosis* 1982;44:211-21.
- Illingworth DR, Stein EA, Mitchel YB, Dujovne CA, Frost PH, Knopp RH, Tun P, Zupkis RV, Greguski RA. Comparative effects of lovastatin and niacin in primary hypercholesterolemia. A prospective trial. *Arch Intern Med* 1994;154:1586-95.
- Innerarity TL, Mahley RW, Weisgraber KH, Bersot TP, Krauss RM, Vega GL, Grundy SM, Friedl W, Davignon J, McCarthy BJ. Familial defective apolipoprotein B-100: a mutation of apolipoprotein B that causes hypercholesterolemia. *J Lipid Res* 1990;31:1337-49.
- Innerarity TL, Weisgraber KH, Arnold KS, Mahey RW, Krauss RM, Vega GL, Grundy SM. Familial defective apolipoprotein B-100: low density lipoproteins with abnormal receptor binding. *Proc Natl Acad Sci U S A* 1987;84:6919-23.
- Insull W Jr., Isaacsohn J, Kwiterovich P, Ra P, Brazg R, Dujovne C, Shan M, Shugrue-Crowley E, Ripa S, Tota R. Efficacy and safety of cerivastatin 0.8 mg in patients with hypercholesterolaemia: the pivotal placebo-controlled clinical trial. Cerivastatin Study Group. *J Int Med Res* 2000;28:47-68.
- Insull W Jr., Marquis NR, Tsianco MC. Comparison of the efficacy of questran light, a new formulation of cholestyramine powder, to regular questran in maintaining lowered plasma cholesterol levels. *Am J Cardiol* 1991;67:501-5.
- Israeli Society for Prevention of Heart Attacks. *Circulation* 2000;102(1):21-7.
- Jacques PF, Selhub J, Bostom AG, Wilson PW, Rosenberg IH. The effect of folic acid fortification on plasma folate and total homocysteine concentrations. *N Engl J Med* 1999;340:1449-54.
- Jeffery RW, Hellerstedt WL, French SA, Baxter JE. A randomized trial of counseling for fat restriction versus calorie restriction in the treatment of obesity. *Int J Obes Relat Metab Disord* 1995;19:132-7.
- Jenkins DJ, Kendall CW, Axelsen M, Augustin LS, Vuksan V. Viscous and nonviscous fibres, nonabsorbable and low glycaemic index carbohydrates, blood lipids and coronary heart disease. *Curr Opin Lipidol* 2000a;11:49-56. Review.

Jenkins DJ, Kendall CW, Vidgen E, Mehling CC, Parker T, Seyler H, Faulkner D, Garsetti M, Griffin LC, Agarwal S, Rao AV, Cunnane SC, Ryan MA, Connelly PW, Leiter LA, Vuksan V, Josse R. The effect on serum lipids and oxidized low-density lipoprotein of supplementing self-selected low-fat diets with soluble fiber, soy, and vegetable protein foods. *Metabolism* 2000b;49:67-72.

Jenkins DJ, Wolever TM, Rao AV, Hegele RA, Mitchell SJ, Ransom TP, Boctor DL, Spadafora PJ, Jenkins AL, Mehling C, Relle LK, Connelly PW, Story JA, Furumoto EJ, Cory P, Würsch P. Effect on blood lipids of very high intakes of fiber in diets low in saturated fat and cholesterol. *N Engl J Med* 1993;329:21-6.

Jensen J, Blankenhorn DH, Kornerup V. Coronary disease in familial hypercholesterolemia. *Circulation* 1967;36(1):77-82.

Jensen J, Nilas L, Christiansen C. Cyclic changes in serum cholesterol and lipoproteins following different doses of combined postmenopausal hormone replacement therapy. *Br J Obstet Gynaecol* 1986;93:613-8.

Jensen T, Borch-Johnsen K, Kofoed-Enevoldsen A, Deckert T. Coronary heart disease in young type 1 (insulin dependent) diabetic patients with and without diabetic nephropathy: incidence and risk factors. *Diabetologia* 1987;30:144-8.

JNC VI. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. *Arch Intern Med* 1997;157:2413-46.

Johannesson M, Agewall S, Hartford M, Hedner T, Fagerberg B. The cost-effectiveness of a cardiovascular multiple-risk-factor intervention programme in treated hypertensive men. *J Int Med* 1995;237:19-26.

Johannesson M, Dahlof B, Lindholm LH, Ekblom T, Hansson L, Oden A, Scherstén B, Wester PO, Jönsson B. The cost-effectiveness of treating hypertension in elderly people—an analysis of the Swedish Trial in Old Patients with Hypertension (STOP Hypertension). *J Int Med* 1993;234:317-23.

Johannesson M, Jönsson B, Kjekshus J, Olsson AG, Pedersen TR, Wedel H. Cost-effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. *N Engl J Med* 1997a;336:332-6.

Johannesson M, Meltzer D, O'Connor RM. Incorporating future costs in medical cost-effectiveness analysis: implications for the cost-effectiveness of the treatment of hypertension. *Med Decis Making* 1997b;17:382-9.

Johannesson M. The cost-effectiveness of hypertension treatment in Sweden: an analysis of the criteria for intervention and the choice of drug treatment. *J Hum Hypertens* 1996;10(suppl 2): S23-6.

Johannesson M. The impact of age on the cost-effectiveness of hypertension treatment: an analysis of randomized drug trials. *Med Decis Making*. 1994;14:236-44.

Joint British recommendations on prevention of coronary heart disease in clinical practice. British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, endorsed by the British Diabetic Association. *Heart* 1998;80(suppl 2):S1-S29.

Joint British recommendations on prevention of coronary heart disease in clinical practice: summary. British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, British Diabetic Association. *BMJ* 2000;320:705-8.

Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Sixth Report. NIH Pub. No. 98-4080, Bethesda, MD: Public Health Service, National Institutes of Health, National Heart, Lung, and Blood Institute, 1997;70.

Jonas MA, Oates JA, Ockene JK, Hennekens CH. Statement on smoking and cardiovascular disease for health care professionals. *Circulation* 1992;86:1664-9.

Jones P, Kafonek S, Laurora I, Hunninghake D, for the CURVES Investigators. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin and fluvastatin in patients with hypercholesterolemia (The CURVES study). *Am J Cardiol* 1998;81:582-7.

Jones TF, Eaton CB. Cost-benefit analysis of walking to prevent coronary heart disease. *Arch Fam Med* 1994;3:703-10.

Jorde LB, Williams RR. Relation between family history of coronary artery disease and coronary risk variables. *Am J Cardiol* 1988;62:708-13.

Judd JT, Baer DJ, Clevidence BA, Muesing RA, Chen SC, Weststrate JA, Meijer GW, Wittes J, Lichtenstein AH, Montserrat VB, Schaefer EJ. Effects of margarine compared with those of butter on blood lipid profiles related to cardiovascular disease risk factors in normolipemic adults fed controlled diets. *Am J Clin Nutr* 1998;68:768-77.

Judd JT, Clevidence BA, Muesing RA, Wittes J, Sunkin ME, Podczasy JJ. Dietary trans fatty acids: effects on plasma lipids and lipoproteins of healthy men and women. *Am J Clin Nutr* 1994;59:861-8.

Jukema JW, Bruschke AV, van Boven AJ, Reiber JH, Bal ET, Zwinderman AH, Jansen H, Boerma GJ, van Rappard FM, Lie KI. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels: The Regression Growth Evaluation Statin Study (REGRESS). *Circulation* 1995;91:2528-40.

Julien P, Vohl MC, Gaudet D, Gagne C, Levesque G, Despres JP, Cadelis F, Brun LD, Nadeau A, Ven Murthy MR. Hyperinsulinemia and abdominal obesity affect the expression of hypertriglyceridemia in heterozygous familial lipoprotein lipase deficiency. *Diabetes* 1997;46:2063-8.

Kagan A, Harris BR, Winkelstein W Jr., Johnson KG, Kato H, Syme SL, Rhoads GG, Gay ML, Nichaman MZ, Hamilton HB, Tillotson J. Epidemiologic studies of coronary heart disease and stroke in Japanese men living in Japan, Hawaii, and California: demographic, physical, dietary and biochemical characteristics. *J Chron Dis* 1974;27:345-64.

Kahn SE, Beard JC, Schwartz MW, Ward WK, Ding HL, Bergman RN, Taborsky GJ Jr., Porte D Jr. Increased beta-cell secretory capacity as mechanism for islet adaptation to nicotinic acid-induced insulin resistance. *Diabetes* 1989;38:562-8.

Kane JP, Malloy MJ, Ports TA, Phillips NR, Diehl JC, Havel RJ. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. *JAMA* 1990;264:3007-12.

Kang SS, Wong PW, Malinow MR. Hyperhomocyst(e)inemia as a risk factor for occlusive vascular disease. *Ann Rev Nutr* 1992;12:279-98.

Kannel WB, Abbott RD, Dannenberg AL: Unrecognized myocardial infarction and hypertension: The Framingham Study. *Am Heart J* 1985a;109(3):581.

Kannel WB, Hjortland MC, McNamara PM, Gordon T. Menopause and risk of cardiovascular disease: The Framingham Study. *Ann Intern Med* 1976;85:447-52.

Kannel WB, McGee DL. Diabetes and cardiovascular disease: The Framingham Study. *JAMA* 1979a;241:2035-8.

Kannel WB, McGee DL. Diabetes and glucose tolerance as risk factors for cardiovascular disease: The Framingham Study. *Diabetes Care* 1979b;2:120-6.

Kannel WB, Neaton JD, Wentworth D, Thomas HE, Stamler J, Hulley SB, Kjelsberg MO. Overall and coronary heart disease mortality rates in relation to major risk factors in 325,348 men screened for the MRFIT. *Am Heart J* 1986;112:825-36.

Kannel WB, Schatzkin A. Sudden death: lessons from subsets in populations studies. *J Am Coll Cardiol* 1985b;5:141B-149B.

Kannel WB. Influence of fibrinogen on cardiovascular disease. *Drugs* 1997;54(suppl 3):32-40.

Kannel WB. Range of serum cholesterol values in the population developing coronary artery disease. *Am J Cardiol* 1995;76:69C-77C.

Karhapaa P, Malkki M, Laakso M. Isolated low HDL cholesterol. An insulin-resistant state. *Diabetes* 1994;43:411-7.

Karlson BW, Wiklund O, Hallgren P, Sjolín M, Lindqvist J, Herlitz J. Ten-year mortality amongst patients with a very small or unconfirmed acute myocardial infarction in relation to clinical history, metabolic screening and signs of myocardial ischaemia. *J Intern Med* 2000;247:449-56.

Karpe F, Boquist S, Tang R, Bond G, de Faire U, Hamsten A. Remnant lipoproteins are related to intima-media thickness of the carotid artery independently of LDL cholesterol and plasma triglycerides. *J Lipid Res* 2001;42:17-21.

Kasiske BL, Umen AJ. Persistent hyperlipidemia in renal transplant patients. *Medicine* 1987;66:309-16.

Kastelein JP, Isaacsohn JL, Ose L, Hunninghake DB, Frohlich J, Davidson MH, Habib R, Dujovne CA, Crouse JR, Liu M, Melino MR, O'Grady L, Mercuri M, Mitchel YB for the Simvastatin Atorvastatin HDL Study Group. Comparison of effects of simvastatin versus atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I levels. *Am J Cardiol* 2000;86:221-3.

Katan MB, Grundy SM, Willett WC. Should a low-fat, high-carbohydrate diet be recommended for everyone? Beyond low-fat diets. *N Engl J Med* 1997;337:563-6.

Katan MB, Zock PL, Mensink RP. Trans fatty acids and their effects on lipoproteins in humans. *Ann Rev Nutr* 1995;15:473-93.

Katan MB. Direct and indirect effects of dietary fibre on plasma lipoproteins in man. *Scand J Gastroenterol Suppl* 1987;129:218-22.

Katan MB. Effect of low-fat diets on plasma high-density lipoprotein concentrations. *Am J Clin Nutr* 1998;67(suppl):573S-576S.

Katan MB. High-oil compared with low-fat, high-carbohydrate diets in the prevention of ischemic heart disease. *Am J Clin Nutr* 1997;66(suppl):974S-9S.

Keenan JM, Wenz JB, Myers S, Ripsin C, Huang Z. Randomized controlled cross-over trial of oat bran in hypercholesterolemic subjects. *J Family Practice* 1991;33:600-8.

Kekalainen P, Sarlund H, Pyörälä K, Laakso M. Family history of coronary heart disease is a stronger predictor of coronary heart morbidity and mortality than family history of non-insulin dependent diabetes mellitus. *Atherosclerosis* 1996;123:203-13.

Kekki M, Nikkila EA. Plasma triglyceride metabolism in the adult nephrotic syndrome. *Eur J Clin Invest* 1971;1:345-51.

Kelley MJ, Hoover-Plow J, Nichols-Bernhard JF, Verity LS, Brewer H. Oat bran lowers total and low-density lipoprotein cholesterol but not lipoprotein(a) in exercising adults with borderline hypercholesterolemia. *JADA* 1994;94:1419-21.

Kelly JJ, Lawson JA, Campbell LV, Storlien LH, Jenkins AB, Whitworth JA, O'Sullivan AJ. Effects of nicotinic acid on insulin sensitivity and blood pressure in healthy subjects. *J Hum Hypertens* 2000;14:567-72.

Kerlikowske K, Salzman P, Phillips KA, Cauley JA, Cummings SR. Continuing screening mammography in women aged 70 to 79 years: impact on life expectancy and cost-effectiveness. *JAMA* 1999;282:2156-63.

Kesaniemi YA, Grundy SM. Dual defect in metabolism of very-low-density lipoprotein triglycerides. Patients with type 5 hyperlipoproteinemia. *JAMA* 1984;251:2542-7.

Keys A, Aravanis C, Blackburn H. Seven countries—a multivariate analysis of death and coronary heart disease. Cambridge, MA: Harvard University Press, 1980;381.

Keys A, Menotti A, Aravanis C, Blackburn H, Djordjevic BS, Buzina R, Dontas AS, Fidanza F, Karvonen MJ, Kimura N, Mohacek I, Nedeljkovic S, Puddu V, Punsar S, Taylor HL, Conti S, Kromhout D, Toshima H. The Seven Countries Study: 2,289 deaths in 15 years. *Prev Med* 1984;13:141-54.

Keys A, Menotti A, Karvonen MJ, Aravanis C, Blackburn H, Buzina R, Djordjevic BS, Dontas AS, Fidanza F, Keys MH, Kromhout D, Nedeljkovic S, Punsar S, Seccareccia F, Toshima H. The diet and 15-year death rate in the seven countries study. *Am J Epidemiol* 1986;124:903-15.

Khaw KT, Barrett-Connor E. Family history of heart attack: a modifiable risk factor? *Circulation* 1986;74:239-44.

King H, Kriska AM. Prevention of type II diabetes by physical training: epidemiological considerations and study methods. *Diabetes Care* 1992;15(suppl 4):1794-9.

King ME, Breslow JL, Lees RS. Plasma-exchange therapy of homozygous familial hypercholesterolemia. *N Engl J Med* 1980;302(26):1457-9.

Kinosian B, Glick H, Preiss L, Puder KL. Cholesterol and coronary heart disease: predicting risks in men by changes in levels and ratios. *J Invest Med* 1995;43:443-50.

Kiortsis DN, Millionis H, Bairaktari E, Elisaf MS. Efficacy of combination of atorvastatin and micronised fenofibrate in the treatment of severe mixed hyperlipidemia. *Eur J Clin Pharmacol* 2000;56:631-5.

Kirkman MS, Weinberger M, Landsman PB, Samsa GP, Shortliffe EA, Simel DL, Feussner JR. A telephone-delivered intervention for patients with NIDDM. *Diabetes Care* 1994;17:840-6.

Kjekshus J, and Pedersen TR for the Scandinavian Simvastatin Survival Study Group. Reducing the risk of coronary events: evidence from the Scandinavian Simvastatin Survival Study (4S). *Am J Cardiol* 1995;76:64C-68C.

Klag MJ, Ford DE, Mead LA, He J, Whelton PK, Liang KY, Levine DM. Serum cholesterol in young men and subsequent cardiovascular disease. *N Engl J Med* 1993;328:313-8.

Klarman HE, Francis JO, Rosenthal JD. Cost-effectiveness analysis applied to the treatment of chronic renal disease. *Medical Care* 1968;6:48-54.



Kliewer EV, Smith KR: Breast cancer mortality among immigrants in Australia and Canada. *J Natl Cancer Inst* 1995;87:1154-61.

Knapp HH, Schrott H, Ma P, Knopp R, Chin B, Gaziano JM, Donovan JM, Burke SK, Davidson MH. Efficacy and safety of combination simvastatin and colesvelam in patients with primary hypercholesterolemia. *Am J Med* 2001;110:352-60.

Knatterud GL, Rosenberg Y, Campeau L, Geller NL, Hunninghake DB, Forman SA, Forrester JS, Gobel FL, Herd JA, Hickey A, Hoogwerf BJ, Terrin ML, White C. Long-term effects on clinical outcomes of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation in the Post Coronary Artery Bypass Graft Trial. *Circulation* 2000;102:157-65.

Knopp RH, Alagona P, Davidson M, Goldberg SD, Kafonek SD, Kashyap M, Sprecher D, Superko HR, Jenkins S, Marcovina S. Equivalent efficacy of a time release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia. *Metabolism* 1998;47:1097-104.

Knopp RH, Ginsberg J, Albers JJ, Hoff C, Ogilvie JT, Warnick GR, Burrows E, Retzlaff B, Poole M. Contrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemic subjects: clues to mechanism of action of niacin. *Metabolism* 1985;34:642-50.

Knopp RH, Walden CE, Retzlaff BM, McCann BS, Dowdy AA, Albers JJ, Gey GO, Cooper MN. Long-term cholesterol-lowering effects of 4 fat-restricted diets in hypercholesterolemic and combined hyperlipidemic men. The Dietary Alternatives Study. *JAMA* 1997;278:1509-15.

Knopp RH. Drug treatment of lipid disorders. *N Engl J Med* 1999;341:498-511.

Knox EG. Evaluation of a proposed breast cancer screening regimen. *BMJ* 1988;297:650-4.

Knuiman JT, West CE, Katan MB, Hautvast JG. Total cholesterol and high density lipoprotein cholesterol levels in populations differing in fat and carbohydrate intake. *Arteriosclerosis* 1987;7:612-9.

Kodlin D. A note on the cost-benefit problem in screening for breast cancer. *Methods Inf Med* 1972;11:242-7.

Koenig W, Sund M, Frohlich M, Fischer HG, Lowel H, Doring A, Hutchinson WL, Pepys MB. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. *Circulation* 1999;99:237-42.

Kokkinos PF, Fernhall B. Physical activity and high density lipoprotein cholesterol levels: what is the relationship? *Sports Med* 1999;28:307-14.

Kolaczynski JW, Caro JF. Insulin resistance: site of the primary defect or how the current and the emerging therapies work. *J Basic Clin Physiol Pharmacol* 1998;9:281-94.

Kolinsky J, Reaven GM, Fuqua JW. Effects of weight reduction on obesity: studies of lipid and carbohydrate metabolism in normal and hyperlipoproteinemic subjects. *J Clin Invest* 1974;53:64-76.

Kolonel LN, Hankin JH, Nomura AM, Chu SY. Dietary fat intake and cancer incidence among five ethnic groups in Hawaii. *Cancer Res* 1981;41:3727-8.

Kolonel LN, Nomura AM, Cooney RV. Dietary fat and prostate cancer: current status. *J Natl Cancer Inst* 1999;91:414-28.

Kolonel LN: Nutrition and prostate cancer. *Cancer Causes and Control* 1996;7:83-94.

Koren E, Corder C, Mueller G, Centurion H, Hallum G, Fesmire J, McConathy WD, Alaupovic P. Triglyceride enriched lipoprotein particles correlate with the severity of coronary artery disease. *Atherosclerosis* 1996;122:105-15.

Korhonen T, Savolainen MJ, Koistinen MJ, Ikaheimo M, Linnaluoto MK, Kervinen K, Kesaniemi YA. Association of lipoprotein cholesterol and triglycerides with the severity of coronary heart disease in men and women. *Atherosclerosis* 1996;127:213-20.

Kornitzer M, Dramaix M, Vandebroek MD, Everaert L, Gerlinger C. Efficacy and tolerance of 200 mg micronised fenofibrate administered over a six month period in hyperlipidemic patients: an open Belgian multicenter study. *Atherosclerosis* 1994;110:(suppl):S49-S54.

Koskinen P, Mänttari M, Manninen V, Huttunen JK, Heinonen OP, Frick MH. Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. *Diabetes Care* 1992;15:820-5.

Kottke TE, Solberg LI, Brekke ML, Conn SA, Maxwell P, Brekke MJ. A controlled trial to integrate smoking cessation advice into primary care practice: doctors helping smokers, round III. *J Fam Pract* 1992;34:701-8.

Krauss RM, Deckelbaum RJ, Ernst N, Fisher E, Howard BV, Knopp RH, Kotchen T, Lichtenstein AH, McGill HC, Pearson PA, Prewitt TE, Stone NJ, Horn LV, Weinberg R. Dietary guidelines for healthy American adults. A statement for health professionals from the Nutrition Committee, American Heart Association. *Circulation* 1996;94:1795-800.

Krauss RM, Eckel RH, Howard B, Appel LJ, Daniels SR, Deckelbaum RJ, Erdman JW Jr., Kris-Etherton P, Goldberg IJ, Kotchen TA, Lichtenstein AH, Mitch WE, Mullis R, Robinson K, Wylie-Rosett J, St. Jeor S, Suttie J, Tribble DL, Bazzarre TL. AHA Dietary Guidelines: revision 2000: A statement for healthcare professionals from the Nutrition Committee of the American Heart Association. *Circulation* 2000;102:2284-99.

Krauss RM, Lindgren FT, Williams PT, Kelsey SF, Brensike J, Vranizan K, Detre KM, Levy RI. Intermediate-density lipoproteins and progression of coronary artery disease in hypercholesterolemic men. *Lancet* 1987;2:62-6.

Krauss RM. Atherogenicity of triglyceride-rich lipoproteins. *Am J Cardiol* 1998;81:13B-17B.

Krauss RM. Regulation of high density lipoprotein levels. *Med Clin North Am* 1982;66:403-30.

Kreisberg RA. Diabetic dyslipidemia. *Am J Cardiol* 1998 Dec 17;82(12A):67U-73U.

Kris-Etherton PM, Pearson TA, Wan Y, Hargrove RL, Moriarty K, Fishell V, Etherton TD. High-monounsaturated fatty acid diets lower both plasma cholesterol and triacylglycerol concentrations. *Am J Clin Nutr* 1999;70:1009-15.

Kris-Etherton PM, Yu S. Individual fatty acid effects on plasma lipids and lipoproteins: human studies. *Am J Clin Nutr* 1997;65(suppl 5):1628S-44S.

Kristal AR, Abrams BF, Thornquist MD, Disogra L, Croyle RT, Shattuck AL, Henry HJ. Development and validation of a food use checklist for evaluation of community nutrition interventions. *Am J Public Health* 1990;80:1318-22.

Kristal AR, Abrams BF, Thornquist MD, Disogra L, Croyle RT, Shattuck AL, Henry HJ. Development and validation of a food use checklist for evaluation of community nutrition interventions. *Am J Public Health* 1990;80:1318-22.

Kristal AR, White E, Shattuck AL, Curry S, Anderson GL, Fowler A, Urban N. Long-term maintenance of a low-fat diet: durability of fat-related dietary habits in the Women's Health Trial. *J Am Diet Assoc* 1992;92:553-9.

Kristein MM. Economic issues in prevention. *Prev Med* 1977;6:252-64.

Krolewski AS, Kosinski EJ, Warram JH, Leland OS, Busick EJ, Asmal AC, Rand LI, Christlieb AR, Bradley RF, Kahn CR. Magnitude and determinants of coronary artery disease in juvenile-onset, insulin dependent diabetes mellitus. *Am J Cardiol* 1987;59:750-5.

Kromhout D, Bloemberg BP, Feskens EJ, Hertog MG, Menotti A, Blackburn H. Alcohol, fish, fibre and antioxidant vitamins intake do not explain population differences in coronary heart disease mortality. *Int J Epidemiol* 1996;25:753-9.

Kromhout D, Coulander CDL. Diet, prevalence, and 10-year mortality from coronary heart disease in 871 middle-aged men: the Zutphen Study. *Am J Epidemiol* 1984;119:733-41.

Kromhout D, Menotti A, Bloemberg BP, Aravanis C, Blackburn H, Buzina R, Dontas AS, Fidanza F, Giampaoli S, Jansen A, Karvonen M, Katan M, Nissinen A, Nedeljkovic S, Pekkanen J, Pekkarinen M, Punsar S, Rasanen L, Simic B, Toshima H. Dietary saturated and trans fatty acids and cholesterol and 25-year mortality from coronary heart disease: The Seven Countries Study. *Prev Med* 1995;24:308-15.

Kronmal RA, Cain KC, Ye Z, Omenn GS. Total serum cholesterol levels and mortality risk as a function of age. *Arch Intern Med* 1993;153:1065-73.

Kroon AA, Aengevaeren WR, van der Werf T, Uijen GJ, Reiber JH, Bruschke AV, Stalenhoef AF. LDL-Apheresis Atherosclerosis Regression Study (LAARS). Effect of aggressive versus conventional lipid lowering treatment on coronary atherosclerosis. *Circulation* 1996;93:1826-35.

Kroon UB, Silfverstolpe G, Tengborn L. The effects of transdermal estradiol and oral conjugated estrogens on haemostasis variables. *Thromb Haemost* 1994;71:420-3.

Krumholz HM, Cohen BJ, Tsevat J, Pasternak RC, Weinstein MC. Cost-effectiveness of a smoking cessation program after myocardial infarction. *J Am Coll Cardiol* 1993;22:1697-1702.

Krumholz HM, Seeman TE, Merrill SS, Mendes de Leon CF, Vaccarino V, Silverman DI, Tsukahara R, Ostfeld AM, Berkman LF. Lack of association between cholesterol and coronary heart disease mortality and morbidity and all-cause mortality in persons older than 70 years. *JAMA* 1994;272:135-40.

Kuchinskiene Z, Carlson LA. Composition, concentration, and size of low density lipoproteins and of subfractions of very low density lipoproteins from serum of normal men and women. *J Lipid Res* 1982;23:762-9.

Kuller L, Borhani N, Furberg C, Gardin J, Manolio T, O'Leary D, Psaty B, Robbins J. Prevalence of subclinical atherosclerosis and cardiovascular disease and association with risk factors in the cardiovascular health study. *Am J Epidemiol* 1994;139:1164-79.

Kuller L, Fisher L, McClelland R, Fried L, Cushman M, Jackson S, Manolio T. Differences in prevalence of and risk factors for subclinical vascular disease among black and white participants in the Cardiovascular Health Study. *Arterioscler Thromb Vasc Biol* 1998;18:283-93.

Kumanyika S, Wilson JF, Guilford-Davenport M. Weight-related attitudes and behaviors of African American women. *J Am Diet Assoc* 1993;93:416-22.

Kushi LH, Lew RA, Stare FJ, et al. Diet and 20 year mortality from coronary heart disease. The Ireland-Boston Diet-Heart Study. *N Engl J Med* 1985;312:811-8.

Kwiterovich PO Jr. Young adults with hypercholesterolemia. *Am J Med* 1999;107(2A):40S-2S.

Kwiterovich PO Jr., Coresh J, Smith HH, Bachorik PS, Derby CA, Pearson TA. Comparison of the plasma levels of apolipoproteins B and A-1, and other risk factors in men and women with premature coronary artery disease. *Am J Cardiol* 1992;69:1015-21.

Kwiterovich PO Jr., White S, Forte T, Bachorik PS, Smith H, Sniderman A. Hyperapobetalipoproteinemia in a kindred with familial combined hyperlipidemia and familial hypercholesterolemia. *Arteriosclerosis* 1987;7:211-25.

La Vecchia C, Favero A, Franceschi S. Monounsaturated and other types of fat, and the risk of breast cancer. *Eur J Cancer Prev* 1998;7:461-4.

Laakso M; Lehto S. Epidemiology of risk factors for cardiovascular disease in diabetes and impaired glucose tolerance. *Atherosclerosis* 1998;137(suppl 1):S65-73.

LaBresh KA, Owen P, Alteri C, Reilly S, Albright PS, Hordes AR, Shaftel PA, Noonan TE, Stoukides CA, Kaul AF. Secondary prevention in a cardiology group practice and hospital setting after a heart-care initiative. *Am J Cardiol* 2000;85:23A-9A.

LaCroix AZ, Lang J, Scherr P, Wallace RB, Cornoni-Huntley J, Berkman L, Curb JB, Evans D, Hennekens CH. Smoking and mortality among older men and women in three communities. *N Engl J Med* 1991;324:1619-25.

Lai MS, Yen MF, Kuo HS, Koong SL, Chen TH, Duffy SW. Efficacy of breast-cancer screening for female relatives of breast-cancer-index cases: Taiwan multicentre cancer screening (TAMCAS). *Int J Cancer* 1998;78:21-6.

Lamarche B, Despres JP, Pouliot MC, Prud'homme D, Moorjani S, Lupien PJ, Nadeau A, Tremblay A, Bouchard C. Metabolic heterogeneity associated with high plasma triglyceride or low HDL cholesterol levels in men. *Arterioscler Thromb* 1993;13:33-40.

Lamarche B, Moorjani S, Lupien PJ, Cantin B, Bernard PM, Dagenais GR, Despres JP. Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Quebec cardiovascular study. *Circulation* 1996;94:273-8.

Landsberg L. Insulin resistance and hypertension. *Clin Exp Hypertens* 1999;21:885-94.

Langer T, Levy RI. The effect of nicotinic acid on the turnover of low density lipoproteins in type II hyperlipoproteinemia. In: Gey KF, Carlson RA, eds. *Metabolic effects of nicotinic acid and its derivatives*. Bern, Germany: Hans Huber Publishers, 1971:641-7.

Lardinois CK, Neuman SL. The effects of antihypertensive agents on serum lipids and lipoproteins. *Arch Intern Med* 1988;148:1280-8.

LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. *JAMA* 1999;282:2340-6.

LaRosa JC. Triglycerides and coronary risk in women and the elderly. *Arch Intern Med* 1997;157:961-8.

Law MR, Thompson SG, Wald NJ. Assessing possible hazards of reducing serum cholesterol. *BMJ* 1994a;308:373-9.

Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? *BMJ* 1994b;308:367-72.

Law MR, Wald NJ, Wu T, Hackshaw A, Bailey A. Systematic underestimation of association between serum cholesterol concentration and ischaemic heart disease in observational studies: data from the BUPA study. *BMJ* 1994c;308:363-6.

Law MR, Wald NJ. An ecologic study of serum cholesterol and ischaemic heart disease between 1950 and 1990. *Eur J Clin Nutr* 1994;48:305-25.

Law MR. Lowering heart disease risk with cholesterol reduction: evidence from observational studies and clinical trials. *Eur Heart J Suppl* 1999;(suppl 1):S3-S8.

Law MR. Plant sterol and stanol margarines and health. *West J Med* 2000;173:43-7.

Leaf A, Jorgensen MB, Jacobs AK, Cote G, Schoenfeld DA, Scheer J, Weiner BH, Slack JD, Kellet MA, Raizner AE, Weber PC, Mahrer PR, Rossouw JE. Do fish oils prevent restenosis after coronary angioplasty? *Circulation* 1994;90:2248-57.

Leaf DA, Connor WE, Illingworth DR, Bacon SP, Sexton G. The hypolipidemic effects of gemfibrozil in type V hyperlipidemia. A double-blind, crossover study. *JAMA* 1989;262:3154-60.

Leary ET, Wang T, Baker DJ, Cilla DD, Zhong J, Warnick GR, Nakajima K, Havel RJ. Evaluation of an immunoseparation method for quantitative measurement of remnant-like particle-cholesterol in serum and plasma. *Clin Chem* 1998;44:2490-8.

Leibel RL, Hirsch J, Appel BE, Checani GC: Energy intake required to maintain body weight is not affected by wide variation in diet composition. *Am J Clin Nutr* 1992;55:350-5.

Leivo T, Sintonen H, Tuominen R, Hakama M, Pukkala E, Heinonen OP. The cost-effectiveness of nationwide breast carcinoma screening in Finland, 1987-1992. *Cancer* 1999;86:638-46.

Lemieux I, Pascot A, Couillard C, Lamarche B, Tchernof A, Almeras N, Bergeron J, Gaudet D, Tremblay G, Prudhomme D, Nadeau A, Despres JP. Hypertriglyceridemic waist: A marker of the atherogenic metabolic triad (hyperinsulinemia; hyperapolipoprotein B; small, dense LDL) in men? *Circulation* 2000;102:179-84.

Lender D, Arauz-Pacheco C, Adams-Huet B, Raskin P. Essential hypertension is associated with decreased insulin clearance and insulin resistance. *Hypertension* 1997;29(1 Pt 1):111-4.

Leng GC, Fowkes FG, Lee AJ, Dunbar J, Housley E, Ruckley CV. Use of ankle brachial pressure index to predict cardiovascular events and death: a cohort study. *BMJ* 1996; 313:1440-4.

Leon AS, Connett J, Jacobs DR Jr., Rauramaa R. Leisure-time physical activity levels and risk of coronary heart disease and death: the Multiple Risk Factor Intervention Trial. *JAMA* 1987;258:2388-95.

Leren P. The effect of plasma cholesterol lowering diet in male survivors of myocardial infarction. A controlled clinical trial. *Acta Med Scand Suppl* 1966;466:1-92.

Leren TP, Hjermann I, Berg K, Leren P, Foss OP, Viksmoen L. Effects of lovastatin alone and in combination with cholestyramine on serum lipids and apolipoproteins in heterozygotes for familial hypercholesterolemia. *Atherosclerosis* 1988;73:135-41.

Lerner DJ, Kannel WB. Patterns of coronary heart disease morbidity and mortality in the sexes: a 26-year follow-up of the Framingham population. *Am Heart J* 1986;111:383-90.

Levin RJ. Carbohydrates. In: Shils ME, Olson JA, Shine M, Ross AC, eds. *Modern nutrition in health and disease*;9th edition. Baltimore: Williams and Wilkins, 1999;63-4.

Levine GN, Keaney JF, Vita JA. Cholesterol reduction in cardiovascular disease. Clinical benefits and possible mechanisms. *N Engl J Med* 1995;332:512-21.

Levinson SS, Wagner SG. Measurement of apolipoprotein B-containing lipoproteins for routine clinical laboratory use in cardiovascular disease. *Arch Pathol Lab Med* 1992;116:1350-4.

Lewis SJ, Moyé LA, Sacks FM, Johnstone DE, Timmis G, Mitchell J, Limacher M, Kell S, Glasser JP, Grant J, Davis BR, Pfeffer MA, Braunwald E. Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) trial. *Ann Intern Med* 1998a;129:681-9.

Lewis SJ, Sacks FM, Mitchell JS, East C, Glasser S, Kell S, Letterer R, Limacher M, Moye LA, Rouleau JL, Pfeffer MA, Braunwald E. Effect of pravastatin on cardiovascular events in women after myocardial infarction. *J Am Coll Cardiol* 1998b;32:140-6.

Li R, Bensen JT, Hutchinson RG, Province MA, Hertz-Picciotto I, Sprafka JM, Tyroler HA. Family risk score of coronary heart disease (CHD) as a predictor of CHD: the Atherosclerosis Risk in Communities (ARIC) study and the NHLBI family heart study. *Genet Epidemiol* 2000;18:236-50.

Li WW, Dammerman MM, Smith JD, Metzger S, Breslow JL, Leff T. Common genetic variation in the promoter of the human apoCIII gene abolishes regulation by insulin and may contribute to hypertriglyceridemia. *J Clin Invest* 1995;96:2601-5.

Liao Y, Cooper RS, Cao G, Kaufman JS, Long AE, McGee DL. Mortality from coronary heart disease and cardiovascular disease among adult U.S. Hispanics: findings from the National Health Interview Survey (1986 to 1994). *J Am Coll Cardiol* 1997;30:1200-5.

Liao Y, Cooper RS, McGee DL, Mensah GA, Ghali JK. The relative effects of left ventricular hypertrophy, coronary artery disease, and ventricular dysfunction on survival among black adults. *JAMA* 1995;273:1592-7.

Libby P, Schoenbeck U, Mach F, Selwyn AP, Ganz P. Current concepts in cardiovascular pathology: the role of LDL cholesterol in plaque rupture and stabilization. *Am J Med* 1998;104(2A):14S-8S.

Libby P. Molecular bases of the acute coronary syndromes. *Circulation* 1995;91:2844-50.

Lichtenstein AH, Ausman LM, Carrasco W, Jenner JL, Ordovas JM, Schaefer EJ. Hydrogenation impairs the hypolipidemic effect of corn oil in humans. Hydrogenation, trans-fatty acids, and plasma lipids. *Arterioscler Thromb* 1993;13:154-61.

Lichtenstein AH, Ausman LM, Jalbert SM, Schaefer EJ. Effects of different forms of dietary hydrogenated fats on serum lipoprotein cholesterol levels. *N Engl J Med* 1999;340:1933-40.

- Lichtlen PR, Hugenholz PG, Rafflenbeul W, Hecker H, Jost S, Deckers JW. Retardation of angiographic progression of coronary artery disease by nifedipine. Results of the International Nifedipine Trial on Antiatherosclerotic Therapy (INTACT). INTACT Group Investigators. *Lancet* 1990;335:1109-13.
- Lin BH, Frazao E, Guthrie J. Away-from-home foods are increasingly important to quality of American diet. Agriculture Information Bulletin no.749. Washington, D.C.: U.S. Department of Agriculture, 1999;26 pages.
- Lind L, Berne C, Lithell H. Prevalence of insulin resistance in essential hypertension. *J Hypertens* 1995;13:1457-62.
- Lindahl B, Weinehall L, Asplund K, Hallmans G. Screening for impaired glucose tolerance. Results from a population-based study in 21,057 individuals. *Diabetes Care* 1999;22:1988-92.
- Lindfors KK, Rosenquist CJ. The cost-effectiveness of mammographic screening strategies. *JAMA* 1995;274:881-4.
- Lindholm LH, Johannesson M. Cost-benefit aspects of treatment of hypertension in the elderly. *Blood Pressure Suppl* 1995;3:11-4.
- Lipid Research Clinics Investigators. The Lipid Research Clinics Coronary Primary Prevention Trial. Results of 6 years of post-trial follow-up. *Arch Intern Med* 1992;152:1399-1410.
- Lipid Research Clinics Program Epidemiology Committee. Plasma lipid distributions in selected North American populations: the Lipid Research Clinics Program Prevalence Study. *Circulation* 1979;60:427-39.
- Lipid Research Clinics Program. The Lipid Research Clinics coronary primary prevention trial results, I: Reduction in the incidence of coronary heart disease. *JAMA* 1984a;251:351-64.
- Lipid Research Clinics Program. The Lipids Research Clinics coronary primary prevention trial results, II: The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. *JAMA* 1984b;251:365-74.
- Lissner L, Heitmann BL. Dietary fat and obesity: evidence from epidemiology. *Eur J Clin Nutr* 1995;49:79-90.
- Littenberg B, Garber AM, Sox HC Jr. Screening for hypertension. *Ann Intern Med* 1990;112:192-202.
- Lloyd-Jones DM, Larson MG, Beiser A, Levy D. Lifetime risk of developing coronary heart disease. *Lancet* 1999;353:89-92.
- Logan AG, Milne BJ, Achber C, Campbell WP, Haynes RB. Work-site treatment of hypertension by specially trained nurses: a controlled trial. *Lancet* 1979;2:1175-8.



Long C, Simpson C, Allott E. Psychological and dietetic counselling combined in the treatment of obesity: a comparative study in a hospital outpatient clinic. *Hum Nutr Appl Nutr* 1983;37:94-102.

Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. *N Engl J Med* 1998;339:1349-57.

Lovastatin Study Group III. A multicenter comparison of lovastatin and cholestyramine therapy for severe primary hypercholesterolemia. *JAMA* 1988;260:359-66.

Luc G, Bard JM, Poulain P, Arveiler D, Evans AE, Cambien F, Fruchart JC, Ducimetiere P. Relationship between low-density lipoprotein size and apolipoprotein A-I-containing particles: the ECTIM Study. *Eur J Clin Invest* 1997;27:242-7.

Ludbrook A. A cost-effectiveness analysis of the treatment of chronic renal failure. *Applied Economics* 1981;13:337-50.

Luria MH. Effects of low-dose niacin on high density lipoprotein cholesterol and total cholesterol/high density lipoprotein cholesterol ratio. *Arch Intern Med* 1988;148:2493-5.

MAAS Investigators. Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS). *Lancet* 1994;344:633-8.

Mabuchi H, Haba T, Tatami R, Miyamoto S, Sakai Y, Wakasugi T, Watanabe A, Koizumi J, Takeda R. Effects of an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase on serum lipoproteins and ubiquinone-3-10 levels in patients with familial hypercholesterolemia. *N Engl J Med* 1981;305:478-82.

Mabuchi H, Michishita I, Sakai T, Sakai Y, Watanabe A, Wakasugi T, Takeda R. Treatment of homozygous patients with familial hypercholesterolemia by double-filtration plasmapheresis. *Atherosclerosis* 1986;61:135-40.

Mabuchi H, Sakai T, Sakai Y, Yoshimura A, Watanabe A, Wakasugi T, Koizumi J, Takeda R. Reduction of serum cholesterol in heterozygous patients with familial hypercholesterolemia. Additive effects of compactin and cholestyramine. *N Engl J Med* 1983;308:609-13.

Mack WJ, Krauss RM, Hodis HN. Lipoprotein subclasses in the Monitored Atherosclerosis Regression Study (MARS). Treatment effects and relation to coronary angiographic progression. *Arterioscler Thromb Vasc Biol* 1996;16:697-704.

MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J, Abbott R, Godwin J, Dyer A, Stamler J. Blood pressure, stroke, and coronary heart disease. Part 1. Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. *Lancet* 1990;335:765-74.

- MacMahon SW, Cutler JA, Furberg CD, Payne GH. The effects of drug treatment for hypertension on morbidity and mortality from cardiovascular disease: a review of randomized controlled trials. *Prog Cardiovasc Dis* 1986;29(suppl 1):99-118.
- Mahley RW, Rall SC Jr. Type III hyperlipoproteinemia (dysbetalipoproteinemia): the role of apolipoprotein E in normal and abnormal lipoprotein metabolism. In: Scriver CR, Beaudet AL, Sly WS, Valle D., eds. *The metabolic and molecular bases of inherited disease*;7th edition. New York: McGraw-Hill, 1995;1953-80.
- Mahley RW, Weisgraber KH, Innerarity TL, Rall SC Jr. Genetic defects in lipoprotein metabolism. Elevation of atherogenic lipoproteins caused by impaired catabolism. *JAMA* 1991;265:78-83.
- Malinow MR, Bostom AG, Krauss RM. Homocyst(e)ine, diet, and cardiovascular diseases: a statement for healthcare professionals from the Nutrition Committee, American Heart Association. *Circulation* 1999;99:178-82.
- Mallick NP, Short CD. The nephrotic syndrome and ischaemic heart disease. *Nephron* 1981;27:54-7.
- Malloy MJ, Kane JP, Kunitake ST. Complementarity of colestipol, niacin, and lovastatin in treatment of severe familial hypercholesterolemia. *Ann Intern Med* 1987;107:616-23.
- Malmberg K, Yusuf S, Gerstein HC, Brown J, Zhao F, Hunt D, Piegas L, Calvin J, Keltai M, Budaj, A for the OASIS Registry Investigators. Impact of diabetes on long-term prognosis in persons with unstable angina and non-Q-wave myocardial infarction. Results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry. *Circulation* 2000;102:1014-9.
- Maly RC, Abrahamse AF, Hirsh SH, Frank FC, Reuben DB. What influences physician practice behavior? An interview study of physicians who received consultative geriatric assessment recommendations. *Arch Fam Med Dev* 1996;5:448-54.
- Mandelblatt J, Freeman H, Winczewski D, Cagney K, Williams S, Towers R, Tang J, Gold K, Lin TH, Kerner J. The costs and effects of cervical and breast cancer screening in a public hospital emergency room. *Amer J Public Health* 1997;87:1182-9.
- Manson JE, Colditz GA, Stampfer MJ, Willett WC, Rosner B, Monson RR, Speizer FE, Hennekens CH. A prospective study of obesity and risk of coronary heart disease in women. *N Engl J Med* 1990;322:882-9.
- Marais AD, Naoumova RP, Firth JC, Penny C, Neuwirth CK, Thompson GR. Decreased production of low density lipoprotein by atorvastatin after apheresis in homozygous familial hypercholesterolemia. *J Lipid Res* 1997;38:2071-8.

Marcovina S, Zoppo A, Graziani MS, Vassanelli C, Catapano AL. Evaluation of apolipoproteins A-I and B as markers of angiographically assessed coronary artery disease. *Ric Clin Lab* 1988;18:319-28.

Marcovina SM, Hegele RA, Koschinsky ML. Lipoprotein(a) and coronary heart disease risk. *Curr Cardiol Rep* 1999;1:105-11.

Marcovina SM, Koschinsky ML. Lipoprotein(a) as a risk factor for coronary artery disease. *Am J Cardiol* 1998;82:57U-66U; discussion 85U-86U.

Markides KS, Coreil J. The health of Hispanics in the southwestern United States: an epidemiologic paradox. *Public Health Rep* 1986;101:253-65.

Marks JS, Koplan JP, Hogue CJR, Dalmat ME. A cost-benefit/cost-effectiveness analysis of smoking cessation for pregnant women. *Am J Prev Med* 1990;6:282-9.

Marmot MG, Syme SL, Kagan A, Kato H, Cohen JB, Belsky J. Epidemiologic studies of coronary heart disease and stroke in Japanese men living in Japan, Hawaii and California: prevalence of coronary and hypertensive heart disease and associated risk factors. *Am J Epidemiol* 1975;102:514-25.

Martin-Jadraque R, Tato F, Mostaza JM, Vega GL, Grundy SM. Effectiveness of low-dose crystalline nicotinic acid in men with low high-density lipoprotein cholesterol levels. *Arch Intern Med* 1996;156:1081-8.

Marz W, Wollschlager H, Klein G, Neiss A, Wehling M. Safety of low-density lipoprotein cholesterol reduction with atorvastatin versus simvastatin in a coronary heart disease population (the TARGET TANGIBLE Trial). *Am J Cardiol* 1999;84:7-13.

Masuoka H, Kamei S, Wagayama H, Ozaki M, Kawasaki A, Tanaka T, Kitamura M, Katoh S, Shintani U, Misaki M, Sugawa M, Ito M, Nakano T. Association of remnant-like particle cholesterol with coronary artery disease in patients with normal total cholesterol levels. *Am Heart J* 2000;139:305-10.

Matzkies FK, Bahner U, Teschner M, Hohage H, Heidland A, Schaefer RM. Efficiency of 1-year treatment with fluvastatin in hyperlipidemic patients with nephrotic syndrome. *Am J Nephrol* 1999;19:492-4.

Mayo Asymptomatic Carotid Endarterectomy Study Group. Results of a randomized controlled trial of carotid endarterectomy for asymptomatic carotid stenosis. *Mayo Clin Proc* 1992;67:513-8.

McBride P, Underbakke G, Plane MB, Massoth K, Brown RL, Solberg L, Ellis L, Schrott HG, Smith K, Swanson T, Spencer E, Pfeifer G, Knox A. Improving practice prevention systems in primary care practices. The health education and research trial (HEART). *J Fam Pract* 2000;49:115-25.

McBride PE. The health consequences of smoking. Cardiovascular diseases. *Med Clin North Am* 1992;76:333-53.

McGee DL, Reed DM, Yano K, Kagan A, Tillotson J. Ten-year incidence of coronary heart disease incidence in the Honolulu Heart Program: relationship to nutrient intake. *Am J Epidemiol* 1984;119:667-76.

McGill HC Jr. Introduction to the geographic pathology of atherosclerosis. *Lab Invest* 1968;18:465-7.

McGill HC Jr. Persistent problems in the pathogenesis of atherosclerosis. *Atherosclerosis* 1984;4:443-51.

McGill HC Jr., McMahan CA, and the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. Determinants of atherosclerosis in the young. *Am J Cardiol* 1998;82: 30T-6T.

McGill HC Jr., McMahan CA, Malcom GT, Oalman MC, Strong JP, for the PDAY Research Group. Effects of serum lipoproteins and smoking on atherosclerosis in young men and women. *Arterioscler Thromb Vasc Biol* 1997;17:95-106.

McGill HC Jr., McMahan CA, Zieske AW, Sloop GD, Walcott JV, Troxclair DA, Malcom GT, Tracy RE, Oalman MC, Strong JP, for the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. Associations of coronary heart disease risk factors with the intermediate lesion of atherosclerosis in youth. *Arterioscler Thromb Vasc Biol* 2000;20:1998-2004.

McKenna M, Wolfson S, Kuller L. The ratio of ankle and arm arterial pressure as an independent predictor of mortality. *Atherosclerosis* 1991;87:119-28.

McKenney JM, Proctor JD, Harris S, Chinchili VM. A comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patients. *JAMA* 1994;271:672-7.

McKenney JM, Slining JM, Henderson HR, Devins D, Barr M. The effect of clinical pharmacy services on patients with essential hypertension. *Circulation* 1973; 48:1104-11.

McMichael A, Giles G: Cancer in migrants to Australia: extending the descriptive epidemiological data. *Cancer Res* 1988;48:751-6.

McNamara JR, Shah PK, Nakajima K, Cupples LA, Wilson PW, Ordovas JM, Schaefer EJ. Remnant lipoprotein cholesterol and triglyceride reference ranges from the Framingham Heart Study. *Clin Chem* 1998;44:1224-32.

Meade TW. Fibrinogen in ischaemic heart disease. *Eur Heart J* 1995;16(suppl A):31-5.

- Meenan RT, Stevens VJ, Hornbrook MC, La Chance PA, Glasgow RE, Hollis JF, Lichtenstein E, Vogt TM. Cost-effectiveness of a hospital-based smoking cessation intervention. *Med Care* 1998;36:670-8.
- Meigs JB, D'Agostino RB Sr., Wilson PW, Cupples LA, Nathan DM, Singer DE. Risk variable clustering in the insulin resistance syndrome. The Framingham Offspring Study. *Diabetes* 1997;46:1594-600.
- Meigs JB, Mittleman MA, Nathan DM, Tofler GH, Singer DE, Murphy-Sheehy PM, Lipinska I, D'Agostino RB, Wilson PW. Hyperinsulinemia, hyperglycemia, and impaired hemostasis: the Framingham Offspring Study. *JAMA* 2000;283:221-8.
- Meigs JB, Nathan DM, Wilson PW, Cupples LA, Singer DE. Metabolic risk factors worsen continuously across the spectrum of nondiabetic glucose tolerance. The Framingham Offspring Study. *Ann Intern Med* 1998;128:524-33.
- Meigs JB. Invited commentary: insulin resistance syndrome? Syndrome X? Multiple metabolic syndrome? A syndrome at all? Factor analysis reveals patterns in the fabric of correlated metabolic risk factors. *Am J Epidemiol* 2000;152:908-11.
- Mekki N, Christofilis MA, Charbonnier M, Atlan-Gepner C, Defoort C, Juhel C, Borel P, Portugal H, Pauli AM, Vialettes B, Lairon D. Influence of obesity and body fat distribution on postprandial lipemia and triglyceride-rich lipoproteins in adult women. *J Clin Endocrinol Metab* 1999;84:184-91.
- Mendall MA, Strachan DP, Butland BK, Ballam L, Morris J, Sweetnam PM, Elwood PC. C-reactive protein: relation to total mortality, cardiovascular mortality and cardiovascular risk factors in men. *Eur Heart J* 2000;21:1584-90.
- Mensink RP, Katan MB. Effects of dietary fatty acids on serum lipids and lipoproteins. A meta-analysis of 27 trials. *Arterioscler Thromb* 1992;12:911-9.
- Mensink RP, Katan MB. Effects of dietary trans-fatty acids on high-density and low-density lipoprotein cholesterol levels in healthy subjects. *N Engl J Med* 1990;323:439-45.
- Mensink RP, Katan MB. Effects of monounsaturated fatty acids versus complex carbohydrates on high-density lipoproteins in healthy men and women. *Lancet* 1987;1:122-5.
- Mercuri M, Bond MG, Sirtori CR, Veglia F, Crepaldi G, Feruglio FS, Descovich G, Ricci G, Rubba P, Mancini M, Gallus G, Bianchi G, D'Alo G, Ventura A. Pravastatin reduces carotid intima-media thickness progression in an asymptomatic hypercholesterolemic Mediterranean population: The Carotid Atherosclerosis Italian Ultrasound Study. *Am J Med* 1996;101:627-34.
- Meschia M, Bruschi F, Soma M, Amicarelli F, Paoletti R, Crosignani P. Effects of oral and transdermal hormone replacement therapy on lipoprotein(A) and lipids: a randomized controlled trial. *Menopause* 1998;5:157-62.

- Miccoli R, Bertolotto A, Navalesi R, Odoguardi L, Boni A, Wessling J, Funke H, Wiebusch H, von Eckardstein A, Assmann G. Compound heterozygosity for a structural apolipoprotein A-I variant, apo A-I (L141RT) Pisa, and an apolipoprotein A-I null allele in patients with absence of HDL cholesterol, corneal opacifications, and coronary heart disease. *Circulation* 1996;94:1622-8.
- Miettinen H, Lehto S, Salomaa V, Mahonen M, Nicmela M, Haffner SM, Pyörälä K, Tuomilehto J, for the FINMONICA myocardial infarction register study group. Impact of diabetes on mortality after the first myocardial infarction. *Diabetes Care* 1998;21:69-75.
- Miettinen M, Karvonen MJ, Turpeinen O, Elosuo R, Paavilainen E. Effect of cholesterol-lowering diet on mortality from coronary heart-disease and other causes. A twelve-year clinical trial in men and women. *Lancet* 1972;2:835-8.
- Miettinen TA, Puska P, Gylling H, Vanhanen H, Vartiainen E. Reduction of serum cholesterol with sitostanol-ester margarine in a mildly hypercholesterolemic population. *N Engl J Med* 1995;333:1308-12.
- Miettinen TA, Pyörälä K, Olsson AG, Musliner TA, Cook TJ, Faergeman O, Berg K, Pedersen T, Kjekshus J, for the Scandinavian Simvastatin Survival Study (4S). Cholesterol lowering therapy in women and older persons with myocardial infarction or angina pectoris. *Circulation* 1997;96:4211-8.
- Miller BD, Alderman EL, Haskell WL, Fair JM, Krauss RM. Predominance of dense low-density lipoprotein particles predicts angiographic benefit of therapy in the Stanford Coronary Risk Intervention Project. *Circulation* 1996;94:2146-53.
- Miller KW, Small DM. Surface-to-core and interparticle equilibrium distributions of triglyceride-rich lipoprotein lipids. *J Biol Chem* 1983;258:13772-84.
- Miller M, Aiello D, Pritchard H, Friel G, Zeller K. Apolipoprotein A-I (Zavalla)(Leu159 →Pro): HDL cholesterol deficiency in a kindred associated with premature coronary artery disease. *Arterioscler Thromb Vasc Biol* 1998;18:1242-7.
- Miller WR, Hedrick KE, Taylor CA. Addictive behaviors and life problems before and after behavioral treatment of problem drinkers. *Addict Behav* 1983b;8(4):403-12.
- Miller WR, Rollnick S. Motivational interviewing: preparing people to change addictive behavior. New York: Guilford Press, 1991;348 pages.
- Minnich A, Kessling A, Roy M, Giry C, DeLangavant G, Lavigne J, Lussier-Cacan S, Davignon J. Prevalence of alleles encoding defective lipoprotein lipase in hypertriglyceridemic patients of French Canadian descent. *J Lipid Res* 1995;36:117-24.
- Moliterno DJ, Jokinen EV, Miserez AR, Lange RA, Willard JE, Boerwinkle E, Hillis LD, Hobbs HH. No association between plasma lipoprotein(a) concentrations and the presence or absence of coronary atherosclerosis in African Americans. *Arterioscler Thromb Vasc Biol* 1995;15:850-5.

Molitero DJ, Lange RA, Meidell RS, Willard JE, Leffert CC, Gerard RD, Boerwinkle E, Hobbs HH, Hillis LD. Relation of plasma lipoprotein(a) to infarct artery patency in survivors of myocardial infarction. *Circulation* 1993;88:935-40.

Montalescot G, Collet JP, Choussat R, Thomas D. Fibrinogen as a risk factor for coronary heart disease. *Eur Heart J* 1998;19(suppl H):H11-7.

Morgan JM, Capuzzi DM, Guyton JR, Centor RM, Goldberg R, Robbin DC, DiPette D, Jenkins S, Marcovino S. Treatment effect of niaspan, a controlled-release niacin, in patients with hypercholesterolemia: a placebo-controlled trial. *J Cardiovasc Pharmacol Ther* 1996;1:195-202.

Morganroth J, Levy RI, Fredrickson DS. The biochemical, clinical, and genetic features of type III hyperlipoproteinemia. *Ann Intern Med* 1975;82:158-74.

Morisky DE, Levine DM, Green LW, Shapiro S, Russell RP, Smith CR. Five-year blood pressure control and mortality following health education for hypertensive patients. *Am J Public Health* 1983;73:153-62.

Morris JN, Clayton DG, Everitt MG, Semmence AM, Burgess EH. Exercise in leisure time: coronary attack and death rates. *Br Heart J* 1990;63:325-34.

Morris MC, Manson JE, Rosner B, Buring JE, Willett WC, Hennekens CH. Fish consumption and cardiovascular disease in the Physicians' Health Study: a prospective study. *Am J Epidemiol* 1995;142:166-175.

Morris S. A comparison of economic modeling and clinical trials in the economic evaluation of cholesterol-modifying pharmacotherapy. *Health Econ* 1997;6:589-601.

Morrow DA, Ridker PM. C-reactive protein, inflammation, and coronary risk. *Med Clin North Am* 2000;84:149-61, ix.

Moskowitz M, Fox S. Cost analysis of aggressive breast cancer screening. *Radiology* 1979;130:253-6.

Mostaza JM, Schulz I, Vega GL, Grundy SM. Comparison of pravastatin with crystalline nicotinic acid monotherapy in treatment of combined hyperlipidemia. *Am J Cardiol* 1997;79:1298-301.

Muldoon MF, Manuck SB, Mathews KA. Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials. *BMJ* 1990;301:309-14.

Muller JE, Kaufmann PG, Luepker RV, Weisfeldt ML, Deedwania PC, Willerson JT. Mechanisms precipitating acute cardiac events: review and recommendations of an NHLBI workshop. *Circulation* 1997;96:3233-9.

Mullin GE, Greenson JK, Mitchell MC. Fulminant hepatic failure after ingestion of sustained-release nicotinic acid. *Ann Intern Med* 1989;111:253-5.

Muls E, Van Ganse E, Closon MC. Cost-effectiveness of pravastatin in secondary prevention of coronary heart disease: comparison between Belgium and the United States of a projected risk model. *Atherosclerosis* 1998;137(suppl):S111-6.

Multiple Risk Factor Intervention Trial (MRFIT). A national study of primary prevention of coronary heart disease. *JAMA* 1976;235:825-7.

Multiple Risk Factor Intervention Trial Research Group. Multiple Risk Factor Intervention Trial (MRFIT). Risk factor changes and mortality results. *JAMA* 1982;248:1465-77.

Mundinger MO, Kane RL, Lenz ER, Totten AM, Tsai WY, Cleary PD, Friedewald WT, Siu AL, Shelanski ML. Primary care outcomes in patients treated by nurse practitioners or physicians. A randomized trial. *JAMA* 2000;283:59-68.

Munro J, Brazier J, Davey R, Nicholl J. Physical activity for the over-65s: Could it be a cost-effective exercise for the NHS? *J Pub Hlth Med* 1997;19:397-402.

Murdock DK, Murdock AK, Murdock RW, Olsen KJ, Frane AM, Kersten ME, Joyce DM, Gantner SE. Long-term safety and efficacy of combination gemfibrozil and HMG-CoA reductase inhibitors for the treatment for mixed lipid disorders. *Am Heart J* 1999;138:151-5.

Mykkanen L, Kuusisto J, Haffner SM, Laakso M, Austin MA. LDL size and risk of coronary heart disease in older men and women. *Arterioscler Thromb Vasc Biol* 1999;19:2742-8.

Napoli C, Lepore S, Chiariello P, Condorelli M, Chiariello M. Long-term treatment with pravastatin alone and in combination with gemfibrozil in familial type IIB hyperlipoproteinemia or combined hyperlipidemia. *J Cardiovasc Pharmacol Ther* 1997;2:17-26.

National Center for Health Statistics. Total serum cholesterol levels of adults 20–74 years of age: United States, 1976–80. No. 236. *Vital Health Stat 2*; Hyattsville, MD: National Center for Health Statistics, 1986:59 pages.

National Cholesterol Education Program. Recommendations on lipoprotein measurement from the Working Group on Lipoprotein Measurement. NIH Pub. No. 95-3044. Bethesda, MD: National Heart, Lung, and Blood Institute, 1995:186 pages.

National Cholesterol Education Program. Recommendations for improving cholesterol measurement. A Report from the Laboratory Standardization Panel of the National Cholesterol Education Program. NIH Pub. No. 93-2964. Bethesda, MD: National Heart, Lung, and Blood Institute, 1993:65 pages.

National Cholesterol Education Program. Report of the Expert Panel on Population Strategies for Blood Cholesterol Reduction. NIH Pub. No. 90-3046. Bethesda, MD: National Heart, Lung, and Blood Institute, 1990:130 pages.

National Cholesterol Education Program. Second report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. NIH Pub. No. 93-3095. Bethesda, MD: National Heart, Lung, and Blood Institute, 1993:180 pages.



National Cholesterol Education Program. Second report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II). *Circulation* 1994;89:1333-445.

National health expenditures amounts, and average annual percent change, by type of expenditure: selected calendar years 1970–2008. Retrieved from <http://www.hcfa.gov>.

National Institutes of Health. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults—the evidence report. NIH Pub. No.98-4083. Bethesda, MD: National Heart, Lung and Blood Institute, 1998a:262 pages.

National Institutes of Health. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults - the evidence report. *Obesity Res* 1998b;6:(suppl 2) 51S-209S.

National Research Council. Diet and health: implications for reducing chronic disease risk. Washington, D.C.: National Academy Press, 1989:7, 171-195, 196-201.

National Research Council. Dietary reference intakes for thiamin, riboflavin, niacin, vitamin B6, folate, vitamin B12, pantothenic acid, biotin, and choline Washington, D.C.: National Academy Press, 2000a:567 pages.

National Research Council. Dietary reference intakes for vitamin C, vitamin E, selenium, and carotenoids. Washington, D.C.: National Academy Press, 2000b:509 pages.

National Research Council. Toxicological effects of methylmercury. Washington, D.C.: National Academy Press, 1999.

Navab M, Hama SY, Anantharamaiah GM, Hassan K, Hough GP, Watson AD, Reddy ST, Sevastian A, Fonarow GC, Fogelman AM. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: Steps 2 and 3. *J Lipid Res* 2000a;41:1495-508.

Navab M, Hama SY, Cooke CJ, Anantharamaiah GM, Chaddha M, Jin L, Subbanagounder G, Faull, KF, Reddy ST, Miller NE, Fogelman AM. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: Step 1. *J Lipid Res* 2000b;41:1481-94.

Neaton JD, Kuller LH, Wentworth D, Borhani NO. Total and cardiovascular mortality in relation to cigarette smoking, serum cholesterol concentration, and diastolic blood pressure among black and white males followed up for five years. *Am Heart J* 1984;108:759-69.

Neaton JD, Wentworth D, for the Multiple Risk Factor Intervention Trial (MRFIT) Research Group. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316,099 white men. *Arch Intern Med* 1992;152:56-64.

- Nelson LH, Tucker LA. Diet composition related to body fat in a multivariate study of 203 men. *J Am Dietetic Assoc* 1996;96:771-7.
- Nessman DG, Carnahan JE, Nugent CA. Increasing compliance: patient-operated hypertension groups. *Arch Intern Med* 1980;140:1427-30.
- Nestel PJ, Noakes M, Belling GB, McArthur R, Clifton PM, Abbey M. Plasma cholesterol-lowering potential of edible-oil blends suitable for commercial use. *Am J Clin Nutr* 1992;55:46-50.
- Neumann PJ, Stone PW, Chapman RH, Sandberg EA, Bell CM. The quality of reporting in published cost-utility analyses, 1976-1997. *Ann Intern Med* 2000;132:964-872.
- Neve BP, Fruchart JC, Staels B. Role of the peroxisome proliferator-activated receptors (PPAR) in atherosclerosis. *Biochem Pharmacol* 2000;60:1245-50.
- Newman AB, Siscovick DS, Manolio TA, Polak J, Fried LP, Borhani NO, Wolfson SK. Ankle-arm index as a marker of atherosclerosis in the Cardiovascular Health Study (CHS). *Circulation* 1993;88:837-45.
- Ng DS, Vezina C, Wolever TS, Kuksis A, Hegele RA, Connelly PW. Apolipoprotein A-I deficiency. Biochemical and metabolic characteristics. *Arterioscler Thromb Vasc Biol* 1995;15:2157-64.
- Nie L, Wang J, Clark LT, Tang A, Vega GL, Grundy SM, Cohen JC. Body mass index and hepatic lipase gene (LIPC) polymorphism jointly influence postheparin plasma hepatic lipase activity. *J Lipid Res* 1998;39:1127-30.
- Niinikoski H, Lapinleimu H, Viikari J, Rönnemaa T, Jokinen E, Seppänen R, Terho P, Tuominen J, Välimäki I, Simell O. Growth until three years of age in a prospective randomized trial of a diet with reduced saturated fat and cholesterol. *Pediatrics* 1997;99:687-94.
- Nilsson PM, Lind L, Pollare T, Berne C, Lithell H. Differences in insulin sensitivity and risk markers due to gender and age in hypertensives. *J Hum Hypertens* 2000;14:51-6.
- Nishino M, Malloy MJ, Naya-Vigne J, Russell J, Kane JP, Redberg RF. Lack of association of lipoprotein(a) levels with coronary calcium deposits in asymptomatic postmenopausal women. *J Am Coll Cardiol* 2000;35:314-20.
- Noakes M, Clifton PM. Oil blends containing partially hydrogenated or interesterified fats: differential effects on plasma lipids. *Am J Clin Nutr* 1998;68:242-7.
- Nordestgaard BG, Lewis B. Intermediate density lipoprotein levels are strong predictors of the extent of aortic atherosclerosis in the St. Thomas's Hospital rabbit strain. *Atherosclerosis* 1991;87:39-46.
- Norris JW, Zhu CZ, Bornstein NM, Chambers BR. Vascular risks of asymptomatic carotid stenosis. *Stroke* 1991;22:1485-90.

Notice to Readers. Publication of Surgeon General's report on physical activity and health. *Morb Mortal Wkly Rep* 1996;45:591-2.

Nygard O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. *N Engl J Med* 1997;337:230-6.

O'Driscoll G, Green D, Taylor RR. Simvastatin, an HMG-Coenzyme A reductase inhibitor, improves endothelial function within 1 month. *Circulation* 1997; 95:1126-31.

O'Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK Jr. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. *N Engl J Med* 1999;340:14-22.

O'Malley PG, Taylor AJ, Jackson JL, Doherty TM, Detrano RC. Prognostic value of coronary electron-beam computed tomography for coronary heart disease events in asymptomatic populations. *Am J Cardiol* 2000;85:945-8.

O'Rourke RA, Brundage BH, Froelicher VF, Greenland P, Grundy SM, Hachamovitch R, Pohost GM, Shaw LJ, Weintraub WS, Winters WL Jr. American College of Cardiology/American Heart Association expert consensus document on electron-beam computed tomography for the diagnosis and prognosis of coronary artery disease. *J Am Coll Cardiol* 2000a;36:326-340.

O'Rourke RA, Brundage BH, Froelicher VF, Greenland P, Grundy SM, Hachamovitch R, Pohost GM, Shaw LJ, Weintraub WS, Winters WL Jr., Forrester JS, Douglas PS, Faxon DP, Fisher JD, Gregoratos G, Hochman JS, Hutter AM Jr., Kaul S, Wolk MJ. American College of Cardiology/American Heart Association expert consensus document on electron-beam computed tomography for the diagnosis and prognosis of coronary artery disease. *Circulation* 2000b;102:126-140.

Obarzanek E, Hunsberger SA, Van Horn L, Hartmuller VV, Barton BA, Stevens VJ, Kwiterovich PO, Franklin FA, Kimm SY, Lasser NL, Simons-Morton DG, Lauer RM. Safety of a fat-reduced diet: the Dietary Intervention Study in Children (DISC). *Pediatrics* 1997;100:51-9.

Obarzanek E, Sacks FM, Vollmer WM, Bray GA, Miller ER III, Lin PH, Karanja NM, Most-Windhauser MM, Moore TJ, Swain JF, Bales CW, Proschan MA. Effects on blood lipids of a blood pressure-lowering diet: the Dietary Approaches to Stop Hypertension (DASH) Trial. *Am J Clin Nutr* 2001;74:80-9.

Ockene IS, Hebert JR, Ockene JK, Merriam PA, Hurley TG, Saperia GM. Effect of training and a structured office practice on physician-delivered nutrition counseling: the Worcester Area Trial for Counseling in Hyperlipidemia (WATCH). *Am J Prev Med* 1996;12:252-8.

Ockene IS, Hebert JR, Ockene JK, Saperia GM, Stanek E, Nicolosi R, Merriam PA, Hurley TG. Effect of physician-delivered nutrition counseling training and an office-support program on saturated fat intake, weight, and serum lipid measurements in a hyperlipidemic population. Worcester Area Trial for Counseling in Hyperlipidemia (WATCH). *Arch Intern Med* 1999;159:725-31.

- Ockene JK, McBride PE, Sallis JF, Bonollo DP, Ockene IS. Synthesis of lessons learned from cardiopulmonary preventive interventions in healthcare practice settings. *Ann Epidemiol* 1997;7:S32-S45.
- Okosun IS, Liao Y, Rotimi CN, Prewitt TE, Cooper RS. Abdominal adiposity and clustering of multiple metabolic syndrome in white, black and hispanic Americans. *Ann Epidemiol* 2000;10:263-70.
- Okubo I, Glick H, Frumkin H, Eisenberg JM. Cost-effectiveness analysis of mass screening for breast cancer in Japan. *Cancer* 1991;67:2021-9.
- Oldridge NB, Jones NL. Improving patient compliance in cardiac exercise rehabilitation: effects of written agreement and self-monitoring. *J Cardiopulm Rehabil* 1983;3:257-62.
- Olefsky J, Reaven GM, Farquhar JW. Effects of weight reduction on obesity. Studies of lipid and carbohydrate metabolism in normal and hyperlipoproteinemic subjects. *J Clin Invest* 1974;53:64-76.
- Oliver MF. Serum cholesterol—the knave of hearts and the joker. *Lancet* 1981;2:1090-5.
- Omenn GS, Goodman GE, Thornquist MD, Balmes J, Cullen MR, Glass A, Keogh JP, Meyskens FL Jr., Valanis B, Williams JH Jr., Barnhart S, Hammar S. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. *N Engl J Med* 1996;334:1150-5.
- Oopik AJ, Dorogy M, Devereux RB, Yeh JL, Okin PM, Lee ET, Cowan L, Fabsitz RR, Howard BV, Welty TK. Major electrocardiographic abnormalities among American Indians aged 45 to 74 years (the Strong Heart Study). *Am J Cardiol* 1996;78:1400-5.
- Ornish D, Brown SE, Scherwitz LW, Billings JH, Armstrong WT, Ports TA, McLanahan SM, Kirkeeide RL, Brand RJ, Gould KL. Can lifestyle changes reverse coronary heart disease? The Lifestyle Heart Trial. *Lancet* 1990;336:129-33.
- Ornstein SM, Garr DR, Jenkins RG, Rust PF, Arnon A. Computer-generated physician and patient reminders. Tools to improve population adherence to selected preventive services. *J Fam Pract* 1991;32:82-90.
- Oster G, Huse DM, Delea TE, Colditz GA. Cost-effectiveness of nicotine gum as an adjunct to physicians' advice against cigarette smoking. *JAMA* 1986;256:1315-8.
- Paffenbarger RS Jr., Hyde RT, Wing AL, Lee I-M, Jung DL, Kampert JB. The association of changes in physical-activity level and other lifestyle characteristics with mortality among men. *N Engl J Med* 1993;328:538-45.
- Palmer RH. Effects of fibric acid derivatives on biliary lipid composition. *Am J Med* 1987;83(suppl 5B):37-43.

- Pan HY, DeVault AR, Swites BJ, Whigan D, Ivashkiv E, Willard DA, Brescia D. Pharmacokinetics and pharmacodynamics of pravastatin alone and with cholestyramine in hypercholesterolemia. *Clin Pharmacol Ther* 1990;48:201-7.
- Pankow JS, Folsom AR, Province MA, Rao DC, Eckfeldt J, Heiss G, Shahar E, Wu KK. Family history of coronary heart disease and hemostatic variables in middle-aged adults. Atherosclerosis Risk in Communities Investigators and Family Heart Study Research Group. *Thromb Haemost* 1997;77:87-93.
- Pate RR, Pratt M, Blair SN, Haskell WL, Macera CA, Bouchard C, Buchner D, Ettinger W, Heath GW, King AC, Kriska A, Leon AS, Marcus BH, Morris J, Paffenbarger RS Jr., Patrick K, Pollock ML, Rippe JM, Sallis J, Wilmore JH. Physical activity and public health. A recommendation from the Centers for Disease Control and Prevention and the American College of Sports Medicine. *JAMA* 1995;273:402-7.
- Pauciullo P, Marotta G, Rubba P, Cortese C, Caruso MG, Gnasso A, Fischetti A, Motti C, Mancini M. Serum lipoproteins, apolipoproteins and very low density lipoprotein subfractions during six-month-fibrate treatment in primary hypertriglyceridaemia. *J Intern Med* 1990;228:425-30.
- Pearson DA, Stranova TJ, Thompson JD. Patient and program costs associated with chronic hemodialysis care. *Inquiry* 1976;13:23-8.
- Pearson TA, Laurora I, Chu H, Kafonek S. The lipid treatment assessment project (L-TAP). A multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. *Arch Intern Med* 2000;160:459-67.
- Pearson TA, Stone EJ, Grundy SM, McBride PE, Van Horn L, Tobin BW. Translation of nutritional sciences into medical education: the Nutrition Academic Award Program. *Am J Clin Nutr* 2001;74:164-70.
- Pearson TA. The undertreatment of LDL-cholesterol: addressing the challenge. *Int J Cardiol* 2000;74 suppl 1:S23-8.
- Pedersen TR, Kjekshus J, Berg K, Olsson AG, Wilhelmsen L, Wedel H, Pyörälä K, Miettinen T, Haghfelt T, Faergeman O, Thorgeirsson G, Jönsson B, Schwartz S. Cholesterol lowering and the uses of healthcare resources. Results of the Scandinavian Simvastatin Survival Study. *Circulation* 1996;93:1796-802.
- Pedersen TR, Kjekshus J, Pyörälä K, Olsson AG, Cook TJ, Musliner TA, Tobert JA, Haghfelt T. Effect of simvastatin on ischemic signs and symptoms in the Scandinavian Simvastatin Survival Study (4S). *Am J Cardiol* 1998a;81:333-5.

Pedersen TR, Olsson AG, Faergeman O, Kjekshus J, Wedel H, Berg K, Wilhelmsen L, Haghfelt T, Thorgeirsson G, Pyörälä K, Miettinen T, Christophersen B, Tobert JA, Musliner TA, Cook TJ. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). *Circulation* 1998b; 97:1453-60.

Peduzzi P, Kamina A, Detre K. Twenty-two-year follow-up in the VA Cooperative Study of Coronary Artery Bypass Surgery for Stable Angina. *Am J Cardiol* 1998;81:1393-9.

Pekkanen J, Linn S, Heiss G, Suchindran CM, Leon A, Rifkind BM, Tyroler HA. Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. *N Engl J Med* 1990;322:1700-7.

Pennisi AJ, Heuser ET, Mickey MR, Lipsey A, Malekzadeh MH, Fine RN. Hyperlipidemia in pediatric hemodialysis and renal transplant patients. *Am J Dis Child* 1976;130:957-61.

Penzak SR, Chuck SK. Hyperlipidemia associated with HIV protease inhibitor use: pathophysiology, prevalence, risk factors and treatment. *Scand J Infect Dis* 2000;32:111-23.

People's Republic of China-United States Cardiovascular and Cardiopulmonary Epidemiology Research Group. An epidemiological study of cardiovascular and cardiopulmonary disease risk factors in four populations in the People's Republic of China. Baseline report from the P.R.C.-U.S.A. Collaborative Study. *Circulation* 1992;85:1083-96.

Perri MG. The maintenance of treatment effects in the long-term management of obesity. *Clin Psychol Sci Prac* 1998;5:526-43.

Perry IJ, Refsum H, Morris RW, Ebrahim SB, Ueland PM, Shaper AG. Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men. *Lancet* 1995;346:1395-8.

Perseghin G, Price TB, Petersen KF, Roden M, Cline GW, Gerow K, Rothman DL, Shulman GI. Increased glucose transport-phosphorylation and muscle glycogen synthesis after exercise training in insulin-resistant subjects. *N Engl J Med* 1996;335:1357-62.

Peters JR, Quiter ES, Brekke ML, Admire J, Brekke MJ, Mullis RM, Hunninghake DB. The eating pattern assessment tool: A simple instrument for assessing dietary fat and cholesterol intake. *J Am Diet Assoc* 1994;94:1008-13.

Peterson GM, McLean S, Millingen KS. A randomized trial of strategies to improve patient compliance with anticonvulsant therapy. *Epilepsia* 1984;25:412-7.

Phillips NR, Havel RJ, Kane JP. Levels and interrelationships of serum and lipoprotein cholesterol and triglycerides. Association with adiposity and the consumption of ethanol, tobacco, and beverages containing caffeine. *Arteriosclerosis* 1981;1:13-24.

Phillips NR, Waters D, Havel RJ. Plasma lipoproteins and progression of coronary artery disease evaluated by angiography and clinical events. *Circulation* 1993;88:2762-70.

Phillips RL, Lilienfeld AM, Diamond EL, Kagan A. Frequency of coronary heart disease and cerebrovascular accidents in parents and sons of coronary heart disease index cases and controls. *Am J Epidemiol* 1974;100:87-100.

Pierce LR, Wysowski DK, Gross TP. Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. *JAMA* 1990;264:71-5.

Pietinen P, Ascherio A, Korhonen P, Hartman AM, Willett WC, Albanes D, Virtamo J. Intake of fatty acids and risk of coronary heart disease in a cohort of Finnish men. The Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study. *Am J of Epidemiol* 1997;145:876-87.

Pineda Torra I, Gervois P, Staels B. Peroxisome proliferator-activated receptor alpha in metabolic disease, inflammation, atherosclerosis and aging. *Curr Opin Lipidol* 1999;10:151-9.

Pitt B, Mancini GBJ, Ellis SG, Rosman HS, Park JS, McGovern ME. Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): reduction in atherosclerosis progression and clinical events. *J Am Coll Cardiol* 1995;26:1133-9.

Pitt B, Waters D, Brown WV, van Boven AJ, Schwartz L, Title LM, Eisenberg D, Shurzinske L, McCormick LS, for the Atorvastatin Versus Revascularization Treatment Investigators . Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease.. *N Engl J Med* 1999;341:70-6.

Plehn JF, Davis BR, Sacks FM, Rouleau JL, Pfeffer MA, Bernstein V, Cuddy TE, Moye LA, Piller LB, Rutherford J, Simpson LM, Braunwald E. Reduction of stroke incidence after myocardial infarction with pravastatin. The Cholesterol and Recurrent Events (CARE) Study. *Circulation* 1999;99:216-23.

Plump AS, Scott CJ, Breslow JL. Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in apolipoprotein E-deficient mouse. *Proc Natl Acad Sci USA* 1994;91:9607-11.

Pohjola-Sintonen S, Rissanen A, Liskola P, Luomanmaki K. Family history as a risk factor of coronary heart disease in patients under 60 years of age. *Eur Heart J* 1998;19:235-9.

Ponticelli C, Barbi GL, Cantaluppi A, et al. Lipid disorders in renal transplant recipients. *Nephron* 1978;20:189-95.

Post Coronary Artery Bypass Graft Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. *N Engl J Med* 1997;336:153-62.

Postiglione A, Montefusco S, Pauciullo P, Mancini M, Piliengo T. Effects of atorvastatin in patients with homozygous familial hypercholesterolemia. *Atherosclerosis* 1999;147:423-4.

Potter JD. Nutrition and colorectal cancer. *Cancer Causes and Control* 1996;7:127-46.

- Poulias GE, Doundoulakis N, Prombonas E, Haddad H, Papaioannou K, Lymberiadis D, Savopoulos G. Aorto-femoral bypass and determinants of early success and late favourable outcome. Experience with 1,000 consecutive cases. *J Cardiovasc Surg* 1992;33:664-78.
- Pravastatin Multicenter Study Group II. Comparative efficacy and safety of pravastatin and cholestyramine alone and combined in persons with hypercholesterolemia. *Arch Intern Med* 1993;153:1321-9.
- Prentice RL, Sheppard L. Dietary fat and cancer: consistency of the epidemiologic data, and disease prevention that may follow from a practical reduction in fat consumption. *Cancer Causes and Control* 1990;1:81-97.
- Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention. *Eur Heart J* 1998;19:1434-503.
- Prochaska JO, DiClemente CC. Stages of changes in the modification of problem behaviors. In: Hersen M, Eisler RM, Miller PM, eds. Progress in behavior modification. Sycamore: Sycamore Press, 1992;184-214.
- Prochaska JO, Velicer WF, Rossi JS, Goldstein MG, Marcus BH, Rakowski W, Fiore C, Harlow LL, Redding CA, Rosenbloom D, Rossi SR. Stages of change and decisional balance for 12 problem behaviors. *Health Psychol* 1994;13:39-46.
- Prochaska JO. Why do we behave the way we do? *Can J Cardiol* 1995;(suppl A):20A-5A.
- Proserpi C, Sparti A, Schutz Y, Di Vetta V, Milon H, Jéquier E. Ad libitum intake of a high-carbohydrate or high-fat diet in young men: effects on nutrient balances. *Am J Clin Nutr* 1997;66:539-45.
- Prosser LA, Stinnett AA, Goldman PA, Williams LW, Hunink MGM, Goldman L, Weinstein MC. Cost-effectiveness of cholesterol-lowering therapies according to selected patient characteristics. *Ann Intern Med* 2000;132:769-79.
- Psaty BM, Furberg CD, Kuller LH, Bild DE, Rautaharju PM, Polak F, Bovill E, Gottdiener JS. Traditional risk factors and subclinical disease measures as predictors of first myocardial infarction in older adults. The Cardiovascular Health Study. *Arch Intern Med* 1999;159:1339-47.
- Public Health Service. Treating Tobacco Use and Dependence: A Systems Approach. Clinical Practice Guideline. U.S. Department of Health and Human Services, June 2000.
- Putnam J, Gerrior S. Trends in the U.S. food supply, 1970-97. In: America's eating habits: changes and consequences. (AIB-750). Washington, D.C.: United States Department of Agriculture, Economic Research Service, 1999;133-60.



Pyörälä K, De Backer G, Graham I, Poole-Wilson P, Wood D. Prevention of coronary heart disease in clinical practice: recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. *Atherosclerosis* 1994;110:121-61.

Pyörälä K, Laakso M, Uusitupa M. Diabetes and atherosclerosis: an epidemiologic view. *Diabetes Metab Rev* 1987;3:463-524.

Pyörälä K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). *Diabetes Care* 1997;20:614-20.

Quinn TG, Alderman EL, McMillan A, Haskell W, for the SCRIP investigators. Development of new coronary atherosclerotic lesions during a 4-year multifactor risk reduction program: the Stanford Coronary Risk Intervention Project (SCRIP). *J Am Coll Cardiol* 1994;24:900-8.

Raal FJ, Pappu AS, Illingworth DR, Pilcher GJ, Marais AD, Firth JC, Kotze MJ, Heinonen TM, Black DM. Inhibition of cholesterol synthesis by atorvastatin in homozygous familial hypercholesterolaemia. *Atherosclerosis* 2000;150:421-8.

Raal FJ, Pilcher G, Rubinsztein DC, Lingenhel A, Utermann G. Statin therapy in a kindred with both apolipoprotein B and low density lipoprotein receptor gene defects. *Atherosclerosis* 1997;129:97-102.

Rabelink AJ, Erkelens DW, Hene RJ, Joles JA, Koomans HA. Effects of simvastatin and cholestyramine on lipoprotein profile in hyperlipidaemia of nephrotic syndrome. *Lancet* 1988;2:1335-8.

Rader DJ, Hoeg JM, Brewer HB Jr. Quantitation of plasma apolipoproteins in the primary and secondary prevention of coronary artery disease. *Ann Intern Med* 1994;120:1012-25.

Rader DJ, Rosas S. Management of selected lipid abnormalities. Hypertriglyceridemia, low HDL cholesterol, lipoprotein(a), in thyroid and renal diseases, and post-transplantation. *Med Clin North Am* 2000;84:43-61.

Rader JI, Calvert RJ, Hathcock JN. Hepatic toxicity of unmodified and time-release preparations of niacin. *Am J Med* 1992;92:77-81.

Raggi P, Callister TQ, Cooil B, He ZX, Lippolis NJ, Russo DJ, Zelinger A, Mahmarian JJ. Identification of patients at increased risk of first unheralded acute myocardial infarction by electron-beam computed tomography. *Circulation* 2000;101:850-5.

Rainwater DL. Lipoprotein correlates of LDL particle size. *Atherosclerosis* 2000;148:151-8.

Randomised trial of endarterectomy for recently symptomatic carotid stenosis: final results of the MRC European Carotid Surgery Trial (ECST). *Lancet* 1998;351:1379-87.

Ravnskov U. Cholesterol lowering trials in coronary heart disease: frequency of citation and outcome. *BMJ* 1992;305:15-9.

Raynor DK, Booth TG, Blenkinsopp A. Effects of computer generated reminder charts on patients' compliance with drug regimens. *BMJ* 1993;306:1158-61.

Reardon MF, Nestel PJ, Craig IH, Harper RW. Lipoprotein predictors of the severity of coronary artery disease in men and women. *Circulation* 1985;71:881-8.

Reaven GM. Pathophysiology of insulin resistance in human disease. *Physiol Rev* 1995;75:473-86.

Refsum H, Ueland PM, Nygard O, Vollset SE. Homocysteine and cardiovascular disease. *Annu Rev Med* 1998;49:31-62.

Reinhart RA, Gani K, Arndt MR, Broste SK. Apolipoproteins A-I and B as predictors of angiographically defined coronary artery disease. *Arch Intern Med* 1990;150:1629-33.

Reisin E, Frohlich ED, Messerli FH, Dreslinski GR, Dunn FG, Jones MM, Batson HM. Cardiovascular changes after weight reduction in obesity hypertension. *Ann Intern Med* 1983;98:315-9.

Renaud S, de Lorgeril M, Delaye J, Guidollet J, Jacquard F, Mamelle N, Martin JL, Monjaud I, Salen P, Toubol P. Cretan Mediterranean diet for prevention of coronary heart disease. *Am J Clin Nutr* 1995;61(suppl):1360S-7S.

Report of the Committee of Principal Investigators. W.H.O. cooperative trial on primary prevention of ischaemic heart disease using clofibrate to lower serum cholesterol: mortality follow-up. *Lancet* 1980;2:379-85.

Report of the Committee of Principal Investigators. W.H.O. cooperative trial on primary prevention of ischaemic heart disease using clofibrate to lower serum cholesterol: final mortality follow-up. *Lancet* 1984;2:600-4.

Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. The Expert Panel. *Arch Intern Med* 1988;148:36-69.

Research Committee of the Scottish Society of Physicians. Ischaemic heart disease: a secondary prevention trial using clofibrate. *BMJ* 1971;4:775-84.

Research Committee to the Medical Research Council. Controlled trial of soya-bean oil in myocardial infarction. *Lancet* 1968;2:693-700.

Research Committee. Low-fat diet in myocardial infarction. A controlled trial. *Lancet* 1965;2:501-4.

Retzlaff BM, Dowdy AA, Walden CE, Bovbjerg VE, Knopp RH. The northwest lipid research clinic fat intake scale: Validation and utility. *Am J Public Health* 1997;87:181-5.

Retzlaff BM, Dowdy AA, Walden CE, Bovbjerg VE, Knopp RH. The northwest lipid research clinic fat intake scale: Validation and utility. *Am J Public Health* 1997;87:181-5.

Rice DP, Hodgson TA, Kopstein AN. The economic costs of illness: a replication and update. *Health Care Financ Rev* 1985;7:61-80.

Richard P, Nilsson BY, Rosenqvist U. The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. *N Engl J Med* 1993;329:304-9.

Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. *Circulation* 1998a;98:731-3.

Ridker PM, Glynn RJ, Hennekens CH. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. *Circulation* 1998b;97:2007-11.

Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. *N Engl J Med* 2000;342:836-43.

Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. *Circulation* 1999;100:230-5.

Rimm EB, Klatsky A, Grobbee D, Stampfer MJ. Review of moderate alcohol consumption and reduced risk of coronary heart disease: is the effect due to beer, wine or spirits? *BMJ* 1996;23:731-6b.

Rimm EB, Stampfer MJ. Antioxidants for vascular disease. *Med Clin North Am* 2000;84:239-49.

Rimm EB, Williams P, Fosher K, Criqui M, Stampfer MJ. Moderate alcohol intake and lower risk of coronary heart disease: meta-analysis of effects on lipids and haemostatic factors. *BMJ* 1999;319:1523-8.

Rissanen AM, Nikkila EA. Coronary artery disease and its risk factors in families of young men with angina pectoris and in controls. *Br Heart J* 1977;39:875-83.

Rissanen AM. Familial aggregation of coronary heart disease in a high incidence area (North Karelia, Finland). *Br Heart J* 1979;42:294-303.

Rissanen T, Voutilainen S, Nyyssonen K, Lakka TA, Salonen JR. Fish oil-derived fatty acids, docosahexaenoic acid and docosapentaenoic acid, and the risk of acute coronary events: the Kuopio ischaemic heart disease risk factor study. *Circulation* 2000;102:2677-9.

Roberts SD, Maxwell DR, Gross TL. Cost-effective care of end-stage renal disease: A billion dollar question. *Ann Intern Med* 1980;92:243-8.

Robinson JG, Conroy C, Wickemeyer WJ. A novel telephone-based system for management of secondary prevention to a low-density lipoprotein cholesterol  $\leq 100$  mg/dL. *Am J Cardiol* 2000;85:305-8.

Roche HM, Gibney MJ. Effects of long-chain n-3 polyunsaturated fatty acids on fasting and postprandial triacylglycerol metabolism. *Am J Clin Nutr* 2000;71:232S-7S.

Rodes J, Cote G, Lesperance J, Bourassa MG, Doucet MG, Doucet S, Bilodeau L, Bertrand OF, Harel F, Gallo R, Tardif JC. Prevention of restenosis after angioplasty in small coronary arteries with probucol. *Circulation* 1998;97:429-36.

Rodgers A, MacMahon S. Blood pressure and the global burden of cardiovascular disease. *Clin Exp Hypertens* 1999;21:543-52.

Romling R, von Eckardstein A, Funke H, Motti C, Fragiaco GC, Nosedà G, Assmann G. A nonsense mutation in the apolipoprotein A-I gene is associated with high-density lipoprotein deficiency and periorbital xanthelasmas. *Arterioscler Thromb* 1994;14:1915-22.

Rosamond WD, Chambless LE, Folsom AR, Cooper LS, Conwill DE, Clegg L, Wang CH, Heiss G. Trends in the incidence of myocardial infarction and in mortality due to coronary heart disease, 1987 to 1994. *N Engl J Med* 1998;339:861-7.

Rose 1964 (Dr. Grundy to provide)

Rose DP. Dietary fatty acids and cancer. *Am J Clin Nutr* 1997;66(suppl 4):998S-1003S.

Rose G, Hamilton PJ, Colwell L, Shipley MJ. A randomised controlled trial of anti-smoking advice: 10-year results. *J Epidemiol Community Health* 1982;36:102-8.

Rosenberg L, Hennekens CH, Rosner B, Belanger C, Rothman KJ, Speizer FE. Early menopause and the risk of myocardial infarction. *Am J Obstet Gynecol* 1981;139:47-51.

Rosenquist CJ, Lindfors KK. Screening mammography in women aged 40-49 years: analysis of cost-effectiveness. *Radiology* 1994;191:647-50.

Rosenson RS, Frauenheim WA. Safety of combined pravastatin-gemfibrozil therapy. *Am J Cardiol* 1994;74:499-500.

Rossouw JE. Clinical trials of lipid-lowering drugs. In: Rifkind BM, ed. Drug treatment of hyperlipidemia. New York: Marcel Dekker, Inc., 1991;67-88.

Rossouw JE, Lewis B, Rifkind BM. The value of lowering cholesterol after myocardial infarction. *N Engl J Med* 1990;323:1112-9.

Rossouw JE. The effects of lowering serum cholesterol on coronary heart disease risk. *Med Clin North Am* 1994;78:181-95.

Rossouw JE. What we still need to learn about hormone replacement therapy. *Infert Reprod Med Clin North Am* 1999;10:189-209.

Rowland ML, Fulwood R. Coronary Heart Disease Risk Factor Trends in African Americans Between the First and Second National Health and Nutrition Examination Surveys, United States, 1971-1980. *Am Heart J* 1984;108:771-9.

Rubin EM, Krauss RM, Spangler EA, Verstuyft JG, Clift SM. Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI. *Nature* 1991;353:265-7.

Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, Faas FH, Linares E, Schaefer EJ, Schectman G, Wilt TJ, Wittes J. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. *N Engl J Med* 1999;341:410-8.

Rudel LL, Parks JS, Sawyer JK. Compared with dietary monounsaturated and saturated fat, polyunsaturated fat protects African green monkeys from coronary artery atherosclerosis. *Arterioscler Thromb Vasc Biol* 1995;15:2101-10.

Rudling MJ, Reihner E, Einarsson K, Ewerth S, Angelin B. Low density lipoprotein receptor-binding activity in human tissues: quantitative importance of hepatic receptors and evidence for regulation of their expression in vivo. *Proc Natl Acad USA* 1990;87:3469-73.

Runyan JW Jr. The Memphis chronic disease program. Comparisons in outcome and the nurse's extended role. *JAMA* 1975;231:264-7.

Ryder RE, Hayes TM, Mulligan IP, Kingswood JC, Williams S, Owens DR. How soon after myocardial infarction should plasma lipid values be assessed? *BMJ* 1984;289:1651-3.

Sackett DL, Haynes RB, Givson ES, Hackett BC, Taylor DW, Roberts RS, Johnson AL. Randomised clinical trial of strategies for improving medication compliance in primary hypertension. *Lancet* 1975;1:1205-7.

Sacks FM, Alaupovic P, Moyé LA, Cole TG, Sussex B, Stampfer MJ, Pfeffer MA, Braunwald E. VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial. *Circulation* 2000a;102:1886-92.

Sacks FM, Moyé LA, Davis BR, Cole TG, Rouleau JL, Nash DT, Pfeffer MA, and Braunwald E. Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial. *Circulation* 1998;97:1446-52.

Sacks FM, Pasternak RC, Gibson CM, Rosner B, Stone PH. Harvard Atherosclerosis Reversibility Project (HARP) Group. Effect on coronary atherosclerosis of decrease in plasma cholesterol concentrations in normocholesterolemic patients.. *Lancet* 1994;344:1182-6.

Sacks FM, Pfeffer MA, Moyé LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JMO, Wun C-C, Davis BR, Braunwald E, for the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. *N Engl J Med* 1996;335:1001-9.

Sacks FM, Stone PH, Gibson CM, Silverman DI, Rosner B, Pasternak RC. Controlled trial of fish oil for regression of human coronary atherosclerosis. *J Am Coll Cardiol* 1995;25:1492-8.

Sacks FM, Svetkey LP, Vollmer WM, Appel LJ, Bray GA, Harsha D, Obarzanek E, Conlin PR, Miller ER, Simons-Morton DG, Karanja N, Lin P-H, Aickin M, Most-Windhauser MM, Moore TJ, Proschan MA, Cutler JA. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. *N Engl J Med* 2001;344:3-10.

Sacks FM, Tonkin AM, Shepherd J, Braunwald E, Cobbe S, Hawkins CM, Keech A, Packard C, Simes J, Byington R, Furberg CD. Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors. The prospective pravastatin pooling project. *Circulation* 2000b;102:1893-900.

Saldanha LF, Hurst KS, Amend WJ, Lazarus JM, Lowrie EG, Ingelfinger J, Grupe W, Levey R. Hyperlipidemia after renal transplantation in children. *Am J Dis Child* 1976;130(9):951-3.

Salenius JP. The course of atherosclerotic diseases after carotid endarterectomy in 279 patients followed-up for 21 years. *J Intern Med* 1989;225:373-8.

Salonen JT, Salonen R. Ultrasonographically assessed carotid morphology and the risk of coronary heart disease. *Arterioscler Thromb* 1991;11:1245-9.

Salonen R, Nyssönen K, Porkkala E, Rummukainen J, Belder R, Park JS, Salonen JT. Kuopio Atherosclerosis Prevention Study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. *Circulation* 1995;92:1758-64.

Saltzman E, Dallal GE, Roberts SB. Effect of high-fat and low-fat diets on voluntary energy intake and substrate oxidation: studies in identical twins consuming diets matched for energy density, fiber, and palatability. *Am J Clin Nutr* 1997;66:1332-9.

Salzmann P, Kerlikowske K, Phillips K. Cost-effectiveness of extending screening mammography guidelines to include women 40 to 49 years of age. *Ann Intern Med* 1997;127:955-65.

Sandvik L, Erikssen J, Thaulow E, Erikssen G, Mundal R, Rodahl K. Physical fitness as a predictor of mortality among healthy, middle-aged Norwegian men. *N Engl J Med* 1993;328:533-7.

Santamarina-Fojo S. The familial chylomicronemia syndrome. *Endocrinol Metab Clin North Am* 1998;27:551-67.

Savage PJ, Pressel SL, Curb JD, Schon EB, Applegate WB, Black HR, Cohen J, Davis BR, Frost P, Smith W, Gonzalez N, Guthrie GP, Oberman A, Rutan G, Probstfield JL, Stamler J. Influence of long-term, low-dose, diuretic-based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension: The Systolic Hypertension in the Elderly Program SHEP Cooperative Research Group. *Arch Intern Med* 1998;158:741-51.

Scandinavian Simvastatin Survival Study Group. Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S). *Lancet* 1995;345:1274-5.

Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4,444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). *Lancet* 1994;344:1383-9.

Scarabin PY, Alhenc-Gelas M, Plu-Bureau G, Taisne P, Agher R, Aiach M. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomized controlled trial. *Arterioscler Thromb Vasc Biol* 1997;17:3071-8.

Schaefer EJ, Lamon-Fava S, Ordovas JM, Cohn SD, Schaefer MM, Castelli WP, Wilson PWF. Factors associated with low and elevated plasma high density lipoprotein cholesterol and apolipoprotein A-I levels in the Framingham Offspring Study. *J Lipid Res* 1994;35:871-2.

Schaefer EJ, McNamara JR, Genest J Jr., Ordovas JM. Clinical significance of hypertriglyceridemia. *Semin Thromb Hemost* 1988;14:143-8.

Schechtman G, Wolff N, Byrd JC, Hiatt JG, Hartz A. Physician extenders for cost-effective management of hypercholesterolemia. *J Gen Intern Med* 1996;11:277-86.

Schoonjans K, Staels B, Auwerx J. Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. *J Lipid Res* 1996;37:907-25.

Schrott HG, Bittner V, Vittinghoff E, Herrington DM, Hulley S. Adherence to National Cholesterol Education Program Treatment goals in postmenopausal women with heart disease. The Heart and Estrogen/Progestin Replacement Study (HERS). *JAMA* 1997;277:1281-6.

Schucker B, Wittes JT, Santanello NC, Weber SJ, McGoldrick D, Donato K, Levy A, Rifkind BM. Change in cholesterol awareness and action. Results from national physician and public surveys. *Arch Intern Med* 1991;151(4):666-73.

Schuler G, Hambrecht R, Schlierf G, Niebauer J, Hauer K, Neumann J, Hoberg E, Drinkmann A, Bacher F, Grunze M, Kübler W. Regular physical exercise and low-fat diet. Effects on progression of coronary artery disease. *Circulation* 1992;86:1-11.

Schuster H, Rauh G, Kormann B, Hepp T, Humphries S, Keller C, Wolfram G, Zollner N. Familial defective apolipoprotein B-100. Comparison with familial hypercholesterolemia in 18 cases detected in Munich. *Arteriosclerosis* 1990;10(4):577-81.

Schutz Y: Macronutrients and energy balance in obesity. *Metabolism* 1995;44:7-11.

Schwartz GG, Olsson AG, Ezkowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A, Chaitman BR, Leslie S, Stern T. Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. *JAMA* 2001;285:1711-8.

Schwartz JS, Boccuzzi SJ, Murray JF, Roehn JB, Cook JR, Glick H, Kinosian B, Pedersen T, Kjekshus J. Cost-effectiveness of LDL-C reduction in Medicare managed care CHD patients: implications from the Scandinavian Simvastatin Survival Study (4S) [Abstract]. *J Am Coll Cardiol* 1997;29:226A.

Secker-Walker RH, Worden JK, Holland RR, Flynn BS, Detsky AS. A mass media programme to prevent smoking among adolescents: costs and cost effectiveness. *Tobacco Control* 1997;6:207-12.

Sedlis SP, Schechtman KB, Ludbrook PA, Sobel BE, Schonfeld G. Plasma apoproteins and the severity of coronary artery disease. *Circulation* 1986;73:978-86.

Seidell JC. Dietary fat and obesity: an epidemiologic perspective. *Am J Clin Nutr* 1998;67 (suppl):546S-50S.

Seidell JC: Time trends in obesity: an epidemiological perspective. *Hormone Metabol Res* 1997;29:155-8.

Selmer R. Blood pressure and twenty-year mortality in the city of Bergen, Norway. *Am J Epidemiol* 1992;136:428-40.

Seman LJ, DeLuca C, Jenner JL, Cupples LA, McNamara JR, Wilson PW, Castelli WP, Ordovas JM, Schaefer EJ. Lipoprotein(a)-cholesterol and coronary heart disease in the Framingham Heart Study. *Clin Chem* 1999;45:1039-46.

Sempos CT, Cleeman JI, Carroll MD, Johnson CL, Bachorik PS, Gordon DJ, Burt VL, Briefel RR, Brown CD, Lippel K, Rifkind BM. Prevalence of high blood cholesterol among U.S. adults. An update based on guidelines from the second report of the National Cholesterol Education Program Adult Treatment Panel. *JAMA* 1993;269:3009-14.

Shaffer J, Wexler J. Reducing low-density lipoprotein cholesterol levels in an ambulatory care system. Results of a multidisciplinary collaborative practice lipid clinic compared with traditional physician-based care. *Arch Intern Med* 1995;155:2330-5.

Shah M, Garg A. High-fat and high-carbohydrate diets and energy balance. *Diabetes Care* 1996;19:1142-52.



Sharrett AR, Sorlie PD, Chambless LE, Folsom AR, Hutchinson RG, Heiss G, Szklo M. Relative importance of various risk factors for asymptomatic carotid atherosclerosis versus coronary heart disease incidence. The Atherosclerosis Risk in Communities Study. *Am J Epidemiol* 1999;149:843-52.

Shea S, Ottman R, Gabrieli C, Stein Z, Nichols A. Family history as an independent risk factor for coronary artery disease. *J Am Coll Cardiol* 1984;4:793-801.

SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). *JAMA* 1991;265:3255-64.

Shepard DS, Stason WB, Perry HM Jr., Carmen BA, Nagurney JT. Multivariate cost-effectiveness analysis: an application to optimizing ambulatory care for hypertension. *Inquiry* 1995;32:320-31.

Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlane PW, McKillop JH, Packard CJ, for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. *N Engl J Med* 1995;333:1301-7.

Shepherd J. Fibrates and statins in the treatment of hyperlipidemia: an appraisal of their efficacy and safety. *Eur Heart J* 1995;16:5-13.

Shepherd J. Preventing coronary artery disease in the West of Scotland: implications for primary prevention. *Am J Cardiol* 1998;82:57T-9T.

Shepherd R, Stockley L. Nutrition knowledge, attitudes, and fat consumption. *J Am Diet Assoc* 1987;87:615-9.

Sherman AM, Bowen DJ, Vitolins M, Perri MG, Rosal MC, Sevick MA, Ockene JK. Dietary adherence: characteristics and interventions. *Control Clin Trials* 2000;21(suppl 5):206S-11S.

Siegmund KD, Province MA, Higgins M, Williams RR, Keller J, Todorov AA. Modeling disease incidence rates in families. *Epidemiology* 1998;9:557-62.

Silberberg JS, Wlodarczyk J, Fryer J, Ray CD, Hensley MJ. Correction for biases in a population-based study of family history and coronary heart disease. The Newcastle Family History Study I. *Am J Epidemiol* 1998a;147:1123-32.

Silberberg JS, Wlodarczyk J, Fryer J, Robertson R, Hensley MJ. Risk associated with various definitions of family history of coronary heart disease. The Newcastle Family History Study II. *Am J Epidemiol* 1998b;147:1133-9.

Simon DG. A cost-effectiveness analysis of cyclosporine in cadaveric kidney transplantation. *Med Decis Making* 1986;6:199-207.

Simons LA, Levis G, Simons J. Apparent discontinuation rates in patients prescribed lipid-lowering drugs. *Med J Aust* 1996;164:208-11.

- Simons LA, Simons J. Diabetes and coronary heart disease. *N Engl J Med* 1998;339:1714-5.
- Simpson KN, Snyder LB. Informing the mammography coverage debate. Results of meta-analysis, computer modeling, and issue analysis. *Int J Technol Assess Health Care* 1991;7:616-31.
- Singh RB, Niaz MA, Sharma JP, Kumar R, Rastogi V, Moshiri M. Randomized, double-blind, placebo-controlled trial of fish oil and mustard oil in patients with suspected acute myocardial infarction: the Indian experiment of infarct survival--4. *Cardiovasc Drugs Ther* 1997;11:485-91.
- Siscovick DS, Raghunathan TE, King I, Weinmann S, Wicklund KG, Albright J, Bovbjerg V, Arbogast P, Smith H, Kushi LH, Cobb LA, Copass MK, Psaty BM, Lemaitre R, Retzlaff B, Childs M, Knopp RH. Dietary intake and cell membrane levels of long-chain n-3 polyunsaturated fatty acids and the risk of primary cardiac arrest. *JAMA* 1995;274:1363-7.
- Slack J. Risks of ischaemic heart-disease in familial hyperlipoproteinaemic states. *Lancet* 1969;2:1380-2.
- Slattery ML, Berry TD, Potter J, Caan B. Diet diversity, diet composition, and risk of colon cancer (United States). *Cancer Causes Control* 1997a;8:872-82.
- Slattery ML, Potter JD, Duncan DM, Berry TD. Dietary fats and colon cancer: assessment of risk associated with specific fatty acids. *Intl J Cancer* 1997b;73:670-7.
- Smith GD, Song F, Sheldon TA. Cholesterol lowering and mortality: the importance of considering initial level of risk. *BMJ* 1993;306:1367-73.
- Smith SC Jr., Amsterdam E, Balady GJ, Bonow RO, Fletcher GF, Froelicher V, Heath G, Limacher MC, Maddahi J, Pryor D, Redberg RF, Roccella E, Ryan T, Smaha L, Wenger NK. Prevention Conference V. Beyond secondary prevention: identifying the high-risk patient for primary prevention. Tests for silent and inducible ischemia. Writing Group II. *Circulation* 2000a;101:E12-6.
- Smith SC Jr., Greenland P, Grundy SM. AHA Conference Proceedings. Prevention Conference V. Beyond secondary prevention: identifying the high-risk patient for primary prevention. Executive summary. *Circulation* 2000b;101:111-16.
- Smith WF. Cost-effectiveness and cost-benefit analyses for public health programs. *Public Health Rep* 1968;83:899-906.
- Smith-Warner SA, Spiegelman D, Yaun S-S, van den Brandt PA, Folsom AR, Goldbohm A, Graham S, Holmberg L, Howe GR, Marshall JR, Miller AB, Potter JD, Speizer FE, Willett WC, Wolk A, Hunter DJ. Alcohol and breast cancer in women: a pooled analysis of cohort studies. *JAMA* 1998;279:535-40.
- Sniderman A, Vu H, Cianflone K. Effect of moderate hypertriglyceridemia on the relation of plasma total and LDL apo B levels. *Atherosclerosis* 1991;89:109-16.

Sniderman AD. Apolipoprotein B and apolipoprotein AI as predictors of coronary artery disease. *Can J Cardiol* 1988;4(suppl A):24A–30A.

Snowden CB, McNamara PM, Garrison RJ, Feinleib M, Kannel WB, Epstein FH. Predicting coronary heart disease in siblings—a multivariate assessment. The Framingham Heart Study. *Am J Epidemiol* 1982;115:217-22.

Sollano JA, Rose EA, Williams DL, Thornton B, Quint E, Apfelbaum M, Wasserman H, Cannavale GA, Smith CR, Reemtsma K, Greene RJ. Cost-effectiveness of coronary artery bypass surgery in octogenarians. *Ann Surg* 1998;228:297-306.

Soria LF, Ludwig EH, Clarke HRG, Vega GL, Grundy SM, McCarthy BJ. Association between a specific apolipoprotein B mutation and familial defective apolipoprotein B-100. *Proc Natl Acad Sci U S A* 1989;86:587-91.

Sorlic PD, Backlund E, Johnson NJ, Rogot E. Mortality by Hispanic status in the United States. *JAMA* 1993;270:2464-8.

Sosenko JM, Kato M, Soto R, Goldberg RB. Plasma lipid levels at diagnosis in type 2 diabetic patients. *Diabet Med* 1993;10:814-9.

Sotelo MM, Johnson SR. The effects of hormone replacement therapy on coronary heart disease. *Endocrinol Metab Clin North Am* 1997;26:313-28.

Sprecher DL, Abrams J, Allen JW, Keane WF, Chrysant SG, Ginsberg H, Fischer JJ, Johnson BF, Theroux P, Jokubaitis L. Low-dose combined therapy with fluvastatin and cholestyramine in hyperlipidemic patients. *Ann Intern Med* 1994;120:537-43.

Sprecher DL, Pearce GL, Cosgrove DM, Lytle BW, Loop FD, Pashkow FJ. Relation of serum triglyceride levels to survival after coronary artery bypass grafting. *Am J Cardiol* 2000;86:285-8.

Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhager WH, Bulpitt CJ, de Leeuw PW, Dollery CT, Fletcher AE, Forette F, Leonetti G, Nachev C, O'Brien ET, Rosenfeld J, Rodicio JL, Tuomilehto J, Zanchetti A. Randomised double-blind comparison of placebo and active treatment for older persons with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. *Lancet* 1997;350:757-64.

Stamler J, Briefel RR, Milas C, Grandits GA, Caggiula AW. Relation of changes in dietary lipids and weight, trial years 1-6, to change in blood lipids in the special intervention and usual care groups in the Multiple Risk Factor Intervention Trial. *Am J Clin Nutr* 1997;65:272S-88S.

Stamler J, Daviglius ML, Garside DB, Dyer AR, Greenland P, Neaton JD. Relationship of baseline serum cholesterol levels in 3 large cohorts of younger men to long-term coronary, cardiovascular, and all-cause mortality and to longevity. *JAMA* 2000;284:311-8.

Stamler J, Shekelle R. Dietary cholesterol and human coronary heart disease. The epidemiologic evidence. *Arch Path Lab Med* 1988;112:1032-40.

Stamler J, Stamler R, Neaton JD. Blood pressure, systolic and diastolic, and cardiovascular risks. U.S. population data. *Arch Intern Med* 1993;153:598-615.

Stamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). *JAMA* 1986;256:2823-8.

Stamos TD, Girard SA, Shaltoni H. Chart prompts significantly improve compliance with national cholesterol guidelines. *Circulation* 1999;100(18 suppl 1):I-239 [Abstract 1241].

Stampfer MJ, Hennekens CH, Manson JE, Colditz G, Rosner B, Willett WC. Vitamin E consumption and the risk of coronary disease in women. *N Engl J Med* 1993;328:1444-9.

Stampfer MJ, Malinow MR, Willett WC, Newcomer LM, Upton B, Ullmann D, Tishler PV, Hennekens CH. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in U.S. physicians. *JAMA* 1992;268:877-81.

Stange PV, Sumner AT. Predicting treatment costs and life expectancy for end-stage renal disease. *N Engl J Med* 1978;298:372-8.

Stary HC, Blankenhorn DH, Chandler AB, Glagov S, Insull W Jr., Richardson M, Rosenfeld ME, Schaffer SA, Schwartz CJ, Wagner WD, Wissler RW. A definition of the intima of human arteries and of its atherosclerosis-prone regions. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. *Circulation* 1992;85:391-405.

Stary HC, Chandler AB, Dinsmore RE, Fuster V, Glagov S, Insull W, Rosenfeld ME, Schwartz CJ, Wagner WD, Wissler RW. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. *Circulation* 1995;92:1355-74.

Stary HC, Chandler AB, Glagov S, Guyton JR, Insull W Jr., Rosenfeld ME, Schaffer SA, Schwartz CJ, Wagner WD, Wissler RW. A definition of initial, fatty streak, and intermediate lesions of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. *Arterioscler Thromb* 1994;14:840-56.

Starzl TE, Putnam CW, Koep LJ. Portacaval shunt and hyperlipidemia. *Arch Surg* 1978;113:71-4.

Stason WB, Weinstein MC. Public-health rounds at the Harvard School of Public Health. Allocation of resources to manage hypertension. *N Engl J Med* 1977;296:732-9.

Stehouwer CDA, Weijenberg MP, van den Berg M, Jakobs C, Feskens EJM, Kromhout D. Serum homocysteine and risk of coronary heart disease and cerebrovascular disease in elderly men. A 10-year follow-up. *Arterioscler Thromb Vasc Biol* 1998;18:1895-901.

- Stein E. Cerivastatin in primary hyperlipidemia: A multicenter analysis of efficacy and safety. *Am J Cardiol* 1998;82:40J-6J.
- Stein EA, Lane M, Laskarzewski P. Comparison of statins in hypertriglyceridemia. *Am J Cardiol* 1998;81(4A):6B-69B.
- Steinberg KK, Smith SJ, Thacker SB, Stroup DF. Breast cancer risk and duration of estrogen use: the role of study design in meta-analysis. *Epidemiology* 1994;4:415-21.
- Steiner G, Adelman AG, Silver MD. Early coronary atherosclerosis in primary type V hyperlipoproteinemia. *Can Med Assoc J* 1971;105:1172-4.
- Steiner G, Schwartz L, Shumak S, Poapst M. The association of increased levels of intermediate-density lipoproteins with smoking and with coronary artery disease. *Circulation* 1987;75:124-30.
- Stenstrand U, Wallentin L. Early statin treatment following acute myocardial infarction and 1-year survival. *JAMA* 2001;285:430-6.
- Stephens NG, Parsons A, Schofield PM, Kelly F, Cheeseman K, Mitchinson MJ. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). *Lancet* 1996;347:781-6.
- Stern MP, Haffner SM. Body fat distribution and hyperinsulinemia as risk factors for diabetes and cardiovascular disease. *Arteriosclerosis* 1986;6:123-30.
- Stirling CM, Isles CG. Rhabdomyolysis due to simvastatin in a transplant patient: Are some statins safer than others? *Nephrol Dial Transplant* 2001;16:873-4.
- Stoffel W, Demant T. Selective removal of apolipoprotein B-containing serum lipoproteins from blood plasma. *Proc Natl Acad Sci U S A* 1981;78:611-5.
- Stone NJ, Levy RI, Fredrickson DS, Verter J. Coronary artery disease in 116 kindred with familial type II hyperlipoproteinemia. *Circulation* 1974;49:476-88.
- Stone NJ. Secondary causes of hyperlipidemia. *Med Clin North Am* 1994;78:117-41.
- Stone PW, Teutsch S, Chapman RH, Bell C, Goldie SJ, Neumann PJ. Cost-utility analyses of clinical preventive services. Published ratios, 1976–1997. *Am J Prev Med* 2000;19:15-23.
- Strandberg TE, Tilvis RS, Lindberg O, Valvanne J, Sairanen S, Ehnholm C, Tuomilehto J. High plasma insulin is associated with lower LDL cholesterol in elderly individuals. *Atherosclerosis* 1996;121:267-73.
- Streitz JM Jr., Ellis FH Jr., Tilden RL, Erickson RV. Endoscopic surveillance of Barrett's esophagus: a cost-effectiveness comparison with mammographic surveillance for breast cancer. *Am J Gastroenterol* 1998;93:911-15.

Stroes ES, Koomans HA, deBruin TW, Rabelink TJ. Vascular function in the forearm of hypercholesterolaemic patients off and on lipid-lowering medication. *Lancet* 1995;346:467-71.

Strong JP, Malcolm GT, Oalman MC, Wissler RW. The PDAY Study: natural history, risk factors, and pathobiology. *Ann NY Acad Sci* 1997;811:226-37.

Strong JP, Malcom GT, McMahan CA, Tracy RE, Newman WP III, Herderick EE, Cornhill JF. Prevalence and extent of atherosclerosis in adolescents and young adults. Implications for prevention from the pathobiological determinants of atherosclerosis in youth study. *JAMA* 1999;281:727-35.

Stuart-Shor E, Skinner SS, Kemper AJ, McCleary NC, Clark SJ, Waldman HM. A nurse-directed, community based, integrated multiple cardiac risk reduction program: physiologic and behavioral outcomes [Abstract]. *Circulation* 1999;100(18 suppl 1):I-100.

Stubbs P, Seed M, Lane D, Collinson P, Kendall F, Noble M. Lipoprotein(a) as a risk predictor for cardiac mortality in patients with acute coronary syndromes. *Eur Heart J* 1998;19:1355-64.

Stuyt PM, Van-t-Laar A. Clinical features of type III hyper-lipoproteinaemia. *Neth J Med* 1983;26(4):104-11.

Su HY, Sheu WH, Chin HM, Jeng CY, Chen YD, Reaven GM. Effect of weight loss on blood pressure and insulin resistance in normotensive and hypertensive obese individuals. *Am J Hypertens* 1995;8:1067-71.

Su W, Campos H, Judge H, Walsh BW, Sacks FM. Metabolism of Apo(a) and ApoB100 of lipoprotein(a) in women: effect of postmenopausal estrogen replacement. *J Clin Endocrinol Metab* 1998;83:3267-76.

Sundquist J, Winkleby MA, Pudaric S. Cardiovascular disease risk factors among older black, Mexican-American, and white women and men: an analysis of NHANES III, 1988-1994. Third National Health and Nutrition Examination Survey. *J Am Geriatr Soc* 2001;49:109-16.

Sundquist J, Winkleby MA. Cardiovascular risk factors in Mexican American adults: a transcultural analysis of NHANES III, 1988-1994. *Am J Public Health* 1999;89:723-30.

Superko HR, Greenland P, Manchester RA, Andreadis NA, Schectman G, Hendriksen West N, Hunninghake D, Haskell WL, Probstfield JL. Effectiveness of low-dose colestipol therapy in patients with moderate hypercholesterolemia. *Am J Cardiol* 1992;70:135-40.

Superko HR, Krauss RM. Differential effects of nicotinic acid in subjects with different LDL subclass patterns. *Atherosclerosis* 1992;95:69-76.

Takata K, Saku K, Ohta T, Takata M, Bai H, Jimi S, Liu R, Sato H, Kajiyama G, Arakawa K. A new case of ApoA-I deficiency showing codon 8 nonsense mutation of the ApoA-I gene without evidence of coronary heart disease. *Arterioscler Thromb Vasc Biol* 1995;15:1866-74.

- Takeichi S, Yukawa N, Nakajima Y, Osawa M, Saito T, Seto Y, Nakano T, Saniabadi AR, Adachi M, Wang T, Nakajima K. Association of plasma triglyceride-rich lipoprotein remnants with coronary atherosclerosis in cases of sudden cardiac death. *Atherosclerosis* 1999;142:309-15.
- Tall AR. An overview of reverse cholesterol transport. *Eur Heart J* 1998;19(suppl A):A31-A35.
- Tamai O, Matsuoka H, Itabe H, Wada Y, Kohno K, Imaizumi T. Single LDL apheresis improves endothelium-dependent vasodilation in hypercholesterolemic humans. *Circulation* 1997;95:76-82.
- Tamura A, Mikuriya Y, Nasu M. Coronary Artery Regression Study (CARS) Group. Effect of pravastatin on progression of coronary atherosclerosis in patients with serum total cholesterol levels from 160 to 220 mg/dL and angiographically documented coronary artery disease. *Am J Cardiol* 1997;79:893-6.
- Tangirala RK, Tsukamoto K, Chun SH, Usher D, Pure E, Rader DJ. Regression of atherosclerosis induced by liver-directed gene transfer of apolipoprotein A-I in mice. *Circulation* 1999;100:1816-22.
- Tardif JC, Cote G, Lesperance J, Bourassa M, Lambert J, Doucet S, Bilodeau L, Nattel S, de Guise P. Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. Multivitamins and Probucol Study Group. *N Engl J Med* 1997;337:365-72.
- Tatami R, Mabuchi H, Ueda K, Ueda R, Haba T, Kametani T, Ito S, Koizumi J, Ohta M, Miyamoto S, Nakayama A, Kanaya H, Oiwake H, Genda A, Takeda R. Intermediate-density lipoprotein and cholesterol-rich very low density lipoprotein in angiographically determined coronary artery disease. *Circulation* 1981;64:1174-84.
- Tato F, Vega GL, Grundy SM. Effects of crystalline nicotinic acid-induced hepatic dysfunction on serum low-density lipoprotein cholesterol and lecithin cholesteryl acyl transferase. *Am J Cardiol* 1998;81:805-7.
- Tato F, Vega GL, Grundy SM. Bimodal distribution of cholesteryl ester transfer protein activities in normotriglyceridemic men with low HDL cholesterol concentrations. *Arterioscler Thromb Vasc Biol* 1995;15(4):446-51.
- Taylor CB, Houston-Miller N, Killen JD, DeBusk RF. Smoking cessation after acute myocardial infarction: effects of a nurse-managed intervention. *Ann Intern Med* 1990;113:118-23.
- Taylor HA, Mickel MC, Chaitman BR, Sopko G, Cutter GR, Rogers WJ. Long-term survival of African Americans in the Coronary Artery Surgery Study (CASS). *J Am Coll Cardiol* 1997;29:358-64.
- Teng B, Sniderman AD, Soutar AK, Thompson GR. Metabolic basis of hyperapobetalipoproteinemia. Turnover of apolipoprotein B in low density lipoprotein and its precursors and subfractions compared with normal and familial hypercholesterolemia. *J Clin Invest* 1986;77:663-72.

Tengs T, personal communication. Data from the "Cost-Effectiveness Database" produced by the Health Priorities Research Group at the University of California, Irvine (<http://www.healthpriorities.uci.edu>).

Tengs TO, Adams ME, Pliskin JS, Safran DG, Siegel JE, Weinstein MC, Graham JD. Five-hundred life-saving interventions and their cost-effectiveness. *Risk Anal* 1995;15:369-90.

Tengs TO, Wallace A. One thousand health-related quality-of-life estimates. *Med Care* 2000;38:583-637.

Theroux P, Fuster V. Acute coronary syndromes: unstable angina and non-Q-wave myocardial infarction. *Circulation* 1998;97:1195-220.

Thomas, TS. Improving care with nurse case managers: practical aspects of designing lipid clinics. *Am J Cardiol* 1997;80:62H-5H.

Thompson GR, Miller JP, Breslow JL. Improved survival of patients with homozygous familial hypercholesterolaemia treated with plasma exchange. *BMJ* 1985;291:1671-3.

Thompson GR, Myant NB. Regression of atherosclerosis. *Atherosclerosis* 1980;35:347-8.

Thompson GR. Angiographic evidence for the role of triglyceride-rich lipoproteins in progression of coronary artery disease. *Eur Heart J* 1998;19(suppl H):H31-6.

Thourani VH, Weintraub WS, Stein B, Gebhart SS, Craver JM, Jones EL, and Guyton RA. Influence of diabetes mellitus on early and late outcome after coronary artery bypass grafting. *Ann Thorac Surg* 1999;67:1045-52.

Thun MJ, Peto R, Lopez AD, Monaco JH, Henley SJ, Heath CW, Doll R. Alcohol consumption and mortality among middle-aged and elderly U.S. adults. *N Engl J Med* 1997;337:1705-14.

Tippett KS, Cleveland LE. How current diets stack up: comparison with dietary guidelines. In: America's eating habits: changes and consequences. Washington, D.C.: United States Department of Agriculture, Economic Research Service, 2000;51-70.

Tobert JA, Bell GD, Birtwell J, James I, Kukovetz WR, Pryor JS, Buntinx A, Holmes IB, Chao YS, Bolognese JA. Cholesterol-lowering effect of mevinolin, an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme a reductase, in healthy volunteers. *J Clin Invest* 1982;69:913-9.

Toor M, Katchalsky A, Agmon J, Allalouf D. Atherosclerosis and related factors in immigrants to Israel. *Circulation* 1960;22:265-79.

Torgerson DJ. HRT and its impact on the menopause, osteoporosis and breast cancer. *Expert Opin Pharmacother* 2000;6:1163-9.

Tornvall P, Bavenholm P, Landou C, de Faire U, Hamsten A. Relation of plasma levels and composition of apolipoprotein B-containing lipoproteins to angiographically defined coronary artery disease in young patients with myocardial infarction. *Circulation* 1993;88:2180-9.



Toto RD, Grundy SM, Vega GL. Pravastatin treatment of very low density, intermediate density and low density lipoproteins in hypercholesterolemia and combined hyperlipidemia secondary to the nephrotic syndrome. *Am J Nephrol* 2000;20:12-7.

Tracy RP, Lemaitre RN, Psaty BM, Ives DG, Evans RW, Cushman M, Meilahn EN, Kuller LH. Relationship of C-reactive protein to risk of cardiovascular disease in the elderly. Results from the Cardiovascular Health Study and the Rural Health Promotion Project. *Arterioscler Thromb Vasc Biol* 1997a;17:1121-7.

Tracy RP, Psaty BM, Macy E, Bovill EG, Cushman M, Cornell ES, Kuller LH. Lifetime smoking exposure affects the association of C-reactive protein with cardiovascular disease in risk factors and subclinical disease in healthy elderly subjects. *Arterioscler Thromb Vasc Biol* 1997b;17:2167-76.

Traven ND, Kuller LH, Ives DG, Rutan GH, Perper JA. Coronary heart disease mortality and sudden death among the 35-44 year age group in Allegheny County, Pennsylvania. *Ann Epidemiol* 1996;6:130-6.

Tripathy D, Carlsson M, Almgren P, Isomaa B, Taskinen MR, Tuomi T, Groop LC. LDL cholesterol. Insulin secretion and insulin sensitivity in relation to glucose tolerance: lessons from the Botnia Study. *Diabetes* 2000;49:975-80.

Tsevat J, Kuntz KM, Orav EJ, Weinstein MC, Sacks FM, Goldman L. Cost-effectiveness of pravastatin therapy for survivors of myocardial infarction with average cholesterol levels. *Am Heart J* 2001;141(5):727-34.

Tsevat J. Impact and cost-effectiveness of smoking interventions. *Am J Med* 1992;93(suppl 1A):43S-7S.

Tsimihodimos V, Miltiados G, Elisaf M. Therapy with statins is effective in some patients with homozygous familial hypercholesterolemia. *Atherosclerosis* 2000;153:527.

Tucker KL, Mahnken B, Wilson PW, Jacques P, Selhub J. Folic acid fortification of the food supply. Potential benefits and risks for the elderly population. *JAMA* 1996a;276:1879-85. (Erratum, *JAMA* 1997;277:714.)

Tucker KL, Selhub J, Wilson PW, Rosenberg IH. Dietary intake patterns relates to plasma folate and homocysteine concentrations in the Framingham Heart Study. *J Nutr* 1996b;126:3025-31.

Tunstall-Pedoe H, Kuulasmaa K, Amouyel P, Arveiler D, Rajakangas AM, Pajak A. Myocardial infarction and coronary deaths in the World Health Organization MONICA Project: Registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents. *Circulation* 1994;90:583-612.

Tunstall-Pedoe H, Kuulasmaa K, Mahonen M, Tolonen H, Ruokokoski E, Amouyel P. Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA Project populations. *Lancet* 1999;353:1547-57.

Turley ML, Skeaff CM, Mann JI, Cox B. The effect of a low-fat, high-carbohydrate diet on serum high density lipoprotein cholesterol and triglyceride. *Eur J Clin Nutr* 1998; 52:728-32.

Twisk J, Gillian-Daniel DL, Tebon A, Wang L, Barrett PH, Attie AD. The role of the LDL receptor in apolipoprotein B secretion. *J Clin Invest* 2000;105:521-32.

Tybjaerg-Hansen A, Gallagher J, Vincent J, Houlston R, Talmud P, Dunning AM, Seed M, Hamsten A, Humphries SE, Myant NB. Familial defective apolipoprotein b-100: Detection in the United Kingdom and Scandinavia, and clinical characteristics of ten cases. *Atherosclerosis* 1990;80(3):235-42.

U.S. Department of Agriculture and U.S. Department of Health and Human Services. Nutrition and your health: dietary guidelines for Americans. 5th edition. Home and Garden Bulletin no. 232. Washington, D.C.: U.S. Department of Agriculture 2000:87 pages.

U.S. Department of Health and Human Services. Food and Drug Administration. Food labeling: health claims; oats and coronary heart disease. Final rule. Federal Register 1997a:3583-3601.

U.S. Department of Health and Human Services. Food and Drug Administration. Food labeling: health claims; oats and coronary heart disease. Proposed rule. Federal Register 1996a:296-337.

U.S. Department of Health and Human Services. Food and Drug Administration. Food labeling: health claims; soluble fiber from certain foods and coronary heart disease. Final rule. Federal Register 1998a:8103-21.

U.S. Department of Health and Human Services. Food and Drug Administration. Food labeling: health claims; soluble fiber from certain foods and coronary heart disease. Proposed rule. Federal Register 1997b:28234-45.

U.S. Department of Health and Human Services. Food and Drug Administration. Food labeling: health claims; soy protein and coronary heart disease. Final rule. Federal Register 1999a:57699-733.

U.S. Department of Health and Human Services. Food and Drug Administration. Food labeling: health claims; soy protein and coronary heart disease. Proposed rule. Federal Register 1998b:6297-301.

U.S. Department of Health and Human Services. Food and Drug Administration. Food labeling: Trans-fatty acids in nutrition labeling, nutrient content claims, and health claims. Proposed rule. Federal Register 1999b:62746-825.

U.S. Department of Health and Human Services. Healthy People 2010; Conference Edition. Volumes I and II. Washington DC: U.S. Department of Health and Human Services, January 2000. 1200 pages.

U.S. Department of Health and Human Services. Physical activity and health: a report of the Surgeon General. Atlanta, Georgia: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, 1996b:300 pages.

U.S. Preventive Services Task Force. Guide to clinical preventive services: report of the U.S. Preventive Services Task Force;2nd edition. Baltimore: Williams & Wilkins, 1996;504 pages.

U.S. Surgeon General. Reducing the consequences of smoking: 25 years of progress. A report of the Surgeon General. DHHS pub. no. (CDC) 89-8411. Bethesda MD: U.S. Department of Health and Human Services, Public Health Service, Office on Smoking and Health, 1989;703.

U.S. Surgeon General. The health benefits of smoking cessation. A report of the Surgeon General. DHHS pub. no. (CDC) 90-8416. Washington, D.C.: U.S. Department of Health and Human Services, 1990.

UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight persons with type 2 diabetes: (UKPDS 34). *Lancet* 1998a;352:854-65.

UK Prospective Diabetes Study (UKPDS) Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: (UKPDS 39). *BMJ* 1998b;317:713-20.

UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). *Lancet* 1998c;352:837-53.

UK Prospective Diabetes Study (UKPDS) Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: (UKPDS 38). *BMJ* 1998d; 317:703-13.

Umans-Eckenhuis MA, Defesche JC, Sijbrands EJ, Scheerder RLJM, Kastelein JJ. Review of first five years of screening for familial hypercholesterolaemia in the Netherlands. *Lancet* 2001;357:165-8.

Unpublished estimates of "The Present Value of Lifetime Earnings by Age and Sex, U.S., 1997" obtained in 2000 from Wendy Max, University of California at San Francisco.

Urquhart, J. Correlates of variable patient compliance in drug trials: Relevance in the new health care environment. *Adv Drug Res* 1995;26:237-57.

Utermann G. Genetic polymorphism of apolipoprotein E-impact on plasma lipoprotein metabolism. In: Crepaldi G, Tiengo A, Baggio G, eds. Diabetes, obesity and hyperlipidemias—III. Amsterdam: Elsevier, 1985;28.

Valeri A, Gelfand J, Blum C, Appel GB. Treatment of the hyperlipidemia of the nephrotic syndrome: a controlled trial. *Am J Kidney Dis* 1986;8:388-96.

van den Hoogen PC, Feskens EJ, Nagelkerke NJ, Menotti A, Nissinen A, Kromhout D. The relation between blood pressure and mortality due to coronary heart disease among men in different parts of the world. Seven Countries Study Research Group. *N Engl J Med* 2000;342:1-8.

van der Maas PJ, de Koning HJ, van Ineveld BM, van Oortmarsen GJ, Habbema JD, Lubbe KT, Geerts AT, Collette HJ, Verbeek AL, Hendriks JH, Rombach JJ. The cost-effectiveness of breast cancer screening. *Int J Cancer* 1989;43:1055-60.

Van Horn L, Kavey RE. Diet and cardiovascular disease prevention: what works? *Ann Behav Med* 1997;19:197-212.

Van Horn L, Liu K, Parker D, Emidy L, Liao Y, Pan WH, Giumetti D, Hewitt J, Stamler J. Serum lipid response to oat product intake with a fat modified diet. *JADA* 1986;86:759-64.

van Lenten BJ, Hama SY, de Beer FC, Stafforini DM, McIntyre TM, Prescott SM, La Du BN, Fogelman AM, Navab M. Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. *J Clin Invest* 1995;96:2758-67.

Vanhala MJ, Kumpusalo EA, Pitkajarvi TK, Notkola IL, Takala JK. Hyperinsulinemia and clustering of cardiovascular risk factors in middle-aged hypertensive Finnish men and women. *J Hypertens* 1997;15:475-81.

Vanhnen HT, Blomqvist S, Ehnholm C, Hyvonen M, Jauhiainen M, Torstila I, Miettinen TA. Serum cholesterol, cholesterol precursors, and plant sterols in hypercholesterolemic subjects with different apoE phenotypes during dietary sitostanol ester treatment. *J Lipid Res* 1993;34:1535-44.

Vasan RS, Larson MG, Evans JC, O'Donnell CJ, Levy D. High normal blood pressure and risk of cardiovascular disease: the Framingham Heart Study. *Circulation* 1999;100(18 suppl 1):34.

Vega GL, Clark LT, Tang A, Marcovina S, Grundy SM, Cohen JC. Hepatic lipase activity is lower in African American men than in white American men: effects of 5' flanking polymorphism in the hepatic lipase gene (LIPC). *J Lipid Res* 1998;39:228-32.

Vega GL, Denke MA, Grundy SM. Metabolic basis of primary hypercholesterolemia. *Circulation* 1991;84:118-28.

Vega GL, Grundy SM. Does measurement of apolipoprotein B have a place in cholesterol management? *Arteriosclerosis* 1990a;10:668-71.

- Vega GL, Grundy SM. Gemfibrozil therapy in primary hypertriglyceridemia associated with coronary heart disease. *JAMA* 1985;253:2398-403.
- Vega GL, Grundy SM. Hypoalphalipoproteinemia (low high density lipoprotein) as a risk factor for coronary heart disease. *Curr Opin Lipidol* 1996;7:209-16.
- Vega GL, Grundy SM. In vivo evidence for reduced binding of low density lipoproteins to receptors as a cause of primary moderate hypercholesterolemia. *J Clin Invest* 1986;78:1410-4.
- Vega GL, Grundy SM. Lipoprotein responses to treatment with lovastatin, gemfibrozil, and nicotinic acid in normolipidemic patients with hypoalphalipoproteinemia. *Arch Intern Med* 1994;154:73-82.
- Vega GL, Grundy SM. Lovastatin therapy in nephrotic hyperlipidemia: effects on lipoprotein metabolism. *Kidney Int* 1988;33:1160-8.
- Vega GL, Grundy SM. Management of primary mixed hyperlipidemia with lovastatin. *Arch Intern Med* 1990b;150:1313-9.
- Vega GL, Grundy SM. Primary hypertriglyceridemia with borderline high cholesterol and elevated apolipoprotein B concentrations. Comparison of gemfibrozil vs. lovastatin therapy. *JAMA* 1990c;264:2759-66.
- Veierod MB, Laake P, Theele DS. Dietary fat intake and risk of prostate cancer: a prospective study of 25,708 Norwegian men. *Intl J Cancer* 1997;73:634-8.
- Venkatesan S, Cullen P, Pacy P, Halliday D, Scott J. Stable isotopes show a direct relation between VLDL apoB overproduction and serum triglyceride levels and indicate a metabolically and biochemically coherent basis for familial combined hyperlipidemia. *Arterioscler Thromb* 1993;13:1110-8.
- Verges BL. Dyslipidaemia in diabetes mellitus. Review of the main lipoprotein abnormalities and their consequences on the development of atherogenesis. *Diabetes Metab* 1999;25(suppl 3):32-40.
- Verhoef P, Kok FJ, Kruyssen DA, Schouten EG, Witteman JC, Grobbee DE, Ueland PM, Refsum H. Plasma total homocysteine, B vitamins, and risk of coronary atherosclerosis. *Arterioscler Thromb Vasc Biol* 1997;17:989-95.
- Vermeer BJ, van Gent CM, Goslings B, Polano MK. Xanthomatosis and other clinical findings in patients with elevated levels of very low density lipoproteins. *Br J Dermatol* 1979;100(6):657-66.
- Visser M, Bouter LM, McQuillan GM, Werner MH, Harris TB. Elevated C-reactive protein levels in overweight and obese adults. *JAMA* 1999;282:2131-5.
- Vogt MT, Cauley JA, Newman AB, Kuller LH, Hulley SB. Decreased ankle/arm blood pressure index and mortality in elderly women. *JAMA* 1993;270:465-9.

von Schacky C, Angerer P, Kothny W, Theisen K, Mudra H. The Effect of dietary  $\omega$ -3 fatty acids on coronary atherosclerosis. A randomized, double-blind, placebo-controlled trial. *Ann Intern Med* 1999;130:554-62.

Vu-Dac N, Schoonjans K, Kosykh V, Dallongeville J, Fruchart JC, Staels B, Auwerx J. Fibrates increase human apolipoprotein A-11 expression through activation of the peroxisome proliferator-activated receptor. *J Clin Invest* 1995;96:741-50.

Vuksan V, Sievenpiper JL, Owen R, Swilley JA, Spadafora P, Jenkins DJ, Vidgen E, Brighenti F, Josse RG, Leiter LA, Xu Z, Novokmet R. Beneficial effects of viscous dietary fiber from Konjac-mannan in subjects with the insulin resistance syndrome: results of a controlled metabolic trial. *Diabetes Care* 2000;23:9-14.

Vuorio AF, Gylling H, Turtola H, Kontula K, Ketonen P, Miettinen TA. Stanol ester margarine alone and with simvastatin lowers serum cholesterol in families with familial hypercholesterolemia caused by the FH-North Karelia Mutation. *Arterio Thromb Vasc Biol* 2000;20:500-6.

Wadden T, Wingate B. Behavioral assessment and treatment of markedly obese persons. In: Wadden T, VanItallie T, eds. *Treatment of the seriously obese patient*. New York: Guilford Press, 1992:290-330.

Wadden TA, Foster GD, Letizia KA, Mullen JL. Long-term effects of dieting on resting metabolic rate in obese outpatients. *JAMA* 1990;264:707-11.

Wadden TA, Sternberg JA, Letizia KA, Stunkard AJ, Foster GD. Treatment of obesity by very low calorie diet, behavior therapy, and their combination: a five-year perspective. *Int J Obes* 1989;13(suppl 2):39-46.

Wadden TA, Stunkard AJ. Controlled trial of very low calorie diet, behavior therapy and their combination in the treatment of obesity. *J Consult Clin Psychol* 1986;54:482-8.

Wakabayashi Y, Okubo M, Shimada H, Sato N, Koide A, Marumo F, Nakamura H. Decreased VLDL apoprotein cii/apoprotein ci ratio may be seen in both normotriglyceridemic and hypertriglyceridemic patients on chronic hemodialysis treatment. *Metabolism* 1987;36(9):815-20.

Walden CE, Retzlaff BM, Buck BL, McCann BS, Knopp RH. Lipoprotein lipid response to the National Cholesterol Education Program Step II diet by hypercholesterolemic and combined hyperlipidemic women and men. *Arterioscler Throm Vasc Biol* 1997;17:375-82.

Walden CE, Retzlaff BM, Buck BL, Wallick S, McCann BS, Knopp RH. Differential effect of National Cholesterol Education Program (NCEP) Step II diet on HDL cholesterol, its subfractions, and apoprotein A-I in hypercholesterolemic women and men after 1 year: the beFIT study. *Arterioscler Throm Vasc Biol* 2000;20:1580-7.

Walsh BW, Kuller LH, Wild RA, Paul S, Farmer M, Lawrence JB, Shah AS, Anderson PW. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. *JAMA* 1998;279:1445-51.

Walsh BW, Li H, Sacks FM. Effects of postmenopausal hormone replacement with oral and transdermal estrogen on high density lipoprotein metabolism. *J Lipid Res* 1994;35:2083-93.

Walsh BW, Schiff I, Rosner B, Greenberg L, Ravnikaar V, Sacks FM. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. *N Engl J Med* 1991;325:1196-204.

Wanner C, Krämer-Guth A, Galle J. Use of HMG-CoA reductase inhibitors after kidney and heart transplantation: lipid-lowering and immunosuppressive effects. *BioDrugs* 1997;8:387-93.

Warner KE, Smith RJ, Smith DG, Fries BE. Health and economic implications of a work-site smoking-cessation program: a simulation analysis. *J Occup Med* 1996;38:981-92.

Wasley MA, McNagny SE, Phillips VL, Ahluwalia JS. The cost-effectiveness of the nicotine transdermal patch for smoking cessation. *Prev Med* 1997;26:264-70.

Waters D, Higginson L, Gladstone P, Boccuzzi SJ, Cook T, Lesperance J, for the CCAIT Study Group. Effects of cholesterol lowering on the progression of coronary atherosclerosis in women. A Canadian Coronary Atherosclerosis Intervention Trial (CCAIT) Substudy. *Circulation* 1995;92:2404-10.

Waters D, Higginson L, Gladstone P, Kimball B, Le May M, Boccuzzi SJ, Lesperance J. Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial. *Circulation* 1994;89:959-68.

Waters D, Lesperance J, Francetich M, Causey D, Theroux P, Chiang YK, Hudon G, Lemarbre L, Reitman M, Joyal M, et al. A controlled clinical trial to assess the effect of a calcium channel blocker on the progression of coronary atherosclerosis. *Circulation* 1990;82:1940-53.

Waters DD, Azar RR. Should intensive cholesterol lowering play a role in the management of acute coronary syndromes? *Am J Cardiol* 2000;86(suppl):35J-43J.

Watkins LO, Neaton JD, Kuller LH. Racial differences in high density lipoprotein cholesterol and coronary heart disease incidence in the usual-care group of the Multiple Risk Factor Intervention Trial. *Am J Cardiol* 1986;57:538-45.

Watts GF, Lewis B, Brunt JN, Lewis ES, Coltart DJ, Smith LD, Mann JI, Swan AV. Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St. Thomas' Atherosclerosis Regression Study (STARS). *Lancet* 1992;339:563-9.

Weggemans RM, Zock PL, Katan MB. Dietary cholesterol from eggs increases the ratio of total cholesterol to high-density lipoprotein cholesterol in humans; a meta-analysis. *Am J Clin Nutr* 2001;73:885-91.

- Wei M, Mitchell BD, Haffner SM, Stern MP. Effects of cigarette smoking, diabetes, high cholesterol, and hypertension on all-cause mortality and cardiovascular disease mortality in Mexican Americans. The San Antonio Heart Study. *Am J Epidemiol* 1996;144:1058-65.
- Weinberger MH. Antihypertensive therapy and lipids: evidence, mechanisms, and implications. *Arch Intern Med* 1985;145:1102-5.
- Weinstein MC, Stason WB. Cost-effectiveness of coronary artery bypass surgery. *Circulation* 1982;66(suppl III):56S-66S.
- Weinstein MC, Stason WB. Foundations of cost effectiveness analysis for health and medical practices. *N Engl J Med* 1977;296:716-21.
- Weinstein MC. From cost-effectiveness ratios to resource allocation: where to draw the line? In: Sloan FA, ed. Valuing health care: costs, benefits, and effectiveness of pharmaceuticals and other medical technologies. New York: Cambridge University Press, 1995;273 pages.
- Weise WJ, Possidente CJ. Fatal rhabdomyolysis associated with simvastatin in a renal transplant patient. *Am J Med* 2000;108:351-2.
- Weisgraber KH, Innerarity TL, Rall SC Jr., Mahley RW. Atherogenic lipoproteins resulting from genetic defects of apolipoproteins B and E. *Ann N Y Acad Sci* 1990;598:37-48.
- Welty TK, Lee ET, Yeh J, Cowan LD, Go O, Fabsitz RR, Le NA, Oopik AJ, Robbins DC, Howard BV. Cardiovascular disease risk factors among American Indians: the Strong Heart Study. *Am J Epidemiol* 1995;142:269-87.
- West CE, Sullivan DR, Katan MB, Halferkamp IL, van der Torre HW. Boys from populations with high-carbohydrate intake have higher fasting triglyceride levels than boys from populations with high-fat intake. *Am J Epidemiol* 1990;131:271-82.
- West MS, Herd A, Ballantyne CM, Pownall HJ, Simpson S, Gould L, Gotto AM Jr. The lipoprotein and coronary atherosclerosis study (LCAS): design, methods and baseline data of a trial of fluvastatin in patients without severe hypercholesterolemia. *Control Clin Trials* 1996;17:550-83.
- Westerveld HT, van Lennep JE, van Lennep HW, Liem AH, de Boo JA, van der Schouw YT, Erkelens DW. Apolipoprotein B and coronary artery disease in women: a cross-sectional study in women undergoing their first coronary angiography. *Arterioscler Thromb Vasc Biol* 1998;18:1101-7.
- Westrate JA, Meijer GW. Plant sterol-enriched margarines and reduction of plasma total- and LDL-cholesterol concentrations in normocholesterolaemic and mildly hypercholesterolaemic subjects. *Eur J Clin Nutr* 1998;52:334-43.
- Whincup PH, Refsum H, Perry IJ, Morris R, Walker M, Lennon L, Thomson A, Ueland PM, Ebrahim SB. Serum total homocysteine and coronary heart disease: prospective study in middle aged men. *Heart* 1999;82:448-54.



White HD, Simes RJ, Anderson NE, Hankey GJ, Watson JD, Hunt D, Colquhoun DM, Glasziou P, MacMahon S, Kirby AC, West MJ, Tonkin AM. Pravastatin therapy and the risk of stroke. *N Engl J Med*. 2000;343:317-26.

Wilcosky T, Hyde J, Anderson JJB, Bangdiwala S, Duncan B. Obesity and mortality in the lipid research clinics program follow-up study. *J Clin Epidemiol* 1990;43:743-52.

Willett WC, Green A, Stampfer MJ, Speizer FE, Colditz GA, Rosner B, Monson RR, Stason W, Hennekens CH. Relative and absolute excess risks of coronary heart disease among women who smoke cigarettes. *N Engl J Med* 1987;317(21):1303-9.

Willett WC, Stampfer MJ, Manson JE, Colditz GA, Speizer FE, Rosner BA, Sampson LA, Hennekens CH. Intake of trans-fatty acids and risk of coronary heart disease among women. *Lancet* 1993;341:581-5.

Willett WC. Is dietary fat a major determinant of body fat? *Am J Clin Nutr* 1998;67 (suppl):556S-62S.

Willett WC: Fat, energy and breast cancer. *J Nutr* 1997;127(5 suppl):921S-32S.

Williams A. Economics of coronary artery bypass grafting. *BMJ* 1985;291:326-9.

Williams RR, Hunt SC, Heiss G, Province MA, Bensen JT, Higgins M, Chamberlain RM, Ware J, Hopkins PN. Usefulness of cardiovascular family history data for population-based preventive medicine and medical research (the Health Family Tree Study and the NHLBI Family Heart Study). *Am J Cardiol* 2001;87:129-35.

Wilson DE, Emi M, Iverius PH, Hata A, Wu LL, Hillas E, Williams RR, Lalouel JM. Phenotypic expression of heterozygous lipoprotein lipase deficiency in the extended pedigree of a proband homozygous for a missense mutation. *J Clin Invest* 1990;86:735-50.

Wilson MA, Vega GL, Gylling H, Grundy SM. Persistence of abnormalities in metabolism of apolipoproteins B-100 and A-I after weight reduction in patients with primary hypertriglyceridemia. *Arteriosclerosis & Thrombosis* 1992;12:976-84.

Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. *Circulation* 1998;97:1837-47.

Wilson PW, Garrison RJ, Castelli WP, Feinleib M, McNamara PM, Kannel WB. Prevalence of coronary heart disease in the Framingham Offspring Study: role of lipoprotein cholesterol. *Am J Cardiol* 1980;46:649-54.

Wingard DL, Barrett-Connor E. Heart disease and diabetes. In: Harris MI, Cowie CC, Stern MP, Boyko EJ, Reiber GE, Bennett PH, eds. Diabetes in America;2nd edition. Bethesda, MD: U.S. Department of Health and Human Services, 1995;429-48.

Winkleby MA, Robinson TN, Sundquist J, Kraemer HC. Ethnic variation in cardiovascular disease risk factors among children and young adults: findings from the Third National Health and Nutrition Examination Survey, 1988–1994. *JAMA* 1999;281:1006-13.

Wolf PA, D'Agostino RB, Kannel WB, Bonita R, Belanger AJ. Cigarette smoking as a risk factor for stroke: the Framingham Study. *JAMA* 1988;259:1025-9.

Wolk A, Bergstrom R, Hunter D, Willett W, Ljung H, Holmberg L, Bergkvist, Bruce A, Adami HO. A prospective study of association of monounsaturated fat and other types of fat with risk of breast cancer. *Arch Intern Med* 1998;158(1):41-5.

Women's Health Initiative Study Group. Design of the Women's Health Initiative clinical trial and observational study. *Control Clin Trials* 1998;19:61-109.

Wong ND, Hsu JC, Detrano RC, Diamond G, Eisenberg H, Gardin JM. Coronary artery calcium evaluation by electron beam computed tomography and its relation to new cardiovascular events. *Am J Cardiol* 2000;86:495-8.

Wong ND, Wilson PWF, Kannel WB. Serum cholesterol as a prognostic factor after myocardial infarction: the Framingham Study. *Ann Intern Med* 1991;115:687-93.

Wood D, De Backer G, Faergeman O, Graham I, Mancia G, Pyörälä K. Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. *Atherosclerosis* 1998;140:199-270.

Wood R, Kubena K, O'Brien B, Tseng S, Martin G. Effect of butter, mono- and polyunsaturated fatty acid-enriched butter, trans fatty acid margarine, and zero trans fatty acid margarine on serum lipids and lipoproteins in healthy men. *J Lipid Res* 1993a;34:1-11.

Wood R, Kubena K, Tseng S, Martin G, Crook R. Effect of palm oil, margarine, butter, and sunflower oil on the serum lipids and lipoproteins of normocholesterolemic middle-aged men. *J Nutr Biochem* 1993b;4:286-97.

Woolf SH. The need for perspective in evidence-based medicine. *JAMA* 1999;282:2358-65.

Working Group on Management of Patients with Hypertension and High Blood Cholesterol. National Education Programs Working Group report on the management of hypertension and high blood cholesterol. *Ann Intern Med* 1991;114:224-37.

Working Group Report on Management of Patients with Hypertension and High Blood Cholesterol. NIH Pub. No. 90-2361. Bethesda, MD: National Heart, Lung and Blood Institute, 1990:30 pages.

Wright JC, Weinstein MC. Gains in life expectancy from medical interventions—standardizing data on outcomes. *N Engl J Med* 1998;339:380-6.

- Yeshurun D, Abukarshin R, Elias N, Lanir A, Naschitz JE. Treatment of severe, resistant familial combined hyperlipidemia with a bezafibrate-lovastatin combination. *Clin Ther* 1993;15:355-63.
- Yusuf S, Wittes J, Probstfield J, Tyroler HA. Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials. *JAMA* 1991;1266:93-8.
- Zambon D, Ros E, Rodriguez-Villar C, Laguna JC, Vazquez M, Sanllehy C, Casals E, Sol JM, Hernandez G. Randomized crossover study of gemfibrozil versus lovastatin in familial combined hyperlipidemia: Additive effects of combination treatment on lipid regulation. *Metabolism* 1999;48:47-54.
- Zema MJ. Gemfibrozil, nicotinic acid and combination therapy in patients with isolated hypoalphalipoproteinemia: a randomized, open-label, crossover study. *J Am Coll Cardiol* 2000;35:640-6.
- Ziegler RG, Hoover RN, Pike MC, Hildesheim A, Nomura AM, West DW, Wu-Williams AH, Kolonel LN, Horn-Ross PL, Rosenthal JF. Migration patterns and breast cancer risk in Asian-American women. *J Natl Cancer Inst* 1993;85(22):1819-27.
- Zilleruelo G, Hsia SL, Freundlich M, Gorman HM, Strauss J. Persistence of serum lipid abnormalities in children with idiopathic nephrotic syndrome. *J Pediatr* 1984;104:61-4.
- Zimetbaum P, Frishman WH, Ooi WL, Derman MP, Aronson M, Gidez LI, Elder HA. Plasma lipids and lipoproteins and the incidence of cardiovascular disease in the very elderly. The Bronx aging study. *Arterioscler Thromb* 1992;12:416-23.
- Zimmet P, Boyko EJ, Collier GR, de Courten M. Etiology of the metabolic syndrome: potential role of insulin resistance, leptin resistance, and other players. *Ann N Y Acad Sci* 1999;892:25-44.
- Zock PL, Katan MB, Mensink RP. Trans-fatty acids and lipoproteins cholesterol. *Am J Clin Nutr* 1995;61:617.
- Zock PL, Katan MB. Hydrogenation alternatives: effects of trans-fatty acids and stearic acid versus linoleic acid on serum lipids and lipoproteins in humans. *J Lipid Res* 1992;33:399-410.